WO2005056766A2 - Administration ciblee de medicaments au moyen de groupes fonctionnels liant epha2 ou epha4 - Google Patents

Administration ciblee de medicaments au moyen de groupes fonctionnels liant epha2 ou epha4 Download PDF

Info

Publication number
WO2005056766A2
WO2005056766A2 PCT/US2004/041020 US2004041020W WO2005056766A2 WO 2005056766 A2 WO2005056766 A2 WO 2005056766A2 US 2004041020 W US2004041020 W US 2004041020W WO 2005056766 A2 WO2005056766 A2 WO 2005056766A2
Authority
WO
WIPO (PCT)
Prior art keywords
epha2
epha4
antibody
cancer
antibodies
Prior art date
Application number
PCT/US2004/041020
Other languages
English (en)
Other versions
WO2005056766A3 (fr
Inventor
Michael S. Kinch
Original Assignee
Medimmune, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/004,794 external-priority patent/US20050153923A1/en
Priority claimed from US11/004,795 external-priority patent/US20050147593A1/en
Application filed by Medimmune, Inc. filed Critical Medimmune, Inc.
Publication of WO2005056766A2 publication Critical patent/WO2005056766A2/fr
Publication of WO2005056766A3 publication Critical patent/WO2005056766A3/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001Receptor protein-tyrosine kinase (2.7.10.1)

Definitions

  • the present invention relates to methods and compositions designed for the treatment, management, or prevention of a hyperproliferative cell disease, particularly cancer.
  • the methods of the invention comprise the administration of an effective amount of a > composition that targets cells expressing an Eph family receptor tyrosine kinase, such as
  • the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety attached to, contained within or otherwise associated with a delivery vehicle, and one or more therapeutic or prophylactic agents that treat or prevent a hyperproliferative disease, where the therapeutic or prophylactic agents are operatively associated with the delivery vehicle.
  • the method of the invention comprises administering to a subject a composition comprising a nucleic acid comprising a nucleotide sequence encoding an EphA2 or E ⁇ hA4 targeting moiety and a therapeutic or prophylactic agent that treats or prevents a hyperproliferative disease, where nucleic acid is attached to, contained within or otherwise associated with the delivery vehicle.
  • the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety and a nucleic acid comprising a nucleotide sequence encoding an agent that treats or prevents a hyperproliferative disease, where the nucleic acid is attached to, contained within or otherwise associated with the delivery vehicle.
  • Pharmaceutical compositions and methods of making said pharmaceutical compositions are also provided by the present invention.
  • a neoplasm, or tumor is a neoplastic mass resulting from abnormal uncontrolled cell growth which can be benign or malignant. Benign tumors generally remain localized. Malignant tumors are collectively termed cancers.
  • malignant generally means that the tumor can invade and destroy neighboring body structures and spread to distant sites to cause death (for review, see Robbins and Angell, 1976, Basic Pathology, 2d Ed., W.B. Saunders Co., Philadelphia, pp. 68-122). Cancer can arise in many sites of the body and behave differently depending upon its origin. Cancerous cells destroy the part of the body in which they originate and then spread to other part(s) of the body where they start new growth and cause more destruction.
  • Cancer is a disease of aberrant signal transduction. Aberrant cell signaling overrides anchorage-dependent constraints on cell growth and survival (Rhim, et al., Critical Reviews in Oncogenesis 8:305, 1997; Patarca, Critical Reviews in Oncogenesis 7:343, 1996; Malik, et al., Biochimica et Biophysica Acta 1287:73, 1996; Cance, et al., Breast Cancer Res Treat 35:105, 1995).
  • Tyrosine kinase activity is induced by ECM anchorage and indeed, the expression or function of tyrosine kinases is usually increased in malignant cells (Rhim, et al., Critical Reviews in Oncogenesis 8:305,1997; Cance, et al., Breast Cancer Res Treat 35:105, 1995; Hunter, Cell 88:333, 1997).
  • tyrosine kinases Based on evidence that tyrosine kinase activity is necessary for malignant cell growth, tyrosine kinases have been targeted with new therapeutics (Levitzki, et al., Science 267: 1782, 1995; Kondapaka, et al., Molecular & Cellular Endocrinology 117:53, 1996; Fry, et al., Current Opinion in BioTechnology 6: 662, 1995). Unfortunately, obstacles associated with specific targeting to tumor cells often limit the application of these drugs. In particular, tyrosine kinase activity is often vital for the function and survival of benign tissues (Levitzki, et al., Science 267:1782, 1995). To minimize collateral toxicity, it is critical to identify and then target tyrosine kinases that are selectively overexpressed in tumor cells.
  • EphA2 is a 130 kDa receptor tyrosine kinase that is expressed in adult epithelia, where it is found at low levels and is enriched within sites of cell-cell adhesion (Zantek, et al, Cell Growth & Differentiation 10:629, 1999; Lindberg, et al., Molecular & Cellular Biology 10: 6316, 1990). This subcellular localization is important because EphA2 binds ligands (known as EphrinsAl to A5) that are anchored to the cell membrane (Eph Nomenclature Committee, 1997, Cell 90:403; Gale, et al., 1997, Cell & Tissue Research 290: 227).
  • EphA2 autophosphorylation (Lindberg, et al., 1990, supra). However, unlike other receptor tyrosine kinases, EphA2 retains enzymatic activity in the absence of ligand binding or phosphotyrosine content (Zantek, et al., 1999, supra). EphA2 is upregulated on a large number of aggressive carcinoma cells.
  • EphA4 is a receptor tyrosine kinase that is expressed in brain, heart, lung, muscle, kidney, placenta, pancreas (Fox, et al, Oncogene 10:897, 1995) and melanocytes (Easty, et al., Int. J. Cancer 71 : 1061, 1997). EphA4 binds cell membrane-anchored ligands (Ephrins Al, A2, A3, A4, A5, B2, and B3; Pasquale, Curr. Opin.
  • EphA4 tyrosine phosphorylation creates a binding region for proteins with Src Homology 2/3 (SH2/SH3) domains, such as the cytoplasmic tyrosine kinase p59fyn (Ellis, et al., supra; Cheng, et al., Cytokine and Growth Factor Reviews 13:75, 2002).
  • Src Homology 2/3 (SH2/SH3) domains such as the cytoplasmic tyrosine kinase p59fyn (Ellis, et al., supra; Cheng, et al., Cytokine and Growth Factor Reviews 13:75, 2002).
  • Activation of EphA4 in Xenopus embryos leads to loss of cadherin-dependent cell adhesion (Winning, et al., Differentiation 70:46, 2002; Cheng, et al., supra), suggesting a role for EphA4 in tumor angiogenesis; however,
  • EphA4 appears to be upregulated in breast cancer, esophageal cancer, and pancreatic cancer (Kuang, et al., Nucleic Acids Res. 26:1116, 1998; Meric, et al, Clinical Cancer Res. 8:361, 2002; Nemoto, et al., Pathobiology 65:195, 1997; Logsdon, et al., Cancer Res. 63:2649, 2003), yet it is downregulated in melanoma tissue (Easty, et al., supra).
  • cancer therapy may involve surgery, chemotherapy, hormonal therapy and/or radiation treatment to eradicate neoplastic cells in a patient (see, for example, Stockdale, 1998, "Principles of Cancer Patient Management,” in Scientific American: Medicine, vol. 3, Rubenstein and Federman, eds., Chapter 12, Section IV).
  • cancer therapy may also involve biological therapy or immunotherapy. All of these approaches can pose significant drawbacks for the patient.
  • Surgery for example, may be contraindicated due to the health of the patient or may be unacceptable to the patient. Additionally, surgery may not completely remove the neoplastic tissue. Radiation therapy is only effective when the neoplastic tissue exhibits a higher sensitivity to radiation than normal tissue, and radiation therapy can also often elicit serious side effects.
  • Hormonal therapy is rarely given as a single agent and, although it can be effective, is often used to prevent or delay recurrence of cancer after other treatments have removed the majority of the cancer cells.
  • Biological therapies/immunotherapies are limited in number and each therapy is generally effective for a very specific type of cancer.
  • chemotherapy there are a variety of chemotherapeutic agents available for treatment of cancer.
  • a significant majority of cancer chemotherapeutic s act by inhibiting DNA synthesis, either directly, or indirectly by inhibiting the biosynthesis of the deoxyribonucleotide triphosphate precursors, to prevent DNA replication and concomitant cell division (see, for example, Gilman et al., Goodman and Gilman's: The Pharmacological Basis of Therapeutics, Eighth Ed. (Pergamom Press, New York, 1990)).
  • agents which include alkylating agents, such as nitrosourea, anti-metabolites, such as methotrexate and hydroxyurea, and other agents, such as etoposides, campathecins, bleomycin, doxorubicin, daunorubicin, etc., although not necessarily cell cycle specific, kill cells during S phase because of their effect on DNA replication.
  • agents specifically colchicine and the vinca alkaloids, such as vinblastine and vincristine, interfere with microtubule assembly resulting in mitotic arrest.
  • Chemotherapy protocols generally involve administration of a combination of chemotherapeutic agents to increase the efficacy of treatment.
  • chemotherapeutic agents have many drawbacks (see, for example, Stockdale, 1998, "Principles Of Cancer Patient Management” in Scientific American Medicine, vol. 3, Rubenstein and Federman, eds., ch. 12, sect. 10). Almost all chemotherapeutic agents are toxic, and chemotherapy causes significant, and often dangerous, side effects, including severe nausea, bone marrow depression, immunosuppression, etc. Additionally, even with administration of combinations of chemotherapeutic agents, many tumor cells are resistant or develop resistance to the chemotherapeutic agents.
  • those cells resistant to the particular chemotherapeutic agents used in the treatment protocol often prove to be resistant to other drugs, even those agents that act by mechanisms different from the mechanisms of action of the drugs used in the specific treatment; this phenomenon is termed pleiotropic drug or multidrug resistance.
  • drug resistance many cancers prove refractory to standard chemotherapeutic treatment protocols.
  • Eph family receptor tyrosine kinases such as EphA2 or EphA4, are overexpressed and functionally altered in a large number of malignant carcinomas. EphA2 and EphA4 are oncoproteins and are sufficient to confer metastatic potential to cancer cells. EphA2 and EphA4 are also associated with other hyperproliferating cells and are implicated in diseases caused by cell hyperproliferation. EphA2 and EphA4 that are overexpressed on malignant cells exhibit kinase activity independent from ligand binding. A decrease in EphA2 or EphA4 levels can decrease proliferation and/or metastatic behavior of a cell.
  • agonistic antibodies may repress hyperproliferation or malignant cell behavior by inducing EphA2 or EphA4 autophosphorylation, thereby causing subsequent EphA2 or EphA4 degradation to down-regulate expression.
  • the present invention encompasses EphA2 and EphA4 antibodies that agonize EphA2/EphA4 signaling and increase phosphorylation of EphA2/EphA4 ("EphA2 agonistic antibodies” and "EphA4 agonistic antibodies”).
  • EphA2 and EphA4 are cell surface molecules that are overexpressed on cancer cells and hyperproliferative cells, they can be used as primary targets for directing therapeutic or prophylactic agents, including, but not limited to, anti- EphA2 agents and anti-EphA4 agents, to cancer or other hyperproliferative cells.
  • cancer cells exhibit phenotypic traits that differ from those of non-cancer cells, for example, formation of colonies in a three-dimensional substrate such as soft agar or formation of tubular networks or weblike matrices in a three-dimensional basement membrane or extracellular matrix preparation, such as MATRIGELTM.
  • Non- cancer cells do not form colonies in soft agar and form distinct sphere-like structures in three-dimensional basement membrane or extracellular matrix preparations.
  • the invention also encompasses antibodies that specifically bind EphA2 and/or EphA4 and inhibit one or more cancer cell phenotypes, such as colony formation in soft agar or tubular network formation in three-dimensional basement membrane or extracellular matrix preparations ("cancer cell phenotype inhibitory EphA2 antibodies” and “cancer cell phenotype inhibitory EphA4 antibodies”). Exposing cancer cells to such cancer cell phenotype inhibitory EphA2 or EphA4 antibodies prevents or decreases the cells' ability to colonize or form tubular networks in these substrates.
  • cancer cell phenotype inhibitory EphA2 antibodies and “cancer cell phenotype inhibitory EphA4 antibodies”
  • Exposing cancer cells to such cancer cell phenotype inhibitory EphA2 or EphA4 antibodies prevents or decreases the cells' ability to colonize or form tubular networks in these substrates.
  • the addition of such cancer cell phenotype inhibitory EphA2 or EphA4 antibodies to already established colonies of cancer cells causes a reduction or elimination of an existing cancer cell colony, i.e., leads to killing of hyperproliferative and/or metastatic cells, for example, through necrosis or apoptosis.
  • the invention further encompasses antibodies that bind EphA2 or EphA4 with a K 0ff of less than 3 X 10 '3 s "1 and, preferably, are EphA2 or EphA4 agonists.
  • EphA2 or EphA4 Differences in the subcellular localization, ligand binding properties or protein organization (e.g., structure, orientation in the cell membrane) can further distinguish the EphA2 or EphA4 that is present on cancer cells from EphA2 or EphA4 on non-cancer cells.
  • EphA2 or EphA4 is expressed at low levels and is localized to sites of cell-cell contact, where it can engage its membrane-anchored ligands.
  • cancer cells generally display decreased cell-cell contacts and this can decrease EphA2 or EphA4 -ligand binding.
  • EphA2 or EphA4 can cause an excess of EphA2 or EphA4 relative to ligand that increases the amount of non- ligand bound EphA2 or EphA4. Consequently, changes in the subcellular distribution or membrane orientation of EphA2 or EphA4 can cause EphA2 or EphA4 to localize to sites in a cancer cell where it is inaccessible to ligand. Additionally, EphA2 or EphA4 may have altered ligand binding properties (e.g., due to an altered conformation) in cancer cells such that it is incapable of stable interactions with its ligand whether or not it is localized to the cell-cell junction.
  • the invention also encompasses antibodies that specifically bind EphA2 or EphA4 but preferably bind an EphA2 or EphA4 epitope exposed on cancer cells but not on non-cancer cells ("exposed EphA2 epitope antibodies” and "exposed EphA4 epitope antibodies”).
  • Exposing cancer cells to such EphA2 or EphA4 antibodies that preferentially bind epitopes on EphA2 or EphA4 that are selectively exposed or increased on cancer cells but not non-cancer cells targets the therapeutic/prophylactic antibody to cancer cells and prevents or decreases the cells' ability to proliferate while sparing non-cancer cells.
  • an EphA2 or EphA4 binding moiety can be used as targeting moieties to direct one or more therapeutic or prophylactic agents (including anti-EphA2 and anti-EphA4 agents) to cancer cells or other hyperproliferative cells that overexpress EphA2 or EphA4, thereby treating or preventing the cancer or other hyperproliferative cell disease.
  • an EphA2 or EphA4 binding moiety is an antibody or a fragment thereof that immunospecifically binds EphA2 or EphA4 epitopes exposed on cancer cells or other hyperproliferative cells (more preferably, differentially exposed on cancer or other hyperproliferative cells and not on non-cancer or non-hyperproliferative cells).
  • the present invention provides methods of treating, preventing or managing a hyperproliferative cell disease associated with overexpression of EphA2 or EphA4 and/or high levels of unphosphorylated EphA2 or EphA4 in a subject in need thereof, said method comprising administering to the subject a therapeutically or prophylactically effective amount of a composition comprising (a) a delivery vehicle conjugated to (or otherwise associated with) a moiety that binds EphA2 or EphA4; (b) one or more therapeutic or prophylactic agents that treat or prevent said hyperproliferative cell disease (e.g., inhibit cell proliferation or kill the hyperproliferative cells); and (c) a pharmaceutically acceptable carrier.
  • a composition comprising (a) a delivery vehicle conjugated to (or otherwise associated with) a moiety that binds EphA2 or EphA4; (b) one or more therapeutic or prophylactic agents that treat or prevent said hyperproliferative cell disease (e.g., inhibit cell proliferation or kill the hyper
  • said one or more therapeutic or prophylactic agents are conjugated to, contained within, or are otherwise associated with the delivery vehicle, so that the delivery vehicle delivers the agent(s) to cells expressing EphA2 or EphA4.
  • the delivery vehicle is conjugated to (or otherwise associated with) the moiety that binds EphA2 or EphA4 in a configuration in which the moiety that binds EphA2 or EphA4 is accessible for binding to EphA2 or EphA4 expressed on a cell.
  • at least one of the one or more therapeutic or prophylactic agents is an agent that reduces EphA2 and/or EphA4 expression and/or activity.
  • the present invention also provides compositions for treating, preventing or managing a hyperproliferative cell disease, said composition comprising (a) a delivery vehicle conjugated to (or otherwise associated with) a moiety that binds EphA2 or EphA4; (b) one or more therapeutic or prophylactic agents effective to treat or prevent said hyperproliferative cell disease (e.g., inhibit cell proliferation or kill the hyperproliferative cells); and (c) a pharmaceutically acceptable carrier.
  • said one or more therapeutic or prophylactic agents are conjugated to, contained within, or are otherwise associated with the delivery vehicle, so that the delivery vehicle delivers the agent(s) to cells expressing EphA2 or EphA4.
  • the delivery vehicle is conjugated to (or otherwise associated with) the moiety that binds EphA2 or EphA4 in a configuration in which the moiety that binds EphA2 or EphA4 is accessible for binding to EphA2 or EphA4 expressed on a cell.
  • at least one of the one or more therapeutic or prophylactic agents is an agent that reduces EphA2 or EphA4 expression or activity.
  • the delivery vehicle is a viral vector, a polycation vector, a peptide vector, a liposome or a hybrid vector.
  • the moiety that binds EphA2 is an anti-EphA2 antibody or an EphA2-binding fragment thereof, particularly an anti-EphA2 antibody that binds EphA2 epitopes exposed on cancer cells, or an EphA2 ligand such as Ephrin Al or an EphA2-binding fragment thereof.
  • the moiety that binds EphA2 in accordance with the present invention is Ephrin Al Fc.
  • the moiety that binds EphA4 is an anti-EphA4 antibody or an EphA4-binding fragment thereof, particularly an anti-EphA4 antibody that binds EphA4 epitopes exposed on cancer cells, or an EphA4 ligand such as Ephrin Al or an EphA4-binding fragment thereof.
  • the moiety that binds EphA4 is any natural ligand of EphA4, including, but not limited to, Ephrin Al, Ephrin A2, Ephrin A3, Ephrin A4, Ephrin A5, Ephrin B2, and Ephrin B3 or EphA4-binding fragments thereof.
  • the moiety that binds EphA4 is Ephrin Al Fc. In other embodiments, the moiety that binds EphA4 is Ephrin A2 Fc, Ephrin A3 Fc, Ephrin A4 Fc, Ephrin A5 Fc, Ephrin B2 Fc or Ephrin B3 Fc.
  • any agent that can be used to treat, prevent or manage a hyperproliferative cell disease can be delivered by using a delivery vehicle conjugated to (or otherwise associated with) a moiety that binds EphA2 or EphA4.
  • the therapeutic or prophylactic agent to be delivered is an anti- cancer agent.
  • the therapeutic or prophylactic agent to be delivered is an agent that elicits an immune response against the hyperproliferative cell disease in the subject.
  • the agent to be delivered is not a low molecular weight protein tyrosine phosphatase (LMW-PTP) inhibitor.
  • the therapeutic or prophylactic agent to be delivered is an agent that inhibits or reduces EphA2 and/or EphA4 expression and/or function.
  • such an agent can be, but is not limited to, an EphA2 or EphA4 agonistic molecule, a peptide that preferentially binds EphA2 or EphA4 epitopes exposed on cancer cells, a cancer cell phenotype inhibiting peptide, a peptide that binds to EphA2 or EphA4 with a low K 0ff rate, an antisense oligonucleotide, a ribozyme, a RNA interference (RNAi) molecule or an aptamer that reduces EphA2 or EphA4 expression (i.e., having some portion of the EphA2 or EphA4 sequence).
  • RNAi RNA interference
  • the therapeutic or prophylactic agent to be delivered does not inhibit or reduce EphA2 and/or EphA4 expression and/or function.
  • the compositions of the invention further comprise an agent that stimulates an immune response against the hyperproliferative cell disease to be treated, prevented or managed in the subject.
  • an agent that stimulates an immune response against a hyperproliferative cell is an EphA2 or EphA4 vaccine that elicits or mediates an immune response against cells that overexpress EphA2 or EphA4.
  • compositions of the invention are used to treat, prevent and/or manage a non-cancer disease or disorder associated with cell hyperproliferation, such as but not limited to, asthma, chronic obstructive pulmonary disease (COPD), psoriasis, lung fibrosis, bronchial hyper responsiveness, seborrheic dermatitis, and cystic fibrosis, inflammatory bowel disease.
  • a non-cancer disease or disorder associated with cell hyperproliferation such as but not limited to, asthma, chronic obstructive pulmonary disease (COPD), psoriasis, lung fibrosis, bronchial hyper responsiveness, seborrheic dermatitis, and cystic fibrosis, inflammatory bowel disease.
  • the hyperproliferative cells are epithelial.
  • the hyperproliferative cells overexpress EphA2 or EphA4.
  • the hyperproliferative cell disorder is characterized by hyperproliferating endothelial cells.
  • Hyperproliferative endothelial cell disorders to be treated, prevented or managed by the methods of the invention include, but are not limited to, restenosis (smooth muscle and/or endothelial), hyperproliferative vascular disease, Behcet's Syndrome, atherosclerosis, and macular degeneration.
  • some EphA2 or EphA4 is not bound to ligand, either as a result of decreased cell-cell contacts, altered subcellular localization, or increases in amount of EphA2 or EphA4 relative to EphA2 or EphA4 ligand.
  • the methods and compositions of the invention are useful not only in untreated patients but are also useful in the treatment of patients partially or completely refractory to current standard and experimental cancer therapies, including but not limited to, chemotherapies, hormonal therapies, biological therapies, radiation therapies, and/or surgery, as well as to improve the efficacy of such treatments.
  • EphA2 or EphA4 expression has been implicated in increasing levels of the cytokine IL-6, which has been associated with the development of cancer cell resistance to different treatment regimens, such as chemotherapy and hormonal therapy.
  • EphA2 or EphA4 overexpression can override the need for estrogen receptor activity thus contributing to tamoxifen resistance in breast cancer cells.
  • the invention provides therapeutic and prophylactic methods for the treatment or prevention of cancer that has been shown to be or may be refractory or non-responsive to therapies other than those comprising administration of EphA2 or EphA4 antibodies of the invention.
  • one or more compositions of the invention are administered to a patient refractory or non-responsive to a non-EphA2 or EphA4-based treatment, particularly tamoxifen treatment or a treatment in which resistance is associated with increased IL-6 levels, to render the patient non-refractory or responsive.
  • the treatment to which the patient had previously been refractory or non-responsive can then be administered with therapeutic effect.
  • EphA2 or EphA4 expression correlates with increased fibronectin expression.
  • high levels of exogenous fibronectin increase cells' ability to form colonies in soft agar while specific inhibitors of cell- fibronectin attachment decrease colony formation of tumor-derived cancer cells in soft agar.
  • fibronectin appears to accommodate tumor cell colonization in foreign environments, e.g., formation and growth of distal metastases.
  • the invention provides methods of treating, preventing, or managing cancer, particularly metastatic disease, by administering an EphA2 or EphA4 targeting moiety conjugated to (or otherwise associated with) a delivery vehicle, which delivers an agent that prevents cell- fibronectin binding and/or fibronectin expression.
  • a delivery vehicle which delivers an agent that prevents cell- fibronectin binding and/or fibronectin expression.
  • the invention further encompasses diagnostic methods using the EphA2 or
  • EphA4 binding moieties of the invention to evaluate the efficacy of cancer therapy, either EphA2- or EphA4-based or not EphA2- or EphA4-based.
  • increased EphA2 or EphA4 expression is associated with increasingly invasive and metastatic cancers.
  • a reduction in EphA2 or EphA4 expression with a particular treatment indicates that the therapy is reducing the invasiveness and/or metastatic potential of cancer.
  • the diagnostic methods of the invention may also be used to prognose or predict the course of cancer or outcomes of cancer therapy.
  • the diagnostic methods of the invention provide methods of imaging and localizing metastases and methods of diagnosis and prognosis using tissues and fluids distal to the primary tumor site (as well as methods using tissues and fluids of the primary tumor), for example, whole blood, sputum, urine, serum, fine needle aspirates (i.e., biopsies).
  • the diagnostic methods of the invention provide methods of imaging and localizing metastases and methods of diagnosis and prognosis in vivo.
  • primary metastatic tumors are detected using an EphA2 or EphA4 binding moiety of the invention, preferably an exposed EphA2 or EphA4 epitope antibody.
  • EphA2-binding moieties of the invention may also be used for immunohistochemical analyses of frozen or fixed cells or tissue assays.
  • the EphA2 or EphA4 binding moieties and diagnostic methods of the invention may be used to diagnose, prognose or monitor therapy of (whether EphA2 or EphA4 based or non-EphA2 or EphA4-based therapy) non-cancer hyperproliferative diseases (particularly associated with EphA2 or EphA4 overexpression), for example, but not limited to, asthma, psoriasis, restenosis, chronic obstructive pulmonary disease, etc.
  • pharmaceutical compositions and methods of making said pharmaceutical compositions are provided.
  • a method of making a pharmaceutical composition comprises associating a delivery vehicle with: a moiety that binds EphA2 or EphA4 expressed on a cell; a therapeutic or prophylactic agent that treats, prevents or manages a hyperproliferative cell disease associated with cells that express EphA2 or EphA4, wherein said agent is contained within or attached to said delivery vehicle; and a pharmaceutically acceptable carrier.
  • kits comprising the pharmaceutical compositions, or diagnostic reagents of the invention are provided.
  • agonist refers to any compound including a protein, polypeptide, peptide, antibody, antibody fragment, large molecule, or small molecule (less than 10 kD), that increases the activity, activation or function of another molecule.
  • EphA2 or EphA4 agonists cause increased phosphorylation and degradation of EphA2 or EphA4 protein.
  • EphA2 or EphA4 antibodies that agonize EphA2 or EphA4 may or may not also inhibit cancer cell phenotype (e.g., colony formation in soft agar or tubular network formation in a three-dimensional basement membrane or extracellular matrix preparation) and may or may not preferentially bind an EphA2 or EphA4 epitope that is exposed in a cancer cell relative to a non-cancer cell and may or may not have a low K 0f f rate.
  • cancer cell phenotype e.g., colony formation in soft agar or tubular network formation in a three-dimensional basement membrane or extracellular matrix preparation
  • EphA2 or EphA4 as used herein refers to antibodies or fragments thereof that specifically bind to an EphA2 or EphA4 polypeptide or a fragment of an EphA2 or EphA4 polypeptide and do not specifically bind to other non-EphA2 or non-EphA4 polypeptides.
  • antibodies or fragments that immunospecifically bind to an EphA2 or EphA4 polypeptide or fragment thereof do not non-specifically cross-react with other antigens (e.g., binding cannot be competed away with a non-EphA2 or non-EphA4 protein, e.g., BSA, in an appropriate immunoassay).
  • Antibodies or fragments that immunospecifically bind to an EphA2 or EphA4 polypeptide can be identified, for example, by immunoassays or other techniques known to those of skill in the art.
  • Antibodies of the invention include, but are not limited to, synthetic antibodies, monoclonal antibodies, recombinantly produced antibodies, intrabodies, multispecific antibodies (including bi-specific antibodies), human antibodies, humanized antibodies, chimeric antibodies, synthetic antibodies, single-chain Fvs (scFv) (including bi-specific scFvs), single chain antibodies Fab fragments, F(ab') fragments, disulfide-linked Fvs (sdFv), and anti-idiotypic (anti-Id) antibodies, and epitope- binding fragments of any of the above.
  • antibodies of the present invention include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds to an EphA2 or EphA4 antigen (e.g., one or more complementarity determining regions (CDRs) of an anti-EphA2 or anti-EphA4 antibody).
  • an EphA2 or EphA4 antigen e.g., one or more complementarity determining regions (CDRs) of an anti-EphA2 or anti-EphA4 antibody.
  • agonistic antibodies or fragments thereof that immunospecifically bind to an EphA2 or EphA4 polypeptide or fragment thereof preferentially agonize EphA2 or EphA4 and do not significantly agonize other molecules or activities.
  • cancer refers to a disease involving cells that have the potential to metastasize to distal sites and exhibit phenotypic traits that differ from those of non-cancer cells, for example, formation of colonies in a three-dimensional substrate such as soft agar or the formation of tubular networks or weblike matrices in a three- dimensional basement membrane or extracellular matrix preparation, such as MATRIGELTM.
  • Non-cancer cells do not form colonies in soft agar and form distinct sphere-like structures in three-dimensional basement membrane or extracellular matrix preparations. Cancer cells acquire a characteristic set of functional capabilities during their development, albeit through various mechanisms.
  • cancer cell is meant to encompass both pre-malignant and malignant cancer cells.
  • cancer cell phenotype inhibiting refers to the ability of a compound to prevent or reduce cancer cell colony formation in soft agar or tubular network formation in a three-dimensional basement membrane or extracellular matrix preparation or any other method that detects a reduction in a cancer cell phenotype, for example, assays that detect an increase in contact inhibition of cell proliferation (e.g., reduction of colony formation in a monolayer cell culture).
  • Cancer cell phenotype inhibiting compounds may also cause a reduction or elimination of colonies when added to established colonies of cancer cells in soft agar or the extent of tubular network formation in a three-dimensional basement membrane or extracellular matrix preparation.
  • EphA2 or EphA4 antibodies that inhibit cancer cell phenotype may or may not also agonize EphA2 or EphA4 and may or may not have a low K 0ff rate.
  • the term "delivery vehicle” refers to a substance that can be used to administer a therapeutic or prophylactic agent to a subject, particular a human.
  • a delivery vehicle may preferentially deliver the therapeutic/prophylactic agent(s) to a particular subset of cells.
  • a delivery vehicle may target certain types of cells, e.g., by virtue of an innate feature of the vehicle or by a moiety conjugated to, contained within (or otherwise associated with such that the moiety and the delivery vehicle stay together sufficiently for the moiety to target the delivery vehicle) the vehicle, which moiety specifically binds a particular subset of cells, e.g., by binding to a cell surface molecule characteristic of the subset of cells to be targeted.
  • a delivery vehicle may also increase the in vivo half-life of the agent to be delivered and/or the bioavailability of the agent to be delivered.
  • a delivery vehicle are a viral vector, a virus-like particle, a polycation vector, a peptide vector, a liposome, and a hybrid vector.
  • the delivery vehicle is not directly conjugated to the moiety that binds EphA2 and/or EphA4.
  • the delivery vehicle is not an antibody that binds EphA2 and/or EphA4.
  • derivatives refers to, for example, but not by way of limitation, a polypeptide that comprises an amino acid sequence of an EphA2 or EphA4 polypeptide, a fragment of an EphA2 or EphA4 polypeptide, an antibody that immunospecifically binds to an EphA2 or EphA4 polypeptide, or an antibody fragment that immunospecifically binds to an EphA2 or EphA4 polypeptide, that has been altered by the introduction of amino acid residue substitutions, deletions or additions (i.e., mutations).
  • an antibody derivative or fragment thereof comprises amino acid residue substitutions, deletions or additions in one or more CDRs.
  • the antibody derivative may have substantially the same binding, better binding, or worse binding when compared to a non-derivative antibody.
  • one, two, three, four, or five amino acid residues of the CDR have been substituted, deleted or added (i.e., mutated).
  • derivative as used herein also refers to a proteinaceous agent which has been modified, i.e., by the covalent attachment of a type of molecule to the proteinaceous agent.
  • derivative as used herein also refers to, for example, but not by way of limitation, an EphA2 or EphA4 polypeptide, a fragment of an EphA2 or EphA4 polypeptide, an antibody that immunospecifically binds to an EphA2 or EphA4 polypeptide, or an antibody fragment that immunospecifically binds to an EphA2 or EphA4 polypeptide which has been modified, i.e, by the covalent attachment of any type of molecule to the polypeptide.
  • an EphA2 or EphA4 polypeptide, a fragment of an EphA2 or EphA4 polypeptide, an antibody, or antibody fragment may be modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc.
  • a derivative of an EphA2 or EphA4 polypeptide, a fragment of an EphA2 or EphA4 polypeptide, an antibody, or antibody fragment may be modified by chemical modifications using techniques known to those of skill in the art, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc.
  • a derivative of a proteinaceous agent may contain one or more non-classical amino acids.
  • a derivative of an EphA2 or EphA4 polypeptide, a fragment of an EphA2 or EphA4 polypeptide, an antibody, or antibody fragment may contain one or more non-classical amino acids.
  • a polypeptide derivative possesses a similar or identical function as an EphA2 or EphA4 polypeptide, a fragment of an EphA2 or EphA4 polypeptide, an antibody, or antibody fragment described herein.
  • a derivative of EphA2 or EphA4 polypeptide, a fragment of an EphA2 or EphA4 polypeptide, an antibody, or antibody fragment has an altered activity when compared to an unaltered polypeptide.
  • a derivative antibody or fragment thereof can bind to its epitope more tightly or be more resistant to proteolysis.
  • epitope refers to a portion of an EphA2 or EphA4 polypeptide having antigenic or immunogenic activity in an animal, preferably in a mammal, and most preferably in a mouse or a human.
  • An epitope having immunogenic activity is a portion of an EphA2 or EphA4 polypeptide that elicits an antibody response in an animal.
  • An epitope having antigenic activity is a portion of an EphA2 or EphA4 polypeptide to which an antibody immunospecifically binds as determined by any method well known in the art, for example, by immunoassays. Antigenic epitopes need not necessarily be immunogenic.
  • EphA2 or “EphA4" refer to any Eph receptor polypeptide that has been identified and recognized by the Eph Nomenclature Committee (Eph Nomenclature Committee, 1997, Cell 90:403-404).
  • an EphA2 or EphA4 receptor polypeptide or fragment thereof is from any species.
  • an EphA2 or EphA4 receptor polypeptide or fragment thereof is human.
  • the nucleotide and/or amino acid sequences of Eph receptor polypeptides can be found in the literature or public databases (e.g., GenBank), or the nucleotide and/or amino acid sequences can be determined using cloning and sequencing techniques known to one of skill in the art.
  • GenBank Accession Nos. for the nucleotide and amino acid sequences of the human EphA2 are NM_004431.2 and NP_004422.2, respectively.
  • the GenBank Accession Nos. for the nucleotide and amino acid sequences of the human EphA4 are NM_004438.3 and NP_004429.1, respectively.
  • Ephrin refers to any Ephrin ligand that has or will be identified and recognized by the Eph Nomenclature Committee (Eph Nomenclature Committee, 1997, Cell 90:403-404).
  • Ephrins of the present invention include, but are not limited to, EphrinAl, EphrinA2, EphrinA3, EphrinA4, EphrinA5, EphrinB 1 , EphrinB2 and EphrinB3.
  • an Ephrin polypeptide, particularly EphrinAl is from any species.
  • an Ephrin polypeptide is human.
  • the nucleotide and/or amino acid sequences of Ephrin polypeptides can be found in the literature or public databases (e.g., GenBank), or the nucleotide and/or amino acid sequences can be determined using cloning and sequencing techniques known to one of skill in the art.
  • GenBank Accession Nos. for the nucleotide and amino acid sequences of human Ephrin Al variant 1 are NM_004428.2 and NP_004419.2, respectively.
  • GenBank Accession Nos. for the nucleotide and amino acid sequences of human Ephrin Al variant 2 are NM_182685.1 and NP_872626.1 for variant 2, respectively.
  • fragments in the context of a polypeptide described herein include a peptide or polypeptide comprising an amino acid sequence of at least 5 contiguous amino acid residues, at least 10 contiguous amino acid residues, at least 15 contiguous amino acid residues, at least 20 contiguous amino acid residues, at least 25 contiguous amino acid residues, at least 40 contiguous amino acid residues, at least 50 contiguous amino acid residues, at least 60 contiguous amino residues, at least 70 contiguous amino acid residues, at least contiguous 80 amino acid residues, at least 90 contiguous amino acid residues, at least contiguous 100 amino acid residues, at least 125 contiguous amino acid residues, at least 150 contiguous amino acid residues, at least 175 contiguous amino acid residues, at least contiguous 200 amino acid residues, or at least 250 contiguous amino acid residues of the amino acid sequence of an EphA2 or EphA4 polypeptide or an antibody that immunospecifically binds
  • humanized antibody refers to forms of non- human (e.g., murine) antibodies that are chimeric antibodies which contain minimal sequence derived from non-human immunoglobulin.
  • humanized antibodies are human immunoglobulins (recipient antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-human species (donor antibody) such as mouse, rat, rabbit or non-human primate having the desired specificity, affinity, and capacity.
  • donor antibody such as mouse, rat, rabbit or non-human primate having the desired specificity, affinity, and capacity.
  • FR Framework Region residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • humanized antibodies may comprise residues which are not found in the recipient antibody or in the donor antibody.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable regions correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence.
  • the humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin that immunospecifically binds to an EphA2 or an EphA4 polypeptide, that has been altered by the introduction of amino acid residue substitutions, deletions or additions (i.e., mutations).
  • a humanized antibody is a derivative.
  • Such a humanized antibody comprises amino acid residue substitutions, deletions or additions in one or more non-human CDRs.
  • the humanized antibody derivative may have substantially the same binding, better binding, or worse binding when compared to a non-derivative humanized antibody.
  • one, two, three, four, or five amino acid residues of the CDR have been substituted, deleted or added (i.e., mutated).
  • European Patent Nos. EP 239,400, EP 592,106, and EP 519,596 International Publication Nos. WO 91/09967 and WO 93/17105; U.S. Patent Nos.
  • hypervariable region refers to the amino acid residues of an antibody which are responsible for antigen binding.
  • the hypervariable region comprises amino acid residues from a "Complementarity Determining Region” or "CDR" (i.e., residues 24-34 (LI), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and 31-35 (HI), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD.
  • CDR Constantarity Determining Region
  • the term “in combination” refers to the use of more than one therapy (e.g., prophylactic and/or therapeutic agents).
  • the use of the term “in combination” does not restrict the order in which prophylactic and/or therapeutic agents are administered to a subject with a hyperproliferative cell disorder, especially cancer.
  • a first therapy (e.g., prophylactic or therapeutic agent) can be administered prior to (e.g., 1 minute, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (e.g., 1 minute, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a second therapy (e.g., prophylactic or therapeutic agent) to a subject which had, has, or is susceptible to a hyperproliferative cell disorder, especially cancer.
  • a second therapy e.g., prophylactic or therapeutic agent
  • the therapies are administered to a subject in a sequence and within a time interval such that the therapy of the invention can act together with the other agent to provide an increased benefit than if they were administered otherwise.
  • Any additional therapy e.g., prophylactic or therapeutic agent
  • can be administered in any order with the other additional therapies e.g., prophylactic or therapeutic agents.
  • the phrase "low tolerance" refers to a state in which the patient suffers from side effects from treatment so that the patient does not benefit from and/or will not continue therapy because of the adverse effects and/or the harm from the side effects outweighs the benefit of the treatment.
  • the terms “manage,” “managing” and “management” refer to the beneficial effects that a subject derives from administration of a therapy (e.g., prophylactic or therapeutic agent), which does not result in a cure of the disease.
  • a subject is administered one or more therapies (e.g., prophylactic or therapeutic agents) to "manage” a disease so as to prevent the progression or worsening of the disease.
  • non-responsive/refractory is used to describe patients treated with one or more currently available therapies (e.g., cancer therapies) such as chemotherapy, radiation therapy, surgery, hormonal therapy and/or biological therapy/immunotherapy, particularly a standard therapeutic regimen for the particular cancer, wherein the therapy is not clinically adequate to treat the patients such that these patients need additional effective therapy, e.g., remain unsusceptible to therapy.
  • therapies e.g., cancer therapies
  • the phrase can also describe patients who respond to therapy yet suffer from side effects, relapse, develop resistance, etc.
  • “non-responsive/refractory” means that at least some significant portion of the cancer cells are not killed or their cell division arrested.
  • a cancer is “non-responsive/refractory” where the number of cancer cells has not been significantly reduced, or has increased during the treatment.
  • potentiate refers to an improvement in the efficacy of a therapeutic agent at its common or approved dose.
  • the terms “prevent,” “preventing” and “prevention” refer to the prevention of the onset, recurrence, or spread of a disease in a subject resulting from the administration of a therapy (e.g., prophylactic or therapeutic agent).
  • a therapy e.g., prophylactic or therapeutic agent.
  • prophylactic agent refers to any agent that can be used in the prevention of the onset, recurrence or spread of a disease or disorder associated with EphA2 or EphA4 overexpression and/or cell hyperproliferative disease, particularly cancer.
  • prophylactic agent refers to any composition comprising a therapeutically or prophylactically effective amount of (a) a delivery vehicle conjugated to (or otherwise associated with) a moiety that binds EphA2 and/or EphA4; (b) one or more therapeutic or prophylactic agents that treat or prevent said hyperproliferative disease; and (c) a pharmaceutically acceptable carrier.
  • the term "prophylactic agent” refers to an EphA2 or EphA4 agonistic antibody, an EphA2 or EphA4 cancer cell phenotype inhibiting antibody, an exposed EphA2 or EphA4 epitope antibody, or an antibody that binds EphA2 or EphA4 with a K 0f rof less than 3 X 10 "3 s "1 (e.g., Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152, EA44, or any of the antibodies listed in Table 1).
  • an EphA4 agonistic antibody for use in the compositions and methods of the invention is EA44, an anti-EphA4 scFV antibody which is disclosed in U.S. Non-Provisional Application Serial No. 10/863,729, filed June 7, 2004 and is inco ⁇ orated by reference herein in its entirety.
  • Cells that express the anti-EphA4 scFv EA44 have been deposited with the American Type Culture Collection (P.O. Box 1549, Manassas, VA 20108) on June 4, 2004 under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedures, and assigned accession number PTA-6044.
  • prophylactic agent refers to cancer chemotherapeutics, radiation therapy, hormonal therapy, biological therapy (e.g., immunotherapy), and/or EphA2 or EphA4 antibodies of the invention. In other embodiments, more than one prophylactic agent may be administered in combination.
  • a prophylactically effective amount refers to that amount of a therapy (e.g., a prophylactic agent) sufficient to result in the prevention of the onset, recurrence or spread of cell hyperproliferative disease, preferably, cancer.
  • a prophylactically effective amount may refer to the amount of a therapy (e.g., a prophylactic agent) sufficient to prevent the onset, recurrence or spread of hyperproliferative disease, particularly cancer, including but not limited to those predisposed to hyperproliferative disease, for example, those genetically predisposed to cancer or previously exposed to carcinogens.
  • a prophylactically effective amount may also refer to the amount of the therapy (e.g., a prophylactic agent) that provides a prophylactic benefit in the prevention of hyperproliferative disease.
  • a prophylactically effective amount with respect to a prophylactic agent of the invention means that amount of prophylactic agent alone, or in combination with other agents, that provides a prophylactic benefit in the prevention of hyperproliferative disease.
  • the term can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of or synergies with another therapy (e.g., a prophylactic agent).
  • a used herein, a "protocol” includes dosing schedules and dosing regimens.
  • side effects encompasses unwanted and adverse effects of a prophylactic or therapeutic agent. Adverse effects are always unwanted, but unwanted effects are not necessarily adverse. An adverse effect from a prophylactic or therapeutic agent might be harmful or uncomfortable or risky.
  • Side effects from chemotherapy include, but are not limited to, gastrointestinal toxicity such as, but not limited to, early and late-forming diarrhea and flatulence, nausea, vomiting, anorexia, leukopenia, anemia, neutropenia, asthenia, abdominal cramping, fever, pain, loss of body weight, dehydration, alopecia, dyspnea, insomnia, dizziness, mucositis, xerostomia, and kidney failure, as well as constipation, nerve and muscle effects, temporary or permanent damage to kidneys and bladder, flu-like symptoms, fluid retention, and temporary or permanent infertility.
  • Side effects from radiation therapy include but are not limited to fatigue, dry mouth, and loss of appetite.
  • Side effects from biological therapies/immunotherapies include but are not limited to rashes or swellings at the site of administration, flu-like symptoms such as fever, chills and fatigue, digestive tract problems and allergic reactions.
  • Side effects from hormonal therapies include but are not limited to nausea, fertility problems, depression, loss of appetite, eye problems, headache, and weight fluctuation. Additional undesired effects typically experienced by patients are numerous and known in the art. Many are described in the Physicians ' Desk Reference (58 th ed., 2004).
  • single-chain Fv or “scFv” refer to antibody fragments comprise the VH and VL domains of antibody, wherein these domains are present in a single polypeptide chain.
  • the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen binding.
  • scFvs include bi-specific scFvs and humanized scFvs.
  • a subject is preferably a mammal such as a non-primate (e.g., cows, pigs, horses, cats, dogs, rats etc.) and a primate (e.g., monkey and human), most preferably a human.
  • a non-primate e.g., cows, pigs, horses, cats, dogs, rats etc.
  • a primate e.g., monkey and human
  • targeting moiety refers to any moiety that, when linked to another agent (such as a delivery vehicle or another compound), enhances the transport of that agent to a target tissue or a subset of cells with a common characteristic, thereby increasing the local concentration of the agent in and around the targeted tissue or subset of cells.
  • a targeting moiety may bind to a molecule on the surface of some or all of the cells in the target tissue or cell subset.
  • a targeting moiety binds to EphA2 or EphA4.
  • a targeting moiety binds to EphA2 or EphA4 on cancer cells (e.g., EphA2 or EphA4 not bound to a ligand) rather than EphA2 or EphA4 on non-cancer cells (e.g., EphA2 or EphA4 bound to a ligand).
  • the terms “treat,” “treating” and “treatment” refer to the eradication, reduction or amelioration of symptoms of a disease or disorder, particularly, the eradication, removal, modification, or control of primary, regional, or metastatic cancer tissue that results from the administration of one or more therapeutic agents. In certain embodiments, such terms refer to the minimizing or delaying the spread of cancer resulting from the administration of one or more therapies (e.g., prophylactic or therapeutic agents) to a subject with such a disease.
  • therapies e.g., prophylactic or therapeutic agents
  • the term "therapeutic agent” refers to any agent that can be used in the prevention, treatment, or management of a disease or disorder associated with overexpression of EphA2, EphA4 and/or cell hyperproliferative diseases or disorders, particularly, cancer.
  • the term “therapeutic agent” refers to any composition comprising a therapeutically or prophylactically effective amount of (a) a delivery vehicle conjugated to (or otherwise associated with) a moiety that binds EphA2 and/or EphA4; (b) one or more therapeutic or prophylactic agents that treat or prevent said hyperproliferative disease; and (c) a pharmaceutically acceptable carrier.
  • the term "therapeutic agent” refers to an EphA2 or EphA4 agonistic antibody, an EphA2 or EphA4 cancer cell phenotype inhibiting antibody, an exposed EphA2 or EphA4 epitope antibody, or an antibody that binds EphA2 or EphA4 with a K 0ff of less than 3 X 10 "3 s "1 (e.g., Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152, EA44 or any of the antibodies listed in Table 1).
  • the term "therapeutic agent” refers to cancer chemotherapeutics, radiation therapy, hormonal therapy, biological therapy/immunotherapy, and/or EphA2 or EphA4 antibody of the invention. In other embodiments, more than one therapeutic agent may be administered in combination.
  • a "therapeutically effective amount” refers to that amount of a therapy (e.g., therapeutic agent) sufficient to treat or manage a disease or disorder associated with EphA2 or EphA4 overexpression and/or cell hyperproliferative disease and, preferably, the amount sufficient to destroy, modify, control or remove primary, regional or metastatic cancer tissue.
  • a therapeutically effective amount may refer to the amount of a therapy (e.g., therapeutic agent) sufficient to delay or minimize the onset of the hyperproliferative disease, e.g., delay or minimize the spread of cancer.
  • a therapeutically effective amount may also refer to the amount of the therapy (e.g., therapeutic agent) that provides a therapeutic benefit in the treatment or management of cancer.
  • a therapeutically effective amount with respect to a therapy (e.g., therapeutic agent) of the invention means that amount of therapeutic agent alone, or in combination with other therapies, that provides a therapeutic benefit in the treatment or management of hyperproliferative disease or cancer.
  • a therapy e.g., therapeutic agent
  • the term can encompass an amount that improves overall therapy, reduces or avoids unwanted effects, or enhances the therapeutic efficacy of or synergies with another therapy (e.g., therapeutic agent).
  • the term “therapy” refers to any protocol, method and/or agent that can be used in the prevention, treatment, management or amelioration of a hyperproliferative disorder.
  • the terms “therapies” and “therapy” refer to a biological therapy, supportive therapy, and/or other therapies useful in treatment, management, prevention, or amelioration of a hyperproliferative disorder or one or more symptoms thereof known to one of skill in the art such as medical personnel.
  • FIG. 1 Eph099B-208.261 can compete with EA2 for binding to EphA2 in a competitive ELISA assay.
  • the ability of labeled EA2 monoclonal antibody to bind EphA2- Fc was assayed by competitive ELISA in presence of either unlabeled monoclonal antibodies EA2 or Eph099B-208.261. Ratios of unlabeled to labeled antibody used in the assay are indicated on the x-axis.
  • EA2 is indicated by diamonds and Eph099B-208.261 is indicated by squares.
  • FIGS. 2A-2D EphA2 antibodies promote EphA2 tyrosine phosphorylation in MDA-MB-231 cells.
  • Monolayers of MDA-MB-231 cells were incubated in the presence of a single dose of 5 ⁇ g/ml (A, C) Eph099B-208.261 or (B, D) EA2 for the indicated time at 37°C.
  • Cell lysates were then immunoprecipitated with an EphA2-specific antibody, resolved by SDS-PAGE and subjected to Western blot analysis with a phosphotyrosine- specific antibody (A, B).
  • FIGS. 3A-3D EphA2 antibodies promote EphA2 degradation in MDA-
  • MB-231 cells Monolayers of MDA-MB-231 cells were incubated in the presence of a single dose of 5 ⁇ g/ml (A, C) Eph099B-208.261 or (B, D) EA2 for the indicated time at 37°C. Cell lysates were then resolved by SDS-PAGE and subjected to Western blot analysis with an EphA2-specific antibody (A, B). The membranes were stripped and re- probed with a ⁇ -catenin-specific antibody as a loading control (C, D). [0062] FIGS.
  • EphA2 Eph099B-233.152 antibody promotes EphA2 tyrosine phosphorylation and EphA2 degradation in MDA-MB-231 cells.
  • Monolayers of MDA-MB-231 cells were incubated in the presence of a single dose of 5 ⁇ g/ml Eph099B- 233.152 at 37°C.
  • Cell lysates were then immunoprecipitated with D7 (an EphA2-specific antibody), resolved by SDS-PAGE and subjected to Western blot analysis with (A) a phosphotyrosine-specific antibody or (B) an EphA2-specific antibody.
  • FIG. 5 EphA2 antibodies inhibit malignant tumor cell growth in soft agar.
  • Eph099B-208.261 black bar
  • EA2 white bar
  • EphA2 antibodies or a negative control antibody 1 A7 (gray bar) were incubated with malignant MDA-MB-231 tumor cells for the indicated time at 37°C in soft agar. Results are reported as colonies per high-powered field (HPF).
  • FIGS. 6A-6B EphA2 Eph099B-233.152 antibody inhibits tumor cell growth in vivo.
  • MDA-MB-231 cells were implanted subcutaneously into athymic mice. After the tumors had grown to an average volume of 100mm , mice were administered 6mg/ml Eph099B-233.152 or PBS control intraperitoneally twice a week for 3 weeks.
  • B Survival.
  • FIGS. 7A-7D The EphA2 antibodies, EA2, Eph099B-208.261 , and
  • MDA-MB-231 breast cancer cells were implanted (A) orthotopically or (B) subcutaneously into athymic mice.
  • A549 lung cancer cells were implanted subcutaneously into athymic mice. After the tumors had grown to an average volume of 100mm 3 , mice were administered 6 mg/kg of the indicated antibody or negative control (PBS or 1A7 antibody) intraperitoneally twice a week for 3 weeks. Tumor growth was assessed and expressed as a ratio of the tumor volume divided by initial tumor volume (100 mm 3 ).
  • D MDA-MB-231 breast cancer cells were implanted subcutaneously into athymic mice.
  • mice were administered 6 mg/kg of the indicated antibody or negative control intraperitoneally twice a week for 3 weeks. Total tumor volume was determined after sacrifice. Negative control is black, EA2 is white, Eph099B-208.261 is dark grey, and Eph099B-233.152 is light grey.
  • FIGS. 8A-8B EphA2 overexpression selectively increases malignant cell growth.
  • A lxlO 5 control (white bar) or MCF-7 EphA2 cells (black bar) were suspended in soft agar in the presence of 1 mg/ml 17 ⁇ -estradiol for 14 days prior to microscopic evaluation. EphA2 -transfected cells formed more colonies (47 colonies/high powered field (HPF)) than matched controls (1 colony/HPF; P ⁇ 0.01).
  • B Monolayer growth assays did not distinguish between the growth of control (white circles) and MCF-7 EphA2 cells (black squares).
  • FIGS. 9A-9B EphA2 overexpression increases tumorigenic potential.
  • Equal amounts of protein lysate, isolated from input cells or resected tumors (T) were evaluated by Western blot analyses with an EphA2 antibody (D7). The membranes were stripped and re-probed with a ⁇ -catenin-specific antibody as a loading control.
  • FIGS. 10A-10C EphA2 overexpression decreases estrogen dependence.
  • FIGS. 11 A-1 IB EphA2 overexpression decreases tamoxifen sensitivity.
  • (A) lxlO 5 MCF-7 or MCF-7 Ep ⁇ cells were suspended in soft agar in the presence of l ⁇ M tamoxifen (TAM) and or l ⁇ M 17 ⁇ -estradiol and colony formation was evaluated microscopically after 14 days.
  • FIGS. 12A-12F Estrogen receptor is expressed but functionally altered in
  • MCF _ 7 EphA2 cellg A ⁇ ER( ⁇ and ( ⁇ ) ER ⁇ leyels were evaluated in MCF-7 neo control cells and MCF-7 EphA2 cells by Western blot analyses with an EphA2-specific antibody (D7).
  • C, D The membranes were stripped and re-probed with a ⁇ -catenin-specific antibody as a loading control.
  • E, F Estrogen receptor activity was measured using a CAT reporter system, revealing comparable estrogen receptor activity in control and MCF-7 EphA2 cells. The average results from three experiments are graphed in (F).
  • E2 indicates estrogen treatment; TAM indicates tamoxifen treatment; % conversion indicates the amount of substrate converted from non-acetylated substrate (non-AC) to acetylated substrate (AC) by CAT enzyme.
  • FIGS. 13A-13C EphA2 agonistic antibody EA2 decreases malignant growth.
  • MCF-7 Ep ⁇ cells were incubated in the presence of 3 ⁇ g/ml of EA2 for the time indicated prior to sample extraction and Western blot analyses with an EphA2-specif ⁇ c antibody (D7).
  • D7 EphA2-specif ⁇ c antibody
  • B The membrane was stripped and re-probed with a ⁇ -catenin-specific antibody as a loading control.
  • C lxlO 5 control or MCF-7 EphA2 cells were suspended in soft agar in the presence or absence of tamoxifen (TAM, l ⁇ M) and EphA2 agonistic antibody (EA2, lO ⁇ g/ml). Note that EA2 increased the sensitivity of MCF-7 EphA2 cells to tamoxifen.
  • FIGS. 14A-14B Decreased EphA2 protein levels are sufficient to reduce tumor cell colonization of soft agar.
  • Monolayers of MDA-MB-231 cells were transfected with 2 ⁇ g/ml of EphA2 antisense or inverse antisense (IAS) oligonucleotides at 37°C for 24 hours.
  • A, B Western blot analysis of whole cell lysates with EphA2-specific D7 antibody confirms that transfection with antisense oligonucleotides decreases EphA2 protein levels (A).
  • the membranes were stripped and reprobed with paxillin antibodies as a loading control (B).
  • the relative mobility of molecular mass standards is shown on the left of panels A and B.
  • FIG. 15 Kinetic analysis of EphA2 monoclonal antibodies. BIACORETM
  • Eph099B-208.261 is indicated by a solid line
  • Eph099B-233.152 is indicated by a dotted line
  • EA2 is indicated by a dashed line
  • the negative control is indicated by squares.
  • FIGS. 16A-16D EphA2 EA2 antibody preferentially binds cancer cells.
  • Non-transformed MCF-10A (A, C) or transformed MDA-MB-231 (B, D) cells were incubated with 10 ⁇ g/ml (A, B) Eph099B-233.152 or (C, D) EA2 at 4°C prior to fixation and immunolabeling with fluorophore-conjugated anti-mouse IgG.
  • FIGS. 17A-17D EphA2 EA2 antibody preferentially binds EphA2 epitopes exposed by decreasing cell-cell contacts.
  • A, B Non-transformed MCF-10A cells were labeled with EA2 at 4°C either before (A) or after (B) treatment with EGTA and prior to fixation and immunolabeling with fluorophore-conjugated anti-mouse IgG.
  • C, D Non- transformed MCF-10A (C) or transformed MDA-MB-231 (D) cells were labeled with EA2 either before (middle) or after (top) treatment with EGTA. Control cells were incubated with secondary antibody alone (bottom). The amount of EA2-EphA2 binding was measured using flow cytometry.
  • FIGS. 18A-18B EphA2 EA2 epitope is distinct from Eph099B-233.152 epitope and ligand binding site.
  • EphA2- F c was incubated with and bound to immobilized Ephrin Al-F c . Labeled Ephrin Al-F c (black), EA2 (white) or Eph099B- 233.152 (grey) was incubated with the EphA2-Ephrin Al-F c complex and amount of binding was measured.
  • EphA2-F c was incubated with and bound to immobilized Ephrin Al-F c .
  • FIG. 19 Sequences of VL and VH of EphA2 antibodies.
  • Eph099B-208.261 Amino acid and nucleic acid sequences of Eph099B-208.261 (A) VL (SEQ ID NOs:l and 9, respectively) and (B) VH (SEQ ID NOs:5 and 13, respectively); Eph099B-233.152 (C) VL (SEQ ID NOs.:17 and 25, respectively) and (D) VH (SEQ ID NOs:21 and 29, respectively). Sequences of the CDRs are indicated.
  • FIG. 20 Sequences of VL and VH of EA2 and EA5 antibodies.
  • A Amino acid and nucleic acid sequences of EA2 VL (SEQ ID NOs:33 and 41, respectively);
  • B amino acid and nucleic acid sequences of EA2 VH (SEQ ID NOs:37 and 45, respectively);
  • C amino acid and nucleic acid sequences of EA5 VL;
  • D amino acid and nucleic acid sequences of EA5 VH. Sequences of the CDRs are indicated.
  • FIG. 21 Sequences of the EphA4 scFV clone EA44. The CDR, VH, and
  • VL domains are indicated.
  • Eph family receptor tyrosine kinases such as EphA2 and EphA4, are overexpressed in cancer cells and other hype ⁇ roliferative cells.
  • EphA2 a receptor tyrosine kinase
  • EphA2 and EphA4 are membrane associated proteins, they can be used as primary targets for delivering one or more therapeutic or prophylactic agents (including anti-EphA2 and anti-EphA4 agents) to cancer cells and other hype ⁇ roliferative cells.
  • the present invention provides methods for preventing, treating or managing a hype ⁇ roliferative disease, particular cancer, comprising administering one or more prophylactic or therapeutic agents effective to treat or prevent said hype ⁇ roliferative disease, which agents are associated with an EphA2 or EphA4 targeting moiety (i.e., EphA2-binding moiety or EphA4-binding moiety).
  • a delivery vehicle conjugated to (or otherwise associated with) an EphA2 -targeting moiety or conjugated to (or otherwise associated with) an EphA4-targeting moiety is used to deliver the prophylactic or therapeutic agents to hype ⁇ roliferative cells overexpressing EphA2 or EphA4.
  • an EphA2 or EphA4 targeting moiety is an EphA2 or EphA4 monoclonal antibody or EphA2 or EphA4 binding fragment thereof.
  • the agent that treats or prevents a hype ⁇ roliferative disease is an EphA2 or EphA4 monoclonal antibody.
  • EphA2 or EphA4 monoclonal antibodies can inhibit cancer cell proliferation and invasiveness by reducing the levels of EphA2 or EphA4 expression in these cancer cells. Decreased EphA2 or EphA4 activity selectively inhibits malignant cancer cell growth.
  • EphA2 or EphA4 can be achieved with EphA2 or EphA4 agonistic monoclonal antibodies.
  • this inhibition of cell growth and/or metastasis is achieved by stimulating (i.e., agonizing) EphA2 or EphA4 signaling thereby causing EphA2 or EphA4 phosphorylation which leads to the degradation of EphA2 or EphA4.
  • Cancer cell growth is decreased due to the decreased EphA2 or EphA4 levels and, therefore, the decreased ligand-independent EphA2 or EphA4 signaling.
  • EphA2 or EphA4 activity may also be achieved with EphA2 or EphA4 cancer cell phenotype inhibiting antibodies or antibodies that preferentially bind an EphA2 or EphA4 epitopes exposed on cancer cells but not non-cancer cells. Additionally, antibodies that bind EphA2 or EphA4 with a low K or ⁇ (e.g. , less than less than 3 X 10 " s " ) can also decrease EphA2 or EphA4 levels.
  • a low K or ⁇ e.g. , less than less than 3 X 10 " s "
  • the present invention relates to methods and compositions that provide for the treatment, inhibition, and management of diseases and disorders associated with overexpression of EphA2 or EphA4 and/or cell hype ⁇ roliferative diseases and disorders.
  • a particular aspect of the invention relates to methods and compositions containing an EphA2 or EphA4 targeting moiety in association with one or more agents that inhibit cancer cell proliferation and invasion, particularly those cancer cells that overexpress EphA2 or EphA4 such that the EphA2 or EphA4 targeting moiety directs the one or more agents to cells that express EphA2 or EphA4.
  • the present invention further relates to methods and compositions for the treatment, inhibition, or management of metastases of cancers of epithelial cell origin, especially human cancers of the breast, lung, skin, prostate, bladder, and pancreas, and renal cell carcinomas and melanomas.
  • Further compositions and methods of the invention include other types of active ingredients in combination with the EphA2 or EphA4 antibodies of the invention.
  • the methods of the invention are used to treat, prevent or manage other diseases or disorders associated with cell hype ⁇ roliferation, for example but not limited to asthma, psoriasis, restenosis, COPD, etc.
  • the present invention also relates to methods for the treatment, inhibition, and management of cancer or other hype ⁇ roliferative cell disorder or disease that has become partially or completely refractory to current or standard cancer treatment, such as chemotherapy, radiation therapy, hormonal therapy, and biological therapy.
  • an EphA2-targeting moiety is used to deliver one or more therapeutic or prophylactic agents against a hype ⁇ roliferative cell disease to hype ⁇ roliferative cells expressing EphA2 or EphA4.
  • the present invention provides a method of treating, preventing or managing a hype ⁇ roliferative cell disease comprising administering to a subject in need thereof a composition comprising (a) an EphA2 or EphA4 targeting moiety conjugated to or otherwise associated with a delivery vehicle, (b) one or more therapeutic or prophylactic agents against said hype ⁇ roliferative cell disease, wherein the agents are contained within, expressed by, conjugated to, or otherwise associated with the delivery vehicle, and (c) a pharmaceutically acceptable carrier.
  • the present invention provides a method of treating, preventing or managing a hype ⁇ roliferative cell disease comprising administering to a subject in need thereof a composition comprising a nucleic acid comprising a nucleotide sequence encoding an EphA2 or EphA4 targeting moiety and nucleotide sequences encoding one or more agents that treat or prevent the hype ⁇ roliferative cell disease.
  • the present invention provides a method of treating, preventing or managing a hype ⁇ roliferative cell disease comprising administering to a subject in need thereof a composition comprising an EphA2 or EphA4 targeting moiety and a nucleic acid comprising nucleotide sequences encoding one or more agents that treat or prevent the hype ⁇ roliferative cell disease.
  • an EphA2 or EphA4 targeting moiety of the invention is not conjugated directly to a therapeutic agent.
  • the invention also encompasses diagnostic methods using the EphA2 or
  • EphA4 targeting moieties of the invention to evaluate the efficacy of cancer treatment, either EphA2 or EphA4 based or not EphA2 or EphA4 based.
  • the diagnostic methods of the invention can also be used to prognose or predict cancer progression.
  • the diagnostic methods of the invention provide methods of imaging and localizing metastases and methods of diagnosis and prognosis using tissues and fluids distal to the primary tumor site (as well as methods using tissues and fluids of the primary tumor).
  • the diagnostic methods of the invention provide methods of imaging and localizing metastases and methods of diagnosis and prognosis in vivo.
  • the invention encompasses methods of screening for anti-cancer agents, particularly anti-metastatic cancer agents, by screening agents for the ability to decrease cell colonization in soft agar and/or tubular network formation in three-dimensional basement membrane and extracellular matrix preparations, such as MATRIGELTM.
  • the invention provides methods of screening for agents for the treatment and prevention of hype ⁇ roliferative diseases and disorders by assaying for the ability to reduce the extent of existing cell colonization in soft agar and/or tubular network formation in three-dimensional basement membrane.
  • the present inventors found that inhibition of cell colonization in soft agar and/or tubular network formation in MATRIGELTM is a far better indication of anti-metastatic activity and may identify potential anti-metastatic agents that would not have been identified by standard cell culture assays.
  • an anti-EphA2 or anti-EphA4 antibody can be used as an EphA2 or EphA4 targeting moiety, and/or an agent that inhibits EphA2 or EphA4 expression or activity.
  • Antibodies that can inhibit EphA2 or EphA4 expression or activity include, but are not limited to, antibodies (preferably monoclonal antibodies) or fragments thereof that immunospecifically bind to and agonize EphA2 or EphA4 signaling ("EphA2 agonistic antibodies” and "EphA4 agonistic antibodies”); inhibit a cancer cell phenotype, e.g., inhibit colony formation in soft agar or tubular network formation in a three-dimensional basement membrane or extracellular matrix preparation, such as MATRIGELTM ("cancer cell phenotype inhibiting antibodies”); preferentially bind epitopes on EphA2 or EphA4 that are selectively exposed or increased on cancer cells but not non-cancer cells ("exposed EphA2 epitope antibodies” and "exposed EphA4 epitope antibodies”); and/or bind EphA2 or EphA4 with a K 0ff of less than 3 X 10 "3 s "1 .
  • the antibody binds to the extracellular domain of EphA2 or EphA4 and, preferably, also agonizes EphA2 or EphA4, e.g., increases EphA2 or EphA4 phosphorylation and, preferably, causes EphA2 or EphA4 degradation.
  • the antibody binds to the extracellular domain of EphA2 or EphA4 and, preferably, also inhibits and, even more preferably, reduces the extent of (e.g., by cell killing mechanisms such as necrosis and apoptosis) colony formation in soft agar or tubular network formation in a three-dimensional basement membrane or extracellular matrix preparation.
  • the antibodies inhibit or reduce a cancer cell phenotype in the presence of another anti-cancer agent, such as a hormonal, biologic, chemotherapeutic or other agent.
  • another anti-cancer agent such as a hormonal, biologic, chemotherapeutic or other agent.
  • the antibody binds to the extracellular domain of EphA2 or EphA4 at an epitope that is exposed in a cancer cell but occluded in a non-cancer cell.
  • the antibody is not EA2 or EA5 (or humanized version thereof).
  • the antibody is not EA44 (or humanized version thereof).
  • the antibody binds to the extracellular domain of EphA2 or EphA4, preferably with a K 0ff of less than 3 X 10 "3 s "1 , more preferably less than 1 X 10 "3 s "1 .
  • the antibody binds to EphA2 or EphA4 with a K off of less than 5 X 10 "3 s “1 , less than 10 '3 s “1 , less than 8 X 10 "4 s “1 , less than 5 X 10 '4 s “1 , less than 10 "4 s “1 , less than 9 X 10 "5 s “1 , less than 5 X 10 "5 s “1 , less than 10 "5 s “1 , less than 5 X 10 "6 s “1 , less than 10 "6 s “1 , less than 10 "6 s “1 , less than 5 X 10 "7 s "1 , less than 10 "7 s “1 , less than 5 X 10 " V, less than 10 "8 s " ', less than 5 X 10 " V, less than 10 " V, or less than 10 "10 s “ '.
  • the antibody is Eph099B-102.147,
  • the antibody binds to an epitope bound by Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152, EA44 or any of the antibodies listed in Table 1 and/or competes for EphA2 or EphA4 binding with Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152, EA44 or any of the antibodies listed in Table 1, e.g. as assayed by ELISA or any other appropriate immunoassay (e.g., ELISA).
  • the antibody is EA2, EA3, EA4, or
  • the antibody binds to an epitope bound by EA2, EA3, EA4, or EA5 and/or competes for EphA2 binding with EA2, EA3, EA4, or EA5, e.g. as assayed by ELISA.
  • the antibody of the invention immunospecifically binds to and agonizes EphA2 signaling and/or preferentially binds an epitope on EphA2 that is selectively exposed or increased on cancer cells but not non-cancer cells and may or may not compete for binding with an EphA2 ligand, e.g., Ephrin Al.
  • the antibody is EA44.
  • the antibody binds to an epitope bound by EA44 and/or competes for EphA4 binding with EA44, e.g. as assayed by ELISA.
  • the antibody of the invention immunospecifically binds to and agonizes EphA4 signaling and/or preferentially binds an epitope on EphA4 that is selectively exposed or increased on cancer cells but not non-cancer cells and may or may not compete for binding with an EphA4 ligand, e.g., Ephrin Al, Ephrin A2, Ephrin A3, Ephrin A4, Ephrin A5, Ephrin B2 or Ephrin B3.
  • EphA4 ligand e.g., Ephrin Al, Ephrin A2, Ephrin A3, Ephrin A4, Ephrin A5, Ephrin B2 or Ephrin B3.
  • the antibody of the invention immunospecifically binds to and agonizes EphA2 signaling, inhibits a cancer cell phenotype, preferentially binds an epitope on EphA2 that is selectively exposed or increased on cancer cells but not non-cancer cells, and/or has a K 0 ff of less than 3 X 10 " s " and may or may not compete for binding with an EphA2 ligand, e.g., Ephrin Al .
  • the antibody of the invention immunospecifically binds to and agonizes EphA4 signaling, inhibits a cancer cell phenotype, preferentially binds an epitope on EphA4 that is selectively exposed or increased on cancer cells but not non-cancer cells, and/or has a K 0 ff of less than 3 X 10 " s " and may or may not compete for binding with an EphA4 ligand, e.g., Ephrin Al, Ephrin A2, Ephrin A3, Ephrin A4, Ephrin A5, Ephrin B2 or Ephrin B3.
  • EphA4 ligand e.g., Ephrin Al, Ephrin A2, Ephrin A3, Ephrin A4, Ephrin A5, Ephrin B2 or Ephrin B3.
  • Eph099B-210.248 have been deposited with the American Type Culture Collection (ATCC, P.O. Box 1549, Manassas, VA 20108) on August 7, 2002 under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Pu ⁇ oses of Patent Procedures, and assigned accession numbers PTA-4572, PTA-4573, and PTA-4574, respectively, and inco ⁇ orated by reference.
  • a hybridoma producing Eph099B- 233.152 has been deposited with the American Type Culture Collection (ATCC, P.O.
  • EA5.12) of the invention have been deposited with the American Type Culture Collection (ATCC, P.O. Box 1549, Manassas, VA 20108) on May 22, 2002 under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Pu ⁇ oses of Patent Procedures, and assigned accession numbers PTA-4380 and PTA-4381, respectively and inco ⁇ orated by reference.
  • the amino acid and nucleic acid sequences of EA2 and EA5 are shown in FIGS 20A-D.
  • the sequences of the EA2 and EA5 CDRs are indicated in Table 1.
  • the antibody is human or has been humanized.
  • EA44 amino acid and nucleic acid sequences of EA44 are shown in FIGS. 21 A- B.
  • the sequences of the EA44 CDRs are indicated in Table 1.
  • the antibody is human or has been humanized.
  • Antibodies of the invention include, but are not limited to, monoclonal antibodies, synthetic antibodies, recombinantly produced antibodies, intrabodies, BiTE molecules, multispecific antibodies (including bi-specific antibodies), human antibodies, humanized antibodies, chimeric antibodies, single-chain Fvs (scFv) (including bi-specific scFvs), single chain antibodies, Fab fragments, F(ab') fragments, disulfide-linked Fvs (sdFv), and epitope-binding fragments of any of the above.
  • antibodies used in the methods of the present invention include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds to EphA2 or EphA4 and is an agonist of EphA2 or EphA4, inhibits or reduces a cancer cell phenotype, preferentially binds an EphA2 or EphA4 epitope exposed on cancer cells but not non-cancer cells, and/or binds EphA2 or EphA4 with a K 0ff ⁇ f less than 3 X 10 " s " .
  • the immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgGi, IgG 2 , IgG 3 , IgG 4 , IgAi and IgA 2 ) or subclass of immunoglobulin molecule.
  • the antibodies used in the methods of the invention may be from any animal origin including birds and mammals (e.g., human, murine, donkey, sheep, rabbit, goat, guinea pig, camel, horse, or chicken).
  • the antibodies are human or humanized monoclonal antibodies.
  • "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from mice or other animals that express antibodies from human genes.
  • the antibodies used in the methods of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity.
  • Multispecific antibodies may immunospecifically bind to different epitopes of an EphA2 or EphA4 polypeptide or may immunospecifically bind to both an EphA2 or EphA4 polypeptide as well as a heterologous epitope, such as a heterologous polypeptide or solid support material.
  • WO 93/17715, WO 92/08802, WO 91/00360, and WO 92/05793 Tutt, et al., 1991, J. Immunol. 147:60-69; U.S. Patent Nos. 4,474,893, 4,714,681, 4,925,648, 5,573,920, and 5,601,819; and Kostelny et al., 1992, J. Immunol. 148:1547- 1553.
  • an antibody used in the methods of the present invention is EA2-EA5, Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152, EA44 or any of the antibodies listed in Table 1, or an antigen-binding fragment thereof (e.g., comprising a variable domain or one or more complementarity determining regions (CDRs) of the afore-mentioned antibodies of the invention; e.g., see Table 1).
  • an antigen-binding fragment thereof e.g., comprising a variable domain or one or more complementarity determining regions (CDRs) of the afore-mentioned antibodies of the invention; e.g., see Table 1.
  • an agonistic antibody used in the methods of the present invention binds to the same epitope as EA2-5, Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152, EA44 or any of the antibodies listed in Table 1 or competes with EA2-5, Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B- 233.152 or any of the antibodies listed in Table 1 for binding to EphA2, e.g., in an ELISA assay.
  • an agonistic antibody used in the methods of the present invention binds to the same epitope as EA44 or competes with EA44 or any of the antibodies listed in Table 1 for binding to EphA4, e.g., in an ELISA assay.
  • the present invention also encompasses antibodies or fragments thereof that immunospecifically bind to EphA2 and agonize EphA2, inhibit a cancer cell phenotype, preferentially bind an EphA2 epitope exposed in cancer cells, and/or bind EphA2 with a K 0ff of less than 3 X 10 " s " , said antibodies comprising a VH CDR having an amino acid sequence of any one of the VH CDRs of EA2-5, Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.l 52, or any of the antibodies listed in Table 1.
  • the present invention also encompasses the use of antibodies that immunospecifically bind to EphA2 and agonize EphA2, inhibit a cancer cell phenotype, preferentially bind an EphA2 epitope exposed in cancer cells, and/or bind EphA2 with a K 0ff of less than 3 X 10 "3 s "1 , said antibodies comprising a VL CDR having an amino acid sequence of any one of the VL CDRs of EA2-5, Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B- 233.152, or any of the antibodies listed in Table 1.
  • the present invention also encompasses the use of antibodies that immunospecifically bind to EphA2 and agonize EphA2, inhibit a cancer cell phenotype, preferentially bind an EphA2 epitope exposed in cancer cells, and/or bind EphA2 with a K o f f of less than 3 X 10 "3 s "1 , said antibodies comprising one or more VH CDRs and one or more VL CDRs of EA2-5, Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152, or any of the antibodies listed in Table 1.
  • the invention encompasses the use of antibodies that immunospecifically bind to EphA2 and agonize EphA2, inhibit a cancer cell phenotype, preferentially bind an EphA2 epitope exposed in cancer cells, and/or bind EphA2 with a K 0ff of less than 3 X 10 "3 s "1 , said antibodies comprising a VH CDRl and a VL CDRl ; a VH CDRl and a VL CDR2; a VH CDRl and a VL CDR3; a VH CDR2 and a VL CDRl ; VH CDR2 and VL CDR2; a VH CDR2 and a VL CDR3; a VH CDR3 and a VL CDRl ; a VH CDR3 and a VL CDR2; a VH CDR3 and a VL CDR3; a VH1 CDRl, a VH CDR2 and
  • the VH CDRl is SEQ ID NO:6 or 22; the VH CDR2 is SEQ ID NO:7 or 23; the VH CDR3 is SEQ ID NO:8 or 24; the VL CDRl is SEQ ID NO:2 or 18; the VL CDR2 is SEQ ID NO:3 or 19; and the VL CDR3 is SEQ ID NO:4 or 20 (see, e.g., Table 1).
  • the VH CDRl is SEQ ID NO:6; the VH CDR2 is SEQ ID NO:7; the VH CDR3 is SEQ ID NO:8; the VL CDRl is SEQ ID NO:2; the VL CDR2 is SEQ ID NO:3; and the VL CDR3 is SEQ ID NO:4.
  • the VH CDRl is SEQ ID NO:22; the VH CDR2 is SEQ ID NO:23; the VH CDR3 is SEQ ID NO:24; the VL CDRl is SEQ ID NO: 18; the VL CDR2 is SEQ ID NO: 19; and the VL CDR3 is SEQ ID NO:20.
  • the invention also encompasses any of the foregoing with one, two, three, four, or five amino acid substitutions, additions, or deletions that bind EphA2.
  • the present invention also encompasses antibodies or fragments thereof that immunospecifically bind to EphA4 and agonize EphA5, inhibit a cancer cell phenotype, preferentially bind an EphA5 epitope exposed in cancer cells, and/or bind EphA5 with a K 0ff of less than 3 X 10 "3 s "1 , said antibodies comprising a VH CDR having an amino acid sequence of any one of the VH CDRs of EA44 as listed in Table 1.
  • the present invention also encompasses the use of antibodies that immunospecifically bind to EphA4 and agonize EphA5, inhibit a cancer cell phenotype, preferentially bind an EphA5 epitope exposed in cancer cells, and/or bind EphA4 with a K 0 f ⁇ of less than 3 X 10 "3 s "1 , said antibodies comprising a VL CDR having an amino acid sequence of any one of the VL CDRs of EA44 as listed in Table 1.
  • the present invention also encompasses the use of antibodies that immunospecifically bind to EphA4 and agonize EphA5, inhibit a cancer cell phenotype, preferentially bind an EphA5 epitope exposed in cancer cells, and/or bind EphA5 with a K 0ff of less than 3 X 10 "3 s "1 , said antibodies comprising one or more VH CDRs and one or more VL CDRs of EA44 as listed in Table 1.
  • the invention encompasses the use of antibodies that immunospecifically bind to EphA4 and agonize EphA4, inhibit a cancer cell phenotype, preferentially bind an EphA4 epitope exposed in cancer cells, and/or bind EphA4 with a K 0ff of less than 3 X 10 "3 s "1 , said antibodies comprising a VH CDRl and a VL CDRl ; a VH CDRl and a VL CDR2; a VH CDRl and a VL CDR3; a VH CDR2 and a VL CDRl ; VH CDR2 and VL CDR2; a VH CDR2 and a VL CDR3; a VH CDR3 and a VL CDRl ; a VH CDR3 and a VL CDR2; a VH CDR3 and a VL CDR3; a VH1 CDRl , a VH CDR2;
  • the VH CDRl is SEQ ID NO: 115; the VH CDR2 is SEQ ID NO:l 16; the VH CDR3 is SEQ ID NO:l 17; the VL CDRl is SEQ ID NO: l 1 1 ; the VL CDR2 is SEQ ID NO:l 12; and the VL CDR3 is SEQ ID NO:l 13 (see, e.g., Table 1).
  • the invention also encompasses any of the foregoing with one, two, three, four, or five amino acid substitutions, additions, or deletions that bind EphA4.
  • an antibody that immunospecifically binds to EphA2 and agonizes EphA2, inhibits a cancer cell phenotype, preferentially binds an EphA2 epitope exposed in cancer cells, and/or binds EphA2 with a K 0ff of less than 3 X 10 "3 s "1 comprises a VH CDRl having the amino acid sequence of SEQ ID NO: 6 and a VL CDRl having the amino acid sequence of SEQ ID NO:2.
  • an antibody that immunospecifically binds to EphA2 and agonizes EphA2, inhibits a cancer cell phenotype, preferentially binds an EphA2 epitope exposed in cancer cells, and/or binds EphA2 with a K off of less than 3 X 10 '3 s "1 comprises a VH CDRl having the amino acid sequence of SEQ ID NO: 6 and a VL CDR2 having the amino acid sequence of SEQ ID NO: 3.
  • an antibody that immunospecifically binds to EphA2 and agonizes EphA2, inhibits a cancer cell phenotype, preferentially binds an EphA2 epitope exposed in cancer cells, and/or binds EphA2 with a K 0ff of less than 3 X 10 "3 s *1 comprises a VH CDRl having the amino acid sequence of SEQ ID NO:6 and a VL CDR3 having the amino acid sequence of SEQ ID NO :4.
  • an antibody that immunospecifically binds to EphA4 and agonizes EphA4, inhibits a cancer cell phenotype, preferentially binds an EphA4 epitope exposed in cancer cells, and/or binds EphA2 with a K 0ff of less than 3 X 10 "3 s "1 comprises a VH CDRl having the amino acid sequence of SEQ ID NO:l 15 and a VL CDRl having the amino acid sequence of SEQ ID NO:l 11.
  • an antibody that immunospecifically binds to EphA4 and agonizes EphA4, inhibits a cancer cell phenotype, preferentially binds an EphA4 epitope exposed in cancer cells, and/or binds EphA4 with a K 0ff of less than 3 X 10 "3 s "1 comprises a VH CDRl having the amino acid sequence of SEQ ID NO:l 15 and a VL CDR2 having the amino acid sequence of SEQ ID NO:l 12.
  • an antibody that immunospecifically binds to EphA4 and agonizes EphA4, inhibits a cancer cell phenotype, preferentially binds an EphA2 epitope exposed in cancer cells, and/or binds EphA2 with a K 0 ff of less than 3 X 10 "3 s "1 comprises a VH CDRl having the amino acid sequence of SEQ ID NO:l 15 and a VL CDR3 having the amino acid sequence of SEQ ID NO:l 13.
  • EphA2 and agonizes EphA2, inhibits a cancer cell phenotype, preferentially binds an EphA2 epitope exposed in cancer cells, and/or binds EphA2 with a K 0 ff of less than 3 X 10 "3 s "1 comprises a VH CDRl having the amino acid sequence of SEQ ID NO:22 and a VL CDRl having the amino acid sequence of SEQ ID NO: 18.
  • an antibody that immunospecifically binds to EphA2 and agonizes EphA2, inhibits a cancer cell phenotype, preferentially binds an EphA2 epitope exposed in cancer cells, and/or binds EphA2 with a K 0ff of less than 3 X 10 '3 s "1 comprises a VH CDRl having the amino acid sequence of SEQ ID NO:22 and a VL CDR2 having the amino acid sequence of SEQ ID NO: 19.
  • an antibody that immunospecifically binds to EphA2 and agonizes EphA2, inhibits a cancer cell phenotype, preferentially binds an EphA2 epitope exposed in cancer cells, and/or binds EphA2 with a K 0ff of less than 3 X 10 "3 s '1 comprises a VH CDRl having the amino acid sequence of SEQ ID NO:22 and a VL CDR3 having the amino acid sequence of SEQ ID NO:20.
  • an antibody that immunospecifically binds to EphA4 and agonizes EphA4, inhibits a cancer cell phenotype, preferentially binds an EphA4 epitope exposed in cancer cells, and/or binds EphA4 with a K 0ff of less than 3 X 10 "3 s "1 comprises a VH CDRl having the amino acid sequence of SEQ ID NO: 115 and a VL CDR2 having the amino acid sequence of SEQ ID NO:l 12.
  • an antibody that immunospecifically binds to EphA4 and agonizes EphA4, inhibits a cancer cell phenotype, preferentially binds an EphA4 epitope exposed in cancer cells, and/or binds EphA4 with a K 0ff of less than 3 X 10 "3 s "1 comprises a VH CDRl having the amino acid sequence of SEQ ID NO: 115 and a VL CDR3 having the amino acid sequence of SEQ ID NO:l 13.
  • EphA2 and agonizes EphA2, inhibits a cancer cell phenotype, preferentially binds an EphA2 epitope exposed in cancer cells, and/or binds EphA2 with a K 0ff of less than 3 X 10 "3 s "1 comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:7 and a VL CDRl having the amino acid sequence of SEQ ID NO:2.
  • an antibody that immunospecifically binds to EphA2 and agonizes EphA2, inhibits a cancer cell phenotype, preferentially binds an EphA2 epitope exposed in cancer cells, and/or binds EphA2 with a K 0ff of less than 3 X 10 "3 s "1 comprises a VH CDR2 having the amino acid sequence of SEQ ID NO: 7 and a VL CDR2 having the amino acid sequence of SEQ ID NO:3.
  • an antibody that immunospecifically binds to EphA2 and agonizes EphA2, inhibits a cancer cell phenotype, preferentially binds an EphA2 epitope exposed in cancer cells, and/or binds EphA2 with a K 0 ff of less than 3 X 10 "3 s "1 comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:7 and a VL CDR3 having the amino acid sequence of SEQ ID NO:4.
  • EphA4 and agonizes EphA4, inhibits a cancer cell phenotype, preferentially binds an EphA4 epitope exposed in cancer cells, and/or binds EphA4 with a K 0t ⁇ of less than 3 X 10 "3 s "1 comprises a VH CDR2 having the amino acid sequence of SEQ ID NO: 116 and a VL CDRl having the amino acid sequence of SEQ ID NO: 111.
  • an antibody that immunospecifically binds to EphA4 and agonizes EphA4, inhibits a cancer cell phenotype, preferentially binds an EphA4 epitope exposed in cancer cells, and/or binds EphA4 with a K 0ff of less than 3 X 10 '3 s '1 comprises a VH CDR2 having the amino acid sequence of SEQ ID NO: 116 and a VL CDR2 having the amino acid sequence of SEQ ID NO:l 12.
  • an antibody that immunospecifically binds to EphA4 and agonizes EphA4, inhibits a cancer cell phenotype, preferentially binds an EphA4 epitope exposed in cancer cells, and/or binds EphA4 with a K 0ff of less than 3 X 10 "3 s "1 comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:l 16 and a VL CDR3 having the amino acid sequence of SEQ ID NO:l 13.
  • EphA2 and agonizes EphA2, inhibits a cancer cell phenotype, preferentially binds an EphA2 epitope exposed in cancer cells, and/or binds EphA2 with a K 0ff of less than 3 X 10 "3 s "1 comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:23 and a VL CDRl having the amino acid sequence of SEQ ID NO: 18.
  • an antibody that immunospecifically binds to EphA2 and agonizes EphA2, inhibits a cancer cell phenotype, preferentially binds an EphA2 epitope exposed in cancer cells, and/or binds EphA2 with a K off of less than 3 X 10 "3 s '1 comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:23 and a VL CDR2 having the amino acid sequence of SEQ ID NO: 19.
  • an antibody that immunospecifically binds to EphA2 and agonizes EphA2, inhibits a cancer cell phenotype, preferentially binds an EphA2 epitope exposed in cancer cells, and/or binds EphA2 with a K 0 ff of less than 3 X 10 "3 s '1 comprises a VH CDR2 having the amino acid sequence of SEQ ID NO: 23 and a VL CDR3 having the amino acid sequence of SEQ ID NO:20.
  • EphA4 and agonizes EphA4, inhibits a cancer cell phenotype, preferentially binds an EphA4 epitope exposed in cancer cells, and/or binds EphA4 with a K 0 ff of less than 3 X 10 "3 s "1 comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:l 16 and a VL CDRl having the amino acid sequence of SEQ ID NO: 111.
  • an antibody that immunospecifically binds to EphA4 and agonizes EphA4, inhibits a cancer cell phenotype, preferentially binds an EphA4 epitope exposed in cancer cells, and/or binds EphA4 with a K 0 ff of less than 3 X 10 "3 s "1 comprises a VH CDR2 having the amino acid sequence of SEQ ID NO: 116 and a VL CDR2 having the amino acid sequence of SEQ ID NO:l 12.
  • an antibody that immunospecifically binds to EphA4 and agonizes EphA4, inhibits a cancer cell phenotype, preferentially binds an EphA4 epitope exposed in cancer cells, and/or binds EphA4 with a K 0ff of less than 3 X 10 "3 s '1 comprises a VH CDR2 having the amino acid sequence of SEQ ID NO: 116 and a VL CDR3 having the amino acid sequence of SEQ ID NO:l 13.
  • an antibody that immunospecifically binds to EphA2 and agonizes EphA2, inhibits a cancer cell phenotype, preferentially binds an EphA2 epitope exposed in cancer cells, and/or binds EphA2 with a K 0ff of less than 3 X 10 "3 s "1 comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:8 and a VL CDR2 having the amino acid sequence of SEQ ID NO:3.
  • an antibody that immunospecifically binds to EphA2 and agonizes EphA2, inhibits a cancer cell phenotype, preferentially binds an EphA2 epitope exposed in cancer cells, and/or binds EphA2 with a K 0ff of less than 3 X 10 "3 s "1 comprises a VH CDR3 having the amino acid sequence of SEQ ID NO: 8 and a VL CDR3 having the amino acid sequence of SEQ ID NO:4.
  • an antibody that immunospecifically binds to EphA4 and agonizes EphA4, inhibits a cancer cell phenotype, preferentially binds an EphA4 epitope exposed in cancer cells, and/or binds EphA4 with a K 0ff of less than 3 X 10 "3 s '1 comprises a VH CDR3 having the amino acid sequence of SEQ ID NO: 117 and a VL CDR2 having the amino acid sequence of SEQ ID NO:l 12.
  • an antibody that immunospecifically binds to EphA4 and agonizes EphA4, inhibits a cancer cell phenotype, preferentially binds an EphA4 epitope exposed in cancer cells, and/or binds EphA4 with a K 0ff of less than 3 X 10 "3 s "1 comprises a VH CDR3 having the amino acid sequence of SEQ ID NO: 117 and a VL CDR3 having the amino acid sequence of SEQ ID NO:l 13.
  • EphA2 and agonizes EphA2, inhibits a cancer cell phenotype, preferentially binds an EphA2 epitope exposed in cancer cells, and/or binds EphA2 with a K 0ff of less than 3 X 10 " s "1 comprises a VH CDR3 having the amino acid sequence of SEQ ID NO: 24 and a VL CDRl having the amino acid sequence of SEQ ID NO: 18.
  • an antibody that immunospecifically binds to EphA2 and agonizes EphA2, inhibits a cancer cell phenotype, preferentially binds an EphA2 epitope exposed in cancer cells, and/or binds EphA2 with a K 0ff of less than 3 X 10 " s " comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:24 and a VL CDR2 having the amino acid sequence of SEQ ID NO: 19.
  • an antibody that immunospecifically binds to EphA2 and agonizes EphA2, inhibits a cancer cell phenotype, preferentially binds an EphA2 epitope exposed in cancer cells, and/or binds EphA2 with a K 0 ff of less than 3 X 10 " s " comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:24 and a VL CDR3 having the amino acid sequence of SEQ ID NO:20.
  • an antibody that immunospecifically binds to EphA4 and agonizes EphA4, inhibits a cancer cell phenotype, preferentially binds an EphA4 epitope exposed in cancer cells, and/or binds EphA4 with a K off of less than 3 X 10 "3 s "1 comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:l 17 and a VL CDR2 having the amino acid sequence of SEQ ID NO:l 12.
  • an antibody that immunospecifically binds to EphA4 and agonizes EphA4, inhibits a cancer cell phenotype, preferentially binds an EphA4 epitope exposed in cancer cells, and/or binds EphA4 with a K 0ff of less than 3 X 10 "3 s "1 comprises a VH CDR3 having the amino acid sequence of SEQ ID NO: 1 17 and a VL CDR3 having the amino acid sequence of SEQ ID NO:l 13.
  • the antibodies used in the methods of the invention include derivatives that are modified, i.e, by the covalent attachment of any type of molecule to the antibody.
  • the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.
  • the present invention also provides antibodies of the invention or fragments thereof that comprise a framework region known to those of skill in the art.
  • the antibody of the invention or fragment thereof is human or humanized.
  • the antibody of the invention or fragment thereof comprises one or more CDRs from EA2-5, Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B- 233.152, or any of the antibodies listed in Table 1 (or any other EphA2 agonistic antibody or EphA2 cancer cell phenotype inhibiting antibody or an EphA2 antibody that binds EphA2 with a K 0 ff of less than 3 X 10 "3 s "1 ), binds EphA2, and, preferably, agonizes EphA2 and/or inhibits a cancer cell phenotype and/or binds EphA2 with a K 0ff of less than 3 X 10 "3 s "1
  • the antibody of the invention or fragment thereof comprises one or more CDRs from EA44 as listed in Table 1 (or any other EphA4 agonistic antibody or EphA4 cancer cell phenotype inhibiting antibody or an EphA4 antibody that binds EphA2 with a K 0ff of less than 3 X 10 " s " ), binds EphA4, and, preferably, agonizes EphA4 and/or inhibits a cancer cell phenotype and/or binds EphA4 with a K olf of less than 3 X 10 " V.
  • the present invention encompasses single domain antibodies, including camelized single domain antibodies (see e.g., Muyldermans et al., 2001 , Trends Biochem. Sci. 26:230; Nuttall et al., 2000, Cur. Pharm. Biotech. 1 :253; Reichmann and Muyldermans, 1999, J Immunol. Meth. 231 :25; International Publication Nos. WO 94/04678 and WO 94/25591 ; U.S. Patent No. 6,005,079; which are inco ⁇ orated herein by reference in their entireties).
  • the present invention provides single domain antibodies comprising two VH domains having the amino acid sequence of any of the VH domains of EA2-5, Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152, EA44 or any of the antibodies listed in Table 1 (or any other EphA2 or EphA4 agonistic antibody, EphA2 or EphA4 cancer cell phenotype inhibiting antibody, exposed EphA2 or EphA4 epitope antibody, or an EphA2 or EphA4 antibody that binds EphA2 or EphA4 with a K 0ff of less than 3 X 10 "3 s '1 ) with modifications such that single domain antibodies are formed.
  • the present invention also provides single domain antibodies comprising two VH domains comprising one or more of the VH CDRs of EA2-5, Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152, EA44 any of the antibodies listed in Table 1 (or any other EphA2 or EphA4 agonistic antibody, EphA2 or EphA4 cancer cell phenotype inhibiting antibody, exposed EphA2 or EphA4 epitope antibody, or an EphA2 or EphA4 antibody that binds EphA2 or EphA4 with a K 0t ⁇ of less than 3 X 10 " V).
  • the methods of the present invention also encompass the use of antibodies or fragments thereof that have half-lives (e.g., serum half-lives) in a mammal, preferably a human, of greater than 15 days, preferably greater than 20 days, greater than 25 days, greater than 30 days, greater than 35 days, greater than 40 days, greater than 45 days, greater than 2 months, greater than 3 months, greater than 4 months, or greater than 5 months.
  • half-lives e.g., serum half-lives
  • the increased half-lives of the antibodies of the present invention or fragments thereof in a mammal, preferably a human, result in a higher serum titer of said antibodies or antibody fragments in the mammal, and thus, reduce the frequency of the administration of said antibodies or antibody fragments and/or reduces the concentration of said antibodies or antibody fragments to be administered.
  • Antibodies or fragments thereof having increased in vivo half-lives can be generated by techniques known to those of skill in the art.
  • antibodies or fragments thereof with increased in vivo half-lives can be generated by modifying (e.g., substituting, deleting or adding) amino acid residues identified as involved in the interaction between the Fc domain and the FcRn receptor (see, e.g., International Publication Nos. WO 97/34631 and WO 02/060919, which are inco ⁇ orated herein by reference in their entireties).
  • Antibodies or fragments thereof with increased in vivo half-lives can be generated by attaching to said antibodies or antibody fragments polymer molecules such as high molecular weight polyethyleneglycol (PEG).
  • PEG high molecular weight polyethyleneglycol
  • PEG can be attached to said antibodies or antibody fragments with or without a multifunctional linker either through site-specific conjugation of the PEG to the N- or C- terminus of said antibodies or antibody fragments or via epsilon-amino groups present on lysine residues.
  • Linear or branched polymer derivatization that results in minimal loss of biological activity will be used.
  • the degree of conjugation will be closely monitored by SDS-PAGE and mass spectrometry to ensure proper conjugation of PEG molecules to the antibodies.
  • Unreacted PEG can be separated from antibody-PEG conjugates by, e.g., size exclusion or ion- exchange chromatography.
  • the present invention also encompasses the use of antibodies or antibody fragments comprising the amino acid sequence of one or both variable domains of EA2-5, Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152, EA44 any of the antibodies listed in Table 1 (e.g., one or more amino acid substitutions) in the variable regions.
  • mutations in these antibodies maintain or enhance the avidity and/or affinity of the antibodies for the particular antigen(s) to which they immunospecifically bind.
  • Standard techniques known to those skilled in the art e.g., immunoassays
  • assays can be used to assay the affinity of an antibody for a particular antigen.
  • Standard techniques known to those skilled in the art can be used to introduce mutations in the nucleotide sequence encoding an antibody, or fragment thereof, including, e.g., site-directed mutagenesis and PCR-mediated mutagenesis, which results in amino acid substitutions.
  • the derivatives include less than 15 amino acid substitutions, less than 10 amino acid substitutions, less than 5 amino acid substitutions, less than 4 amino acid substitutions, less than 3 amino acid substitutions, or less than 2 amino acid substitutions relative to the original antibody or fragment thereof.
  • the derivatives have conservative amino acid substitutions made at one or more predicted non-essential amino acid residues.
  • the present invention also encompasses antibodies or fragments thereof that immunospecifically bind to EphA2 and agonize EphA2 and/or inhibit a cancer cell phenotype, preferentially bind an EphA2 epitope exposed in cancer cells, and/or bind EphA2 with a K 0ff of less than 3 X 10 "3 s "1 , said antibodies or antibody fragments comprising an amino acid sequence of a variable light chain and/or variable heavy chain that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of the variable light chain and/or heavy chain of EA2-5, Eph099B- 102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152, or any of the antibodies listed in Table 1.
  • antibodies or antibody fragments of the invention immunospecifically bind to EphA2 and comprise an amino acid sequence of a variable light chain that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%), at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO:l or 17.
  • antibodies or antibody fragments of the invention immunospecifically bind to EphA2 and comprise an amino acid sequence of a variable heavy chain that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%o, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 5 or 21.
  • antibodies or antibody fragments of the invention immunospecifically bind to EphA2 and comprise an amino acid sequence of a variable light chain that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%), at least 85%, at least 90%, at least 95%, or at least 99%) identical to SEQ ID NO: 1 or 17 and a variable heavy chain that is at least 45%), at least 50%, at least 55%), at least 60%), at least 65%), at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%), or at least 99%) identical to SEQ ID NO:5 or 21.
  • the present invention also encompasses antibodies or fragments thereof that immunospecifically bind to EphA4 and agonize EphA4 and/or inhibit a cancer cell phenotype, preferentially bind an EphA4 epitope exposed in cancer cells, and/or bind EphA4 with a K 0ff of less than 3 X 10 " s " , said antibodies or antibody fragments comprising an amino acid sequence of a variable light chain and/or variable heavy chain that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%), at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of the variable light chain and/or heavy chain of EA44 listed in Table 1.
  • antibodies or antibody fragments of the invention immunospecifically bind to EphA4 and comprise an amino acid sequence of a variable light chain that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%), at least 70%), at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO:l 10.
  • antibodies or antibody fragments of the invention immunospecifically bind to EphA4 and comprise an amino acid sequence of a variable heavy chain that is at least 45%, at least 50%, at least 55%), at least 60%, at least 65%), at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99%> identical to SEQ ID NO:l 14.
  • antibodies or antibody fragments of the invention immunospecifically bind to EphA4 and comprise an amino acid sequence of a variable light chain that is at least 45%, at least 50%), at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO:l 10 and a variable heavy chain that is at least 45%., at least 50%), at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 114.
  • the present invention further encompasses antibodies or fragments thereof that immunospecifically bind to EphA2 and agonize EphA2 and/or inhibit a cancer cell phenotype, preferentially bind an EphA2 epitope exposed in cancer cells, and/or bind EphA2 with a K 0ff of less than 3 X 10 "3 s '1 , said antibodies or antibody fragments comprising an amino acid sequence of one or more CDRs that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 15%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of one or more CDRs of EA2-5, Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152, or any of the antibodies listed in Table 1.
  • antibodies or antibody fragments of the invention immunospecifically bind to EphA2 and comprise an amino acid sequence of a CDR that is at least 45%), at least 50%, at least 55%), at least 60%, at least 65%, at least 70%, at least 75%, at least 80%), at least 85%, at least 90%), at least 95%, or at least 99% identical to SEQ ID NO:2, 3, or 4.
  • antibodies or antibody fragments of the invention immunospecifically bind to EphA2 and comprise an amino acid sequence of a CDR that is at least 45%, at least 50%, at least 55%o, at least 60%), at least 65%, at least 70%, at least 75%, at least 80%, at least 85%), at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 18, 19, or 20.
  • antibodies or antibody fragments of the invention immunospecifically bind to EphA2 and comprise an amino acid sequence of a CDR that is at least 45%, at least 50%, at least 55%), at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO:6, 7, or 8.
  • antibodies or antibody fragments of the invention immunospecifically bind to EphA2 and comprise an amino acid sequence of a CDR that is at least 45%, at least 50%, at least 55%., at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO:22, 23, or 24.
  • the present invention further encompasses antibodies or fragments thereof that immunospecifically bind to EphA4 and agonize EphA4 and/or inhibit a cancer cell phenotype, preferentially bind an EphA4 epitope exposed in cancer cells, and/or bind EphA4 with a K 0ff of less than 3 X 10 "3 s "1 , said antibodies or antibody fragments comprising an amino acid sequence of one or more CDRs that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%), at least 85%o, at least 90%), at least 95%), or at least 99% identical to the amino acid sequence of one or more CDRs of EA44 listed in Table 1.
  • antibodies or antibody fragments of the invention immunospecifically bind to EphA4 and comprise an amino acid sequence of a CDR that is at least 45%, at least 50%, at least 55%), at least 60%, at least 65%, at least 70%, at least 15%, at least 80%, at least 85%, at least 90%), at least 95%, or at least 99%o identical to SEQ ID NO:l 11, 112 or 113.
  • antibodies or antibody fragments of the invention immunospecifically bind to EphA4 and comprise an amino acid sequence of a CDR that is at least 45%>, at least 50%, at least 55%, at least 60%>, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 1 15, 1 16 or 117.
  • the determination of percent identity of two amino acid sequences can be determined by any method known to one skilled in the art, including BLAST protein searches.
  • the present invention further encompasses antibodies or fragments thereof that immunospecifically bind to EphA2 and agonize EphA2 and/or inhibit a cancer cell phenotype, preferentially bind an EphA2 epitope exposed in cancer cells, and/or bind EphA2 with a K 0ff of less than 3 X 10 "3 s "1 , said antibodies or antibody fragments comprising an amino acid sequence of one or more CDRs comprising amino acid residue substitutions, deletions or additions as compared to SEQ ID NO: 2, 3, 4, 6, 7, 8, 18, 19, 20, 22, 23, or 24.
  • the antibody comprising the one or more CDRs comprising amino acid residue substitutions, deletions or additions may have substantially the same binding, better binding, or worse binding when compared to an antibody comprising one or more CDRs without amino acid residue substitutions, deletions or additions.
  • one, two, three, four, or five amino acid residues of the CDR have been substituted, deleted or added (i.e., mutated).
  • the present invention further encompasses antibodies or fragments thereof that immunospecifically bind to EphA4 and agonize EphA4 and/or inhibit a cancer cell phenotype, preferentially bind an EphA4 epitope exposed in cancer cells, and/or bind EphA4 with a K 0ff of less than 3 X 10 "3 s '1 , said antibodies or antibody fragments comprising an amino acid sequence of one or more CDRs comprising amino acid residue substitutions, deletions or additions as compared to SEQ ID NO: 111, 1 12, 113, 1 15, 1 16 or 117.
  • the antibody comprising the one or more CDRs comprising amino acid residue substitutions, deletions or additions may have substantially the same binding, better binding, or worse binding when compared to an antibody comprising one or more CDRs without amino acid residue substitutions, deletions or additions.
  • one, two, three, four, or five amino acid residues of the CDR have been substituted, deleted or added (i.e., mutated).
  • the present invention also encompasses the use of antibodies or antibody fragments that immunospecifically bind to EphA2 or EphA4 and agonize EphA2 or EphA4 and/or inhibit a cancer cell phenotype, preferentially bind epitopes on EphA2 or EphA4 that are selectively exposed or increased on cancer cells but not non-cancer cells and/or bind EphA2 or EphA4 with a K 0ff less than 3 X 10 '3 s "1 , where said antibodies or antibody fragments are encoded by a nucleotide sequence that hybridizes to the nucleotide sequence of EA2-5, Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152, EA44 any of the antibodies listed in Table 1 under stringent conditions.
  • the invention provides antibodies or fragments thereof that immunospecifically bind to EphA2 or EphA4 and agonize EphA2 or EphA4 and/or inhibit a cancer cell phenotype, preferentially bind an epitope on EphA2 that is selectively exposed or increased on cancer cells but not non-cancer cells and/or bind EphA2 or EphA4 with a K 0ff less than 3 X 10 "3 s "1 , said antibodies or antibody fragments comprising a variable light chain encoded by a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of the variable light chain of EA2-5, Eph099B-102.147, Eph099B- 208.261, Eph099B-210.248, Eph099B-233.152, EA44 any of the antibodies listed in Table 1.
  • the invention provides antibodies or fragments that immunospecifically bind to EphA2 and comprise a variable light chain encoded by a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO:9 or 25.
  • the invention provides antibodies or fragments thereof that immunospecifically bind to EphA2 and agonize EphA2 and/or inhibit a cancer cell phenotype, preferentially bind an epitope on EphA2 that is selectively exposed or increased on cancer cells but not non-cancer cells and/or bind EphA2 with a K 0ff less than 3 X 10 "3 s "1 , said antibodies or antibody fragments comprising a variable heavy chain encoded by a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of the variable heavy chain of EA2-5, Eph099B-102.147, Eph099B- 208.261, Eph099B-210.248, Eph099B-233.152, or any of the antibodies listed in Table 1.
  • the invention provides antibodies or fragments thereof that immunospecifically bind to EphA2 and comprise a variable heavy chain encoded by a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: 13 or 29.
  • antibodies or antibody fragments of the invention immunospecifically bind to EphA2 and comprise a variable light chain encoded by a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO:9 or 25 and a variable heavy chain encoded by a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: 13 or 29.
  • the invention provides antibodies or fragments that immunospecifically bind to EphA and comprise a variable light chain encoded by a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: 118.
  • the invention provides antibodies or fragments thereof that immunospecifically bind to EphA4 and agonize EphA4 and/or inhibit a cancer cell phenotype, preferentially bind an epitope on EphA4 that is selectively exposed or increased on cancer cells but not non-cancer cells and/or bind EphA4 with a K off less than 3 X 10 " s " , said antibodies or antibody fragments comprising a variable heavy chain encoded by a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of the variable heavy chain of EA44 listed in Table 1.
  • the invention provides antibodies or fragments thereof that immunospecifically bind to EphA4 and comprise a variable heavy chain encoded by a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: 122.
  • antibodies or antibody fragments of the invention immunospecifically bind to EphA4 and comprise a variable light chain encoded by a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: 118 and a variable heavy chain encoded by a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: 122.
  • the invention provides antibodies or fragments thereof that immunospecifically bind to EphA2 and agonize EphA2 and/or inhibit a cancer cell phenotype, preferentially bind an EphA2 epitope exposed on cancer cells but not non- cancer cells and/or bind EphA2 with a K 0ff less than 3 X 10 "3 s '1 , said antibodies or antibody fragments comprising one or more CDRs encoded by a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of one or more CDRs of EA2-5, Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152, or any of the antibodies listed in Table 1.
  • the antibodies or fragments of the invention immunospecifically bind to EphA2 and comprise a CDR encoded by a nucleotide sequence that hybridizes under stringent conditions the nucleotide sequence of SEQ ID NO: 10, 11, or 12.
  • the antibodies or fragments of the invention immunospecifically bind to E ⁇ hA2 and comprise a CDR encoded by a nucleotide sequence that hybridizes under stringent conditions the nucleotide sequence of SEQ ID NO:26, 27, or 28.
  • the antibodies or fragments of the invention immunospecifically bind to EphA2 and comprise a CDR encoded by a nucleotide sequence that hybridizes under stringent conditions the nucleotide sequence of SEQ ID NO: 14, 15, or 16.
  • the antibodies or fragments of the invention immunospecifically bind to EphA2 and comprise a CDR encoded by a nucleotide sequence that hybridizes under stringent conditions the nucleotide sequence of SEQ ID NO:30, 31, or 32.
  • the invention provides antibodies or fragments thereof that immunospecifically bind to EphA4 and agonize EphA4 and/or inhibit a cancer cell phenotype, preferentially bind an EphA4 epitope exposed on cancer cells but not non- cancer cells and/or bind EphA4 with a K 0ff less than 3 X 10 " s " , said antibodies or antibody fragments comprising one or more CDRs encoded by a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of one or more CDRs of EA44 listed in Table 1.
  • the antibodies or fragments of the invention immunospecifically bind to EphA4 and comprise a CDR encoded by a nucleotide sequence that hybridizes under stringent conditions the nucleotide sequence of SEQ ID NO: l 19, 120 or 121.
  • the antibodies or fragments of the invention immunospecifically bind to EphA2 and comprise a CDR encoded by a nucleotide sequence that hybridizes under stringent conditions the nucleotide sequence of SEQ ID NO: 123, 124 or 125.
  • Stringent hybridization conditions include, but are not limited to, hybridization to filter-bound DNA in 6X sodium chloride/sodium citrate (SSC) at about 45°C followed by one or more washes in 0.2X SSC/0.1% SDS at about 50-65°C, highly stringent conditions such as hybridization to filter-bound DNA in 6X SSC at about 45°C followed by one or more washes in 0.1X SSC/0.2%> SDS at about 60°C, or any other stringent hybridization conditions known to those skilled in the art (see, for example, Ausubel, F.M. et al., eds. 1989 Current Protocols in Molecular Biology, vol. 1 , Green Publishing Associates, Inc. and John Wiley and Sons, Inc., NY at pages 6.3.1 to 6.3.6 and 2.10.3).
  • SSC sodium chloride/sodium citrate
  • the present invention further encompasses antibodies or fragments thereof that immunospecifically bind to EphA2 and agonize EphA2 and/or inhibit a cancer cell phenotype, preferentially bind an EphA2 epitope exposed in cancer cells, and/or bind EphA2 with a K 0ff of less than 3 X 10 "3 s "1 , said antibodies or antibody fragments said antibodies or antibody fragments comprising one or more CDRs encoded by a nucleotide sequence of one or more CDRs comprising nucleic acid residue substitutions, deletions or additions as compared to SEQ ID NO: 10, 11, 12, 14, 15, 16, 26, 27, 28, 30, 31, or 32.
  • the antibody comprising the one or more CDRs comprising nucleic acid residue substitutions, deletions or additions may have substantially the same binding, better binding, or worse binding when compared to an antibody comprising one or more CDRs without nucleic acid residue substitutions, deletions or additions.
  • one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or fifteen nucleic acid residues of the CDR have been substituted, deleted or added (i.e., mutated).
  • the nucleic acid substitutions may or may not change the amino acid sequence of the mutated CDR.
  • the present invention further encompasses antibodies or fragments thereof that immunospecifically bind to EphA4 and agonize EphA42 and/or inhibit a cancer cell phenotype, preferentially bind an EphA4 epitope exposed in cancer cells, and/or bind EphA4 with a K 0ff of less than 3 X 10 "3 s "1 , said antibodies or antibody fragments said antibodies or antibody fragments comprising one or more CDRs encoded by a nucleotide sequence of one or more CDRs comprising nucleic acid residue substitutions, deletions or additions as compared to SEQ ID NO: 119, 120, 121, 123, 124 or 125.
  • the antibody comprising the one or more CDRs comprising nucleic acid residue substitutions, deletions or additions may have substantially the same binding, better binding, or worse binding when compared to an antibody comprising one or more CDRs without nucleic acid residue substitutions, deletions or additions.
  • one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or fifteen nucleic acid residues of the CDR have been substituted, deleted or added (i.e., mutated).
  • the nucleic acid substitutions may or may not change the amino acid sequence of the mutated CDR.
  • the antibody to be used with the invention binds to an intracellular epitope, i.e., is an intrabody.
  • An intrabody comprises at least a portion of an antibody that is capable of immunospecifically binding an antigen and preferably does not contain sequences coding for its secretion. Such antibodies will bind antigen intracellularly.
  • the intrabody comprises a single-chain Fv ("scFv"). scFvs are antibody fragments comprising the V H and V domains of antibody, wherein these domains are present in a single polypeptide chain.
  • the scFv polypeptide further comprises a polypeptide linker between the V H and V L domains which enables the scFv to form the desired structure for antigen binding.
  • a polypeptide linker between the V H and V L domains which enables the scFv to form the desired structure for antigen binding.
  • intrabodies of the invention retain at least about 75% of the binding effectiveness of the complete antibody (i.e., having the entire constant domain as well as the variable regions) to the antigen. More preferably, the intrabody retains at least 85%) of the binding effectiveness of the complete antibody. Still more preferably, the intrabody retains at least 90%> of the binding effectiveness of the complete antibody. Even more preferably, the intrabody retains at least 95% of the binding effectiveness of the complete antibody.
  • polynucleotides encoding variable region for both the V H and V chains of interest can be cloned by using, for example, hybridoma mRNA or splenic mRNA as a template for PCR amplification of such domains (Huse et al., 1989, Science 246:1276).
  • the polynucleotides encoding the V H and V L domains are joined by a polynucleotide sequence encoding a linker to make a single chain antibody (sFv).
  • the sFv typically comprises a single peptide with the sequence V H -linkerN L or V L -linker-VH.
  • the linker is chosen to permit the heavy chain and light chain to bind together in their proper conformational orientation (see for example, Huston, et al., 1991, Methods in Enzym. 203:46-121, which is inco ⁇ orated herein by reference).
  • the linker can span the distance between its points of fusion to each of the variable domains (e.g., 3.5 nm) to minimize distortion of the native Fv conformation.
  • the linker is a polypeptide of at least 5 amino acid residues, at least 10 amino acid residues, at least 15 amino acid residues, or greater.
  • the linker should not cause a steric interference with the V H and V domains of the combining site.
  • the linker is 35 amino acids or less, 30 amino acids or less, or 25 amino acids or less.
  • the linker is between 15-25 amino acid residues in length.
  • the linker is hydrophilic and sufficiently flexible such that the V H and V L domains can adopt the conformation necessary to detect antigen. Intrabodies can be generated with different linker sequences inserted between identical V H and V L domains. A linker with the appropriate properties for a particular pair of V H and V L domains can be determined empirically by assessing the degree of antigen binding for each. Examples of linkers include, but are not limited to, those sequences disclosed in Table 2.
  • intrabodies are expressed in the cytoplasm.
  • the intrabodies are localized to various intracellular locations.
  • specific localization sequences can be attached to the intrabody polypeptide to direct the intrabody to a specific location.
  • Intrabodies can be localized, for example, to the following intracellular locations: endoplasmic reticulum (Munro et al., 1987, Cell 48:899-907; Hangejorden et al., 1991, J. Biol. Chem.
  • nucleus (Lanford et al, 1986, Cell 46:575; Stanton et al.,1986, PNAS 83:1772; Harlow et al., 1985, Mol Cell Biol. 5:1605; Pap et al., 2002, Exp. Cell Res. 265:288-93); nucleolar region (Seomi et al., 1990, J. Virology 64:1803; Kubota et al., 1989, Biochem. Biophys. Res. Comm.
  • V H and V domains are made up of the immunoglobulin domains that generally have a conserved structural disulfide bond.
  • the intrabodies are expressed in a reducing environment (e.g., the cytoplasm), such a structural feature cannot exist. Mutations can be made to the intrabody polypeptide sequence to compensate for the decreased stability of the immunoglobulin structure resulting from the absence of disulfide bond formation.
  • the V H and/or V L domains of the intrabodies contain one or more point mutations such that their expression is stabilized in reducing environments (see Steipe et al., 1994, J. Mol. Biol.
  • the recombinantly expressed intrabody protein is administered to a patient.
  • Such an intrabody polypeptide must be intracellular to mediate a prophylactic or therapeutic effect.
  • the intrabody polypeptide is associated with a "membrane permeable sequence".
  • Membrane permeable sequences are polypeptides capable of penetrating through the cell membrane from outside of the cell to the interior of the cell. When linked to another polypeptide, membrane permeable sequences can also direct the translocation of that polypeptide across the cell membrane as well.
  • the membrane permeable sequence is the hydrophobic region of a signal peptide (see, e.g., Hawiger, 1999, Curr. Opin. Chem. Biol. 3:89-94; Hawiger, 1997, Curr. Opin. Immunol. 9:189-94; U.S. Patent Nos. 5,807,746 and 6,043,339, which are inco ⁇ orated herein by reference in their entireties).
  • the sequence of a membrane permeable sequence can be based on the hydrophobic region of any signal peptide.
  • the signal peptides can be selected, e.g., from the SIGPEP database (see e.g., von Heijne, 1987, Prot. Seq.
  • the membrane permeable sequence is preferably based on a signal peptide endogenous to that cell type.
  • the membrane permeable sequence is a viral protein (e.g., He ⁇ es Virus Protein VP22) or fragment thereof (see e.g., Phelan et al., 1998, Nat. Biotechnol. 16:440-3).
  • a membrane permeable sequence with the appropriate properties for a particular intrabody and/or a particular target cell type can be determined empirically by assessing the ability of each membrane permeable sequence to direct the translocation of the intrabody across the cell membrane.
  • Examples of membrane permeable sequences include, but are not limited to, those sequences disclosed in Table 4.
  • the membrane permeable sequence can be a derivative.
  • the amino acid sequence of a membrane permeable sequence has been altered by the introduction of amino acid residue substitutions, deletions, additions, and/or modifications.
  • a polypeptide may be modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc.
  • a derivative of a membrane permeable sequence polypeptide may be modified by chemical modifications using techniques known to those of skill in the art, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Further, a derivative of a membrane permeable sequence polypeptide may contain one or more non-classical amino acids. In one embodiment, a polypeptide derivative possesses a similar or identical function as an unaltered polypeptide. In another embodiment, a derivative of a membrane permeable sequence polypeptide has an altered activity when compared to an unaltered polypeptide. For example, a derivative membrane permeable sequence polypeptide can translocate through the cell membrane more efficiently or be more resistant to proteolysis.
  • the membrane permeable sequence can be attached to the intrabody in a number of ways.
  • the membrane permeable sequence and the intrabody are expressed as a fusion protein.
  • the nucleic acid encoding the membrane permeable sequence is attached to the nucleic acid encoding the intrabody using standard recombinant DNA techniques (see e.g., Rojas et al., 1998, Nat. Biotechnol. 16:370-5).
  • the membrane permeable sequence polypeptide is attached to the intrabody polypeptide after each is separately expressed recombinantly (see e.g., Zhang et al., 1998, PNAS 95:9184-9).
  • the polypeptides can be linked by a peptide bond or a non-peptide bond (e.g. with a crosslinking reagent such as glutaraldehyde or a thiazolidino linkage see e.g., Hawiger, 1999, Curr. Opin. Chem. Biol 3:89-94) by methods standard in the art.
  • the administration of the membrane permeable sequence-intrabody polypeptide can be by parenteral administration, e.g., by intravenous injection including regional perfusion through a blood vessel supplying the tissues(s) or organ(s) having the target cell(s), or by inhalation of an aerosol, subcutaneous or intramuscular injection, topical administration such as to skin wounds and lesions, direct transfection into, e.g., bone marrow cells prepared for transplantation and subsequent transplantation into the subject, and direcUransfection into an organ that is subsequently transplanted into the subject.
  • Further administration methods include oral administration, particularly when the complex is encapsulated, or rectal administration, particularly when the complex is in suppository form.
  • a pharmaceutically acceptable carrier includes any material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual along with the selected complex without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.
  • Conditions for the administration of the membrane permeable sequence- intrabody polypeptide can be readily be determined, given the teachings in the art (see e.g., Remington 's Pharmaceutical Sciences, 18 th Ed., E. W. Martin (ed.), Mack Publishing Co., Easton, Pa. (1990)). If a particular cell type in vivo is to be targeted, for example, by regional perfusion of an organ or section of artery /blood vessel, cells from the target tissue can be biopsied and optimal dosages for import of the complex into that tissue can be determined in vitro to optimize the in vivo dosage, including concentration and time length. Alternatively, culture cells of the same cell type can also be used to optimize the dosage for the target cells in vivo.
  • a polynucleotide encoding an intrabody is administered to a patient (e.g., as in gene therapy).
  • methods as described in Section 5.3 or 5.6.5 can be used to administer the polynucleotide of the invention.
  • the present invention encompasses the use of antibodies or fragments thereof recombinantly fused or chemically conjugated (including both covalent and non- covalent conjugations) to a heterologous agent to generate a fusion protein as both targeting moieties and anti-EphA2 or anti-EphA4 agents.
  • the heterologous agent may be a polypeptide (or portion thereof, preferably to a polypeptide of at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 or at least 100 amino acids), nucleic acid, small molecule (less than 1000 daltons), or inorganic or organic compound.
  • the fusion does not necessarily need to be direct, but may occur through linker sequences.
  • Antibodies fused or conjugated to heterologous agents may be used in vivo to detect, treat, manage, or monitor the progression of a disorder using methods known in the art. See e.g., International Publication WO 93/21232; EP 439,095; Naramura et al., 1994, Immunol. Lett. 39:91-99; U.S. Patent 5,474,981; Gillies et al., 1992, PNAS 89:1428-1432; and Fell et al., 1991, J. Immunol. 146:2446-2452, which are inco ⁇ orated by reference in their entireties.
  • the disorder to be detected, treated, managed, or monitored is malignant cancer that overexpresses EphA2 or EphA4.
  • the disorder to be detected, treated, managed, or monitored is a pre-cancerous condition associated with cells that overexpress EphA2 or EphA4.
  • the pre-cancerous condition is high-grade prostatic intraepithelial neoplasia (PIN), fibroadenoma of the breast, fibrocystic disease, or compound nevi.
  • PIN prostatic intraepithelial neoplasia
  • fibroadenoma of the breast fibrocystic disease
  • compound nevi compound nevi.
  • the heterologous polypeptides may be fused or conjugated to a Fab fragment, Fd fragment, Fv fragment, F(ab) 2 fragment, or portion thereof.
  • Methods for fusing or conjugating polypeptides to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603, 5,622,929, 5,359,046, 5,349,053, 5,447,851, and 5,1 12,946; EP 307,434; EP 367,166; International Publication Nos. WO 96/04388 and WO 91/06570; Ashkenazi et al., 1991, PNAS 88: 10535-10539; Zheng et al., 1995, J. Immunol. 154:5590-5600; and Vil et al., 1992, PNAS 89:11337- 11341 (said references inco ⁇ orated by reference in their entireties).
  • Eph099B-210.248, Eph099B-233.152 any of the antibodies listed in Table 1 or EA44 (or any other EphA2/EphA4 agonistic antibody or EphA2/ EphA4 cancer cell phenotype inhibiting antibody or exposed EphA2/ EphA4 epitope antibody or EphA2/ EphA4 antibody that binds EphA2 or EphA4 with a K 0ff of less than 3 X 10 "3 s "1 ), may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling").
  • DNA shuffling codon-shuffling
  • DNA shuffling may be employed to alter the activities of antibodies of the invention or fragments thereof (e.g., antibodies or fragments thereof with higher affinities and lower dissociation rates). See, generally, U.S. Patent Nos. 5,605,793; 5,81 1,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., 1997, Cwrr. Opinion Biotechnol. 8:724-33; Harayama, 1998, Trends Biotechnol 16:76; Hansson, et al., 1999, J.
  • Antibodies or fragments thereof, or the encoded antibodies or fragments thereof may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination.
  • One or more portions of a polynucleotide encoding an antibody or antibody fragment, which portions immunospecifically bind to EphA2 or EphA4 may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous agents.
  • antibodies of the present invention or fragments or variants thereof are conjugated to a marker sequence, such as a peptide, to facilitate purification.
  • the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 9131 1), among others, many of which are commercially available.
  • a pQE vector QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 9131 1
  • hexa-histidine provides for convenient purification of the fusion protein.
  • peptide tags useful for purification include, but are not limited to, the hemagglutinin "HA” tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., 1984, Cell 37:767) and the "flag" tag.
  • antibodies of the present invention or fragments or variants thereof are conjugated to a diagnostic or detectable agent.
  • Such antibodies can be useful for monitoring or prognosing the development or progression of a cancer as part of a clinical testing procedure, such as determining the efficacy of a particular therapy.
  • such antibodies can be useful for monitoring or prognosing the development or progression of a pre-cancerous condition associated with cells that overexpress EphA2 or EphA4 (e.g., high-grade prostatic intraepithelial neoplasia (PIN), fibroadenoma of the breast, fibrocystic disease ,or compound nevi).
  • EphA2 or EphA4 e.g., high-grade prostatic intraepithelial neoplasia (PIN), fibroadenoma of the breast, fibrocystic disease ,or compound nevi).
  • an exposed EphA2 or EphA4 epitope antibody is conjugated to a diagnostic or detectable agent.
  • diagnosis and detection can accomplished by coupling the antibody to detectable substances including, but not limited to various enzymes, such as but not limited to horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; prosthetic groups, such as but not limited to streptavidin biotin and avidin/biotin; fluorescent materials, such as but not limited to, umbelliferone, fluorescein, fluorescein isothiocynate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; luminescent materials, such as but not limited to, luminol; bioluminescent materials, such as but not limited to, luciferase, luciferin, and aequorin; radioactive materials, such as
  • antibodies of the present invention or fragments or variants thereof are conjugated to a therapeutic agent such as a cytotoxin, e.g., a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters.
  • a cytotoxin or cytotoxic agent includes any agent that is detrimental to cells.
  • Examples include paclitaxel, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1- dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, epirubicin, and cyclophosphamide and analogs or homologs thereof.
  • Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6- mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BCNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cisdichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti- mitotic agents (e.g.
  • antibodies of the present invention or fragments or variants thereof are conjugated to a therapeutic agent or drug moiety that modifies a given biological response.
  • Therapeutic agents or drug moieties are not to be construed as limited to classical chemical therapeutic agents.
  • the drug moiety may be a protein or polypeptide possessing a desired biological activity.
  • Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, cholera toxin, or diphtheria toxin; a protein such as tumor necrosis factor, ⁇ -interferon, ⁇ -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- ⁇ , TNF- ⁇ , AIM I (see, International Publication No. WO 97/33899), AIM II (see, International Publication No. WO 97/34911), Fas Ligand (Takahashi et al., 1994, J.
  • a toxin such as abrin, ricin A, pseudomonas exotoxin, cholera toxin, or diphtheria toxin
  • a protein such as tumor necrosis factor, ⁇ -interferon, ⁇ -interferon, nerve growth factor, platelet derived growth
  • a thrombotic agent or an anti-angiogenic agent e.g. , angiostatin or endostatin
  • a biological response modifier such as, for example, a lymphokine (e.g., interleukin- 1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-4 (“IL-4"), interleukin-6 ("IL-6"), interleukin-7 (“IL-7”), interleukin-9 (“IL-9”), interleukin- 15 (“IL-15”), interleukin- 12 (“IL-12”), granulocyte macrophage colony stimulating factor (“GM-CSF”), and granulocyte colony stimulating factor (“G-CSF”)), or a growth factor (e.g., growth hormone (“GH”)).
  • IL-1 interleukin- 1
  • IL-2 interleukin-2
  • IL-4 interleukin-4
  • IL-6 interleukin-6
  • IL-7 interleukin-7
  • IL-9 interleukin-9
  • antibodies of the present invention or fragments or variants thereof are conjugated to a therapeutic agent such as a radioactive materials or macrocyclic chelators useful for conjugating radiometal ions (see above for examples of radioactive materials).
  • the macrocyclic chelator is 1,4,7,10- tetraazacyclododecane-N,N',N",N"-tetraacetic acid (DOTA) which can be attached to the antibody via a linker molecule.
  • linker molecules are commonly known in the art and described in Denardo et al., 1998, Clin Cancer Res. 4:2483-90; Peterson et al., 1999, Bioconjug. Chem. 10:553; and Zimmerman et al., 1999, Nucl. Med. Biol. 26:943-50 each inco ⁇ orated by reference in their entireties.
  • the conjugated antibody is an EphA2 or EphA4 antibody that preferably binds an EphA2 or EphA4 epitope exposed on cancer cells but not on non-cancer cells (i.e., exposed EphA2 or EphA4 epitope antibody).
  • the conjugated antibody is not EA2 or EA4.
  • the conjugated antibody is not EA44.
  • Moieties can be conjugated to antibodies by any method known in the art, including, but not limited to aldehyde/Schiff linkage, sulphydryl linkage, acid-labile linkage, cis-aconityl linkage, hydrazone linkage, enzymatically degradable linkage (see generally Garnett, 2002, Adv. Drug Deliv. Rev. 53:171-216).
  • linker molecules are commonly known in the art and described in Denardo et al., 1998, Clin Cancer Res. 4:2483-90; Peterson et al., 1999, Bioconjug. Chem. 10:553; Zimmerman et al., 1999, Nucl. Med. Biol. 26:943-50; Garnett, 2002, Adv. Drug Deliv. Rev. 53: 171-216, each of which is inco ⁇ orated herein by reference in its entirety.
  • an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is inco ⁇ orated herein by reference in its entirety.
  • Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen.
  • solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.
  • bispecific T cell engagers are bispecific antibodies that can redirect T cells for antigen-specific elimination of targets.
  • a BiTE molecule has an antigen-binding domain that binds to a T cell antigen (e.g. CD3) at one end of the molecule and an antigen binding domain that will bind to an antigen on the target cell.
  • a T cell antigen e.g. CD3
  • a BiTE molecule was described in International Publication No. WO 99/54440, which is herein inco ⁇ orated by reference. This publication describes a novel single-chain multifunctional polypeptide that comprises binding sites for the CD 19 and CD3 antigens (CD19xCD3).
  • This molecule was derived from two antibodies, one that binds to CD 19 on the B cell and an antibody that binds to CD3 on the T cells.
  • the variable regions of these different antibodies are linked by a polypeptide sequence, thus creating a single molecule.
  • an antibody or ligand that immunospecifically binds a polypeptide of interest e.g., EphA2 and/or EphA4 will comprise a portion of the BiTE molecule.
  • V H and/or V L preferably a scFV
  • an antibody that binds a polypeptide of interest e.g., EphA2 and/or EphA4
  • an anti-CD3 binding portion such as that of the molecule described above, thus creating a BiTE molecule that targets the polypeptide of interest (e.g., EphA2 and/or EphA4).
  • the BiTE molecule can comprise a molecule that binds to other T cell antigens (other than CD3).
  • ligands and/or antibodies that immunospecifically bind to T-cell antigens like CD2, CD4, CD8, CD1 la, TCR, and CD28 are contemplated to be part of this invention.
  • These molecules can include the VH and/or VL portions of the antibody or natural ligands (for example LFA3 whose natural ligand is CD3).
  • the antibodies or fragments thereof can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.
  • Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof.
  • monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: Monoclonal Antibodies and T-Cell Hybridomas 563-681 (Elsevier, N.Y., 1981) (said references inco ⁇ orated by reference in their entireties).
  • the term “monoclonal antibody” as used herein is not limited to antibodies produced through hybridoma technology.
  • the term “monoclonal antibody” refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.
  • mice can be immunized with EphA2 or EphA4 (either the full length protein or a domain thereof, e.g., the extracellular domain or the ligand binding domain) and once an immune response is detected, e.g., antibodies specific for EphA2 or EphA4 are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution.
  • Hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.
  • monoclonal antibodies can be generated by culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with EphA2 or EphA4 or fragment thereof with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind EphA2 or EphA4.
  • Antibody fragments which recognize specific EphA2 or EphA4 epitopes may be generated by any technique known to those of skill in the art.
  • Fab and F(ab')2 fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments).
  • F(ab')2 fragments contain the variable region, the light chain constant region and the CHI domain of the heavy chain.
  • the antibodies of the present invention can also be generated using various phage display methods known in the art.
  • phage display methods functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them.
  • DNA sequences encoding VH and VL domains are amplified from animal cDNA libraries (e.g., human or murine cDNA libraries of lymphoid tissues).
  • the DNA encoding the VH and VL domains are recombined together with an scFv linker by PCR and cloned into a phagemid vector (e.g., p CANTAB 6 or pComb 3 HSS).
  • the vector is electroporated in E. coli and the E. coli is infected with helper phage.
  • Phage used in these methods are typically filamentous phage including fd and Ml 3 and the VH and VL domains are usually recombinantly fused to either the phage gene III or gene VIII.
  • Phage expressing an antigen binding domain that binds to the EphA2 epitope of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead.
  • Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., 1995, J. Immunol Methods 182:41-50; Ames et al., 1995, J.
  • Phage may be screened for EphA2 binding, particularly to the extracellular domain of EphA2 or EphA4.
  • Agonizing EphA2 or EphA4 activity e.g., increasing EphA2 or EphA4 phosphorylation, reducing EphA2 or EphA4 levels
  • cancer cell phenotype inhibiting activity e.g., reducing colony formation in soft agar or tubular network formation in a three-dimensional basement membrane or extracellular matrix preparation, such as MATRIGELTM
  • preferentially binding to an EphA2 or EphA4 epitope exposed on cancer cells but not non-cancer cells e.g., binding poorly to EphA2 or EphA4 that is bound to ligand in cell-cell contacts while binding well to EphA2 or EphA4 that is not bound to ligand or in cell-cell contacts
  • non-cancer cells e.g., binding poorly to EphA2 or EphA4 that is bound to ligand in cell-cell
  • the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described below.
  • Techniques to recombinantly produce Fab, Fab' and F(ab')2 fragments can also be employed using methods known in the art such as those disclosed in International Publication No.
  • PCR primers including VH or VL nucleotide sequences, a restriction site, and a flanking sequence to protect the restriction site can be used to amplify the VH or VL sequences in scFv clones.
  • VH constant region e.g., the human gamma 4 constant region
  • VL constant region e.g., human kappa or lambda constant regions.
  • the vectors for expressing the VH or VL domains comprise an EF-l ⁇ promoter, a secretion signal, a cloning site for the variable domain, constant domains, and a selection marker such as neomycin.
  • the VH and VL domains may also be cloned into one vector expressing the necessary constant regions.
  • the heavy chain conversion vectors and light chain conversion vectors are then co-transfected into cell lines to generate stable or transient cell lines that express full-length antibodies, e.g., IgG, using techniques known to those of skill in the art.
  • human or chimeric antibodies For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use human or chimeric antibodies. Completely human antibodies are particularly desirable for therapeutic treatment of human subjects.
  • Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also U.S. Patent Nos. 4,444,887 and 4,716,111; and International Publication Nos.
  • Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes.
  • the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells.
  • the human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes.
  • the mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the J H region prevents endogenous antibody production.
  • the modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice.
  • the chimeric mice are then be bred to produce homozygous offspring which express human antibodies.
  • the transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention.
  • Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology.
  • the human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation.
  • a chimeric antibody is a molecule in which different portions of the antibody are derived from different immunoglobulin molecules such as antibodies having a variable region derived from a non-human antibody and a human immunoglobulin constant region.
  • Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, 1985, Science 229:1202; Oi et al., 1986, BioTechniques 4:214; Gillies et al., 1989, J Immunol Methods 125:191-202; and U.S. Patent Nos. 6,311,415, 5,807,715, 4,816,567, and 4,816,397, which are inco ⁇ orated herein by reference in their entirety.
  • Chimeric antibodies comprising one or more CDRs from a non-human species and framework regions from a human immunoglobulin molecule can be produced using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; International Publication No. WO 91/09967; and U.S. Patent Nos. 5,225,539, 5,530,101, and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, 1991, Molecular Immunology 28(4/5):489-498; Studnicka et al., 1994, Protein Engineering 7:805; and Roguska et al, 1994, PNAS 91 :969), and chain shuffling (U.S.
  • a chimeric antibody of the invention immunospecifically binds EphA2 and comprises one, two, or three VL CDRs having an amino acid sequence of any of the VL CDRs of EA2-5, Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B- 233.152 within human framework regions.
  • a chimeric antibody of the invention immunospecifically binds EphA4 and comprises one, two, or three VL CDRs having an amino acid sequence of any of the VL CDRs of EA44 (as disclosed in U.S. Non- Provisional Application Serial No.
  • a chimeric antibody of the invention immunospecifically binds EphA2 and comprises a VL CDR having an amino acid sequence of SEQ ID NO: 2, 3, 4, 18, 19, or 20.
  • a chimeric antibody of the invention immunospecifically binds EphA2 and comprises one, two, or three VH CDRs having an amino acid sequence of any of the VH CDRs of EA2-5, Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, or Eph099B-233.152 within human framework regions.
  • a chimeric antibody of the invention immunospecifically binds EphA2 and comprises a VH CDR having an amino acid sequence of SEQ ID NO:6, 7, 8, 22, 23, or 24.
  • a chimeric antibody of the invention immunospecifically binds EphA4 and comprises one, two, or three VH CDRs having an amino acid sequence of any of the VH CDRs of EA44 (as disclosed in U.S. Non- Provisional Application Serial No. 10/863,729, filed June 7, 2004) within human framework regions.
  • a chimeric antibody of the invention immunospecifically binds EphA2 and comprises one, two, or three VL CDRs having an amino acid sequence of any of the VL CDRs of EA2-5, Eph099B-102.147, Eph099B- 208.261, Eph099B-210.248, or Eph099B-233.152 and further comprises one, two, or three VH CDRs having an amino acid sequence of any of the VH CDRs of EA2-5, Eph099B- 102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152 within human framework regions.
  • a chimeric antibody of the invention immunospecifically binds EphA4 and comprises one, two, or three VL CDRs having an amino acid sequence of any of the VL CDRs of EA44 and further comprises one, two, or three VH CDRs having an amino acid sequence of any of the VH CDRs of EA44 within human framework regions.
  • a chimeric antibody of the invention immunospecifically binds EphA2 and comprises a VL CDR having an amino acid sequence of SEQ ID NO: 2, 3, 4, 18, 19, or 20 and further comprises a VH CDR having an amino acid sequence of SEQ ID NO:6, 7, 8, 22, 23, or 24.
  • a chimeric antibody of the invention immunospecifically binds EphA2 and comprises three VL CDRs having an amino acid sequence of any of the VL CDRs of EA2-5, Eph099B- 102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152 and three VH CDRs having an amino acid sequence of any of the VH CDRs of EA2-5, Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152 within human framework regions.
  • a chimeric antibody of the invention immunospecifically binds EphA2 and comprises VL CDRs having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 3, 4, 18, 19, or 20 and further comprises VH CDRs having an amino acid sequence selected from the group consisting of SEQ ID NO:6, 7, 8, 22, 23, or 24.
  • framework residues in the framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding.
  • These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., U.S. Patent No. 5,585,089; and Riechmann et al., 1988, Nature 332:323, which are inco ⁇ orated herein by reference in their entireties.)
  • a humanized antibody is an antibody or its variant or fragment thereof which is capable of binding to a predetermined antigen and which comprises a framework region having substantially the amino acid sequence of a human immunoglobulin and a CDR having substantially the amino acid sequence of a non-human immunoglobulin.
  • a humanized antibody comprises substantially all of at least one, and typically two, variable domains in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin (i.e., donor antibody) and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence.
  • a humanized antibody also comprises at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • the antibody will contain both the light chain as well as at least the variable domain of a heavy chain.
  • the antibody also may include the CHI, hinge, CH2, CH3, and CH4 regions of the heavy chain.
  • the humanized antibody can be selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA and IgE, and any isotype, including IgGi, IgG 2 , IgG and IgG 4 .
  • the constant domain is a complement fixing constant domain where it is desired that the humanized antibody exhibit cytotoxic activity, and the class is typically IgGi. Where such cytotoxic activity is not desirable, the constant domain may be of the IgG 2 class.
  • the humanized antibody may comprise sequences from more than one class or isotype, and selecting particular constant domains to optimize desired effector functions is within the ordinary skill in the art.
  • the framework and CDR regions of a humanized antibody need not correspond precisely to the parental sequences, e.g., the donor CDR or the consensus framework may be mutagenized by substitution, insertion or deletion of at least one residue so that the CDR or framework residue at that site does not correspond to either the consensus or the import antibody. Such mutations, however, will not be extensive. Usually, at least 15% of the humanized antibody residues will correspond to those of the parental framework region (FR) and CDR sequences, more often 90%>, and most preferably greater than 95%o.
  • FR parental framework region
  • Humanized antibodies can be produced using variety of techniques known in the art, including but not limited to, CDR-grafting (European Patent No. EP 239,400; International Publication No. WO 91/09967; and U.S. Patent Nos. 5,225,539, 5,530,101, and 5,585,089), veneering or resurfacing (European Patent Nos. EP 592,106 and EP 519,596; Padlan, 1991, Molecular Immunology 28(4/5):489-498; Studnicka et al., 1994, Protein Engineering 7(6):805-814; and Roguska et al., 1994, PNAS 91 :969-973), chain shuffling (U.S. Patent No.
  • framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; and Riechmann et al., 1988, Nature 332:323, which are inco ⁇ orated herein by reference in their entireties.)
  • the antibodies of the invention can, in turn, be utilized to generate anti-idiotype antibodies using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, 1989, FASEB J. 7:437-444; and Nissinoff, 1991, J Immunol. 147:2429-2438).
  • the invention provides methods employing the use of polynucleotides comprising a nucleotide sequence encoding an antibody of the invention or a fragment thereof.
  • the methods of the invention also encompass polynucleotides that hybridize under high stringency, intermediate or lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody of the invention.
  • the polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art.
  • nucleotide sequences encoding these antibodies can be determined using methods well known in the art, i.e., nucleotide codons known to encode particular amino acids are assembled in such a way to generate a nucleic acid that encodes the antibody or fragment thereof of the invention.
  • Such a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., 1994, BioTechniques 17:242), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.
  • chemically synthesized oligonucleotides e.g., as described in Kutmeier et al., 1994, BioTechniques 17:242
  • oligonucleotides e.g., as described in Kutmeier et al., 1994, BioTechniques 17:242
  • a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody is known (e.g., see FIG.
  • a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention, e.g., clones deposited in the ATCC as PTA-4572, PTA-4573, PTA-4574, PTA- 4380, PTA-4381) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the primer
  • nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc.
  • one or more of the CDRs is inserted within framework regions using routine recombinant DNA techniques.
  • the framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., 1998, J. Mol Biol. 278: 457-479 for a listing of human framework regions).
  • the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds to EphA2 or EphA4.
  • one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen.
  • Such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibodies lacking one or more intrachain disulfide bonds.
  • Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.
  • an antibody of the invention e.g., a heavy or light chain of an antibody of the invention or a portion thereof or a single chain antibody of the invention
  • an expression vector containing a polynucleotide that encodes the antibody Once a polynucleotide encoding an antibody or a heavy or light chain of an antibody, or portion thereof (preferably, but not necessarily, containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the antibody may be produced by recombinant DNA technology using techniques well known in the art.
  • a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination.
  • the invention thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody of the invention, a heavy or light chain of an antibody, a heavy or light chain variable domain of an antibody or a portion thereof, or a heavy or light chain CDR, operably linked to a promoter.
  • Such vectors may include the nucleotide sequence encoding the constant region of the antibody (see, e.g., International Publication Nos. WO 86/05807 and WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy, the entire light chain, or both the entire heavy and light chains.
  • the expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention.
  • the invention includes host cells containing a polynucleotide encoding an antibody of the invention or fragments thereof, or a heavy or light chain thereof, or portion thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter.
  • vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.
  • a variety of host-expression vector systems may be utilized to express the antibodies of the invention (see, e.g., U.S.
  • Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody of the invention in situ.
  • These include but are not limited to microorganisms such as bacteria (e.g., E. coli and B.
  • subtilis transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., Saccharomyces Pichia) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, NS0, and 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter)
  • bacterial cells such as Escherichia coli, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody, are used for the expression of a recombinant antibody.
  • mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., 1986, Gene 45:101 ; and Cockett et al., 1990, BioTechnology 8:2).
  • the expression of nucleotide sequences encoding antibodies or fragments thereof which immunospecifically bind to ⁇ phA2 or EphA4 and agonize EphA2 or EphA4, inhibit a cancer cell phenotype, preferentially bind epitopes on EphA2 or EphA4 that are selectively exposed or increased on cancer cells but not non-cancer cells and/or have a K 0 ff less than 3 X 10 "3 s "1 is regulated by a constitutive promoter, inducible promoter or tissue specific promoter.
  • a number of expression vectors may be advantageously selected depending upon the use intended for the antibody being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable.
  • vectors include, but are not limited to, the E. coli expression vector pUR278 (Ruther et al., 1983, EMBO 12:1791), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, 1985, Nucleic Acids Res.
  • pG ⁇ X vectors may also be used to express foreign polypeptides as fusion proteins with glutathione 5-transferase (GST).
  • GST glutathione 5-transferase
  • fusion proteins are soluble and can easily be purified from lysed cells by adso ⁇ tion and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione.
  • the pG ⁇ X vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.
  • AcNPV is used as a vector to express foreign genes.
  • the virus grows in Spodoptera frugiperda cells.
  • the antibody coding sequence may be cloned individually into non- essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).
  • a number of viral-based expression systems may be utilized.
  • the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination.
  • Insertion in a non-essential region of the viral genome will result in a recombinant virus that is viable and capable of expressing the antibody in infected hosts (e.g., see Logan & Shenk, 1984, PNAS 8 1 :6355-6359).
  • Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert.
  • These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic.
  • telomeres may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein.
  • Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed.
  • eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used.
  • mammalian host cells include but are not limited to CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, W138, BT483, Hs578T, HTB2, BT2O, NS1 and T47D, NS0 (a murine myeloma cell line that does not endogenously produce any immunoglobulin chains), CRL7O3O and HsS78Bst cells.
  • cell lines which stably express the antibody may be engineered.
  • host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker.
  • appropriate expression control elements e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.
  • engineered cells may be allowed to grow for 1 -2 days in an enriched media, and then are switched to a selective media.
  • the selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines.
  • This method may advantageously be used to engineer cell lines which express the antibody.
  • engineered cell lines may be particularly useful in screening and evaluation of compositions that interact directly or indirectly with the antibody.
  • a number of selection systems may be used, including but not limited to, the he ⁇ es simplex virus thymidine kinase (Wigler et al., 1977, Cell 1 1 :223), glutamine synthetase, hypoxanthine guanine phosphonbosyltransferase (Szybalska & Szybalski, 1992, Proc. Natl. Acad. Sci. USA 48:202), and adenine phosphonbosyltransferase (Lowy et al., 1980, Cell 22:8-17) genes can be employed in tk-, gs-, hgprt- or aprt- cells, respectively.
  • antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., 1980, PNAS 77:357; O'Hare et al., 1981, PNAS 78: 1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, PNAS 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Wu and Wu, 1991, Biotherapy 3:87; Tolstoshev, 1993, Ann. Rev. Pharmacol. Toxicol. 32:573; Mulligan, 1993, Science 260:926; and Morgan and Anderson, 1993, Ann. Rev.
  • the expression levels of an antibody can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol.3. (Academic Press, New York, 1987)).
  • vector amplification for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol.3. (Academic Press, New York, 1987)).
  • a marker in the vector system expressing antibody is amplifiable
  • increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., 1983, Mol Cell. Biol. 3:257).
  • the host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide.
  • the two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides.
  • a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, 1986, N ⁇ twre 322:52; and Kohler, 1980, PNAS 77:2197).
  • the coding sequences for the heavy and light chains may comprise cD ⁇ A or genomic D ⁇ A.
  • an antibody of the invention may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins.
  • chromatography e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography
  • centrifugation e.g., centrifugation, differential solubility, or by any other standard technique for the purification of proteins.
  • the antibodies of the present invention or fragments thereof may be fused to heterologous polypeptide sequences described herein or otherwise known in the art to facilitate purification.
  • moieties that bind to cells expressing EphA2 and/or EphA4 can be used to target agents that treat or prevent a hype ⁇ roliferative cell disease associated with overexpression of EphA2 and/or EphA4 to such cells.
  • targeting moieties that bind to EphA2 are used.
  • targeting moieties that bind to EphA4 are used.
  • EphA2 or EphA4 targeting moieties are all or an EphA2/EphA4 binding portion of its ligand, e.g., Ephrin Al, and an anti-EphA2 or anti-EphA4 antibody (particularly that bind the extracellular domain, i.e., EphA2 or EphA4 on the cell surface).
  • moieties bind to EphA2 or EphA4 on cancer cells (e.g., EphA2 or EphA4 not bound to ligand) rather than EphA2 or EphA4 on non-cancer cells (e.g., EphA2 or EphA4 bound to ligand) are used in accordance with the present invention.
  • Ephrin Al Fc or Ephrin Al Fc fused to another peptide is used in accordance with the present invention.
  • the EphA2 or EphA4 targeting moiety is not Ephrin Al or a fragment thereof, or is not Ephrin Al Fc.
  • the EphA2 and/or EphA4 targeting moieties bind to EphA2 and/or EphA4 on hype ⁇ roliferative cells, particularly cancer cells, as opposed to EphA2 and/or EphA4 on non-hype ⁇ roliferative (i.e., non-cancer cells) or non-EphA2 and/or non-EphA4 antigens, with at least, 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%), at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%, or at least 1.5 fold, at least 2 fold, at least 2.5 fold, at least 3 fold, at least 3.5 fold, at least 4 fold, at least 4.5, at least 5 fold, at least 7 fold or at least 10 fold relative higher relative to a control (e.g., phosphate buffered saline or
  • a nucleic acid molecule can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., International Publication Nos. WO 92/06180; WO 92/22635; WO 92/20316; WO 93/14188, WO 93/20221), preferably, by targeting EphA2 or EphA4.
  • an EphA2 or EphA4 targeting moiety used in the ⁇ compositions and methods of the invention is any one of the peptides disclosed in Table 1 of U.S. Patent Publication No. US 2004/0180823 Al (Sep. 16, 2004) by Pasquale et al or International Publication No. WO 2004/028551 Al (April 8, 2004) by Pasquale et al. that bind to EphA2 and/or EphA4.
  • a targeting moiety of the invention is not any of the peptides disclosed in U.S. Patent Publication No. US 2004/0180823 Al (Sep. 16, 2004) by Pasquale et al or International Publication No. WO 2004/028551 Al (April 8, 2004) by Pasquale et al.
  • the agents that inhibit or reduce EphA2 or EphA4 expression or function as described in Section 5.1 may preferentially bind to EphA2 or EphA4, and thus can also be used as targeting moieties to direct another substance (such as a delivery vehicle or another compound) to cells that expressing EphA2 and/or EphA4.
  • a nucleic acid can be a target moiety and used in vivo for cell specific uptake and expression, by targeting a specific receptor, preferably EphA2 or EphA4.
  • a specific receptor preferably EphA2 or EphA4.
  • any substance that has preference for cancer cells or non-cancer hype ⁇ roliferative cells that express EphA2 or EphA4 can be used to direct a therapeutic or prophylactic agent to such cells in accordance with the present invention.
  • targeting moieties can be, but are not limited to, antibodies or fragments thereof, receptors, ligands, peptides and other molecules that bind to cells of, or in the vicinity of, the target tissue.
  • An antibody targeting moiety may be an intact (whole) molecule, a fragment thereof, or a functional equivalent thereof. Examples of antibody fragments are F(ab')2, Fab', Fab, Fv fragments and single chain Fvs, which may be produced by conventional methods or by genetic or protein engineering.
  • a targeting moiety in accordance with the present invention specifically targets EphA2 or EphA4. EphA2 monoclonal antibodes are disclosed in the U.S. Patent Application Nos.
  • a targeting moiety is any polypeptide (or fragment thereof) that is a natural ligand of EphA2 (e.g., Ephrin Al) or EphA4 (e.g., Ephrin Al, -A2, -A3, -A4, -A5, -B2 and -B3).
  • EphA2 e.g., Ephrin Al
  • EphA4 e.g., Ephrin Al, -A2, -A3, -A4, -A5, -B2 and -B3
  • the amino acid sequences for Ephrin A1-B3 may be found, for example, in any publicly available database, such as GenBank.
  • a targeting moiety of the invention is an Ephrin
  • Ephrin Al Fragment preferably retains the ability to bind to EphA2 or EphA4.
  • an Ephrin Al Fragment of the invention agonizes EphA2 and/or EphA4 signaling.
  • EphA2 or EphA4 signaling may be measured to determine whether EphA2 or EphA4 signaling is activated upon ligand binding by measuring the amount of phosphorylated EphA2 or EphA4 present in Ephrin A 1 -treated cells relative to control cells that are not treated with Ephrin Al .
  • EphA2 or EphA4 may be isolated using any protein immunoprecipitation method known to one of skill in the art and an EphA2 or EphA4 antibody of the invention.
  • Phosphorylated EphA2 or EphA4 may then be measured using anti-phosphotyrosine antibodies (Upstate Tiotechnology, Inc., Lake Placid, New York) using any standard immunoblotting method known to one of skill in the art. See, e.g., Cheng et al., 2002, Cytokine & Growth Factor Rev. 13:75-85.
  • MAPK phosphorylation may be measured to determine whether EphA2 or EphA4 signaling is activated upon ligand binding by measuring the amount of phosphorylated MAPK present in Ephrin A 1 -treated cells relative to control cells that are not treated with Ephrin Al using standard immunoprecipitation and immunoblotting assays known to one of skill in the art (see, e.g., Miao et al, 2003, J. Cell Biol. 7:1281-1292, which is inco ⁇ orated by reference herein in its entirety).
  • Ephrin Al Fragments include, but are not limited to, any fragment of human Ephrin Al as disclosed in the GenBank database (e.g., GenBank Accession Nos. NP_004419 (variant 1) and NP_872626 (variant 2)).
  • an Ephrin Al Fragment is soluble (i.e., not membrane-bound).
  • an Ephrin Al Fragment of the invention comprises the extracellular domain of human Ephrin Al or a portion thereof.
  • an Ephrin Al Fragment of the invention comprises the extracellular domain of human Ephrin Al or a fragment thereof and is not membrane-bound.
  • an Ephrin Al Fragment of the invention comprises specific fragments of the extracellular domain of human Ephrin Al variant 1 or a fragment thereof and is not membrane bound. In other specific embodiments, an Ephrin Al Fragment of the invention comprises specific fragments of the extracellular domain of human Ephrin Al variant 2 or a fragment thereof and is not membrane-bound. [00204] The Ephrin Al Fragments include polypeptides that are 100%, 98%, 95%,
  • Ephrin Al Fragments of the invention can be analogs or derivatives of Ephrin Al.
  • Ephrin Al Fragments of the invention include derivatives that are modified, i.e., by covalent attachment of any type of molecule to the polypeptide.
  • the polypeptide derivatives include polypeptides that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.
  • a targeting moiety of the invention is an
  • Ephrin Al fusion protein may be soluble (e.g., not membrane-bound).
  • Ephrin Al fusion proteins include soluble forms of Ephrin Al such as Ephrin Al Fc (see, e.g., Duxbury et al., 2004, Biochem. & Biophys. Res. Comm. 320:1096-1102, which is inco ⁇ orated by reference herein in its entirety).
  • an Ephrin Al fusion protein comprises Ephrin Al fused to an Fc domain of human immunoglobulin IgG.
  • an Ephrin Al fusion protein comprises an Ephrin Al Fragment which retains its ability to bind EphA2 or EphA4 fused to the Fc domain of human immunoglobulin IgG.
  • an Ephrin Al fusion protein comprises an Ephrin Al Fragment which retains its ability to bind EphA2 or EphA4 fused to a heterologous protein (e.g., human serum albumin).
  • a targeting moiety of the invention is an Ephrin A2, Ephrin A3, Ephrin A4, Ephrin A5, Ephrin B2 or Ephrin B3 fusion protein.
  • Non-limiting examples of such fusion proteins include soluble forms of Ephrin A2, Ephrin A3, Ephrin A4, Ephrin A5, Ephrin B2 or Ephrin B3 fused to an Fc domain of human immunoglobulin IgG (e.g., Ephrin A2 Fc, Ephrin A3 Fc, Ephrin A4 Fc, Ephrin A5 Fc, Ephrin B2 Fc and Ephrin B3 Fc).
  • such fusion proteins retain their ability to bind EphA2 and/or EphA4 and agonize EphA2 and/or EphA4 signaling.
  • such fusion proteins which retain their ability to bind EphA2 and/or EphA4 are fused to a heterologous protein (e.g., human serum albumin).
  • a heterologous protein e.g., human serum albumin.
  • Non-limiting examples of methods for detecting protein binding include GST-affinity binding assays, far- Western Blot analysis, surface plasmon resonance (SRP), fluorescence resonance energy transfer (FRET), fluorescence polarization (FP), isothermal titration calorimetry (ITC), circular dichroism (CD), protein fragment complementation assays (PCA), various two-hybrid systems, and proteomics and bioinformatics-based approaches, such as the Scansite program for computational analysis (see, e.g., Fu, H., 2004, Protein-Protein Interactions: Methods and Applications (Humana Press, Totowa, NJ); and Protein-Protein Interaction
  • the present invention provides methods and compositions designed for treatment, management, or prevention of a hype ⁇ roliferative cell disease, particular cancer.
  • a hype ⁇ roliferative cell disease e.g., anti-cancer agents
  • the methods and compositions of the invention preferably target certain types of cells or specific tissues, particularly cells expressing EphA2 or EphA4.
  • Any delivery vehicle known in the art can be used in accordance with the present invention.
  • compositions of the invention e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the antibody or antibody fragment, receptor-mediated endocytosis (see, e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429- 4432), construction of a nucleic acid as part of a retroviral or other vector, etc.
  • nucleic acid molecules can be delivered by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or transfecting agents that are conjugated to (or otherwise associated with) an EphA2 or EphA4 targeting moiety, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, or by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429) (which can be used to target cell types specifically expressing the receptors), etc.
  • microparticle bombardment e.g., a gene gun; Biolistic, Dupont
  • lipids or transfecting agents that are conjugated to (or otherwise associated with) an EphA2 or EphA4 targeting moiety
  • the nucleic acid sequences are directly administered in vivo. This can be accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector (e.g., vectors as described above and target to EphA2 or EphA4) and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No.
  • nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation.
  • the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor, preferably EphA2 or EphA4 (see Section 5.2, supra).
  • the nucleic acid can be introduced intracellularly and inco ⁇ orated within host cell DNA for expression, by homologous recombination (Koller and Smithies, 1989, PNAS 86:8932; and Zijlstra et al, 1989, Nature 342:435).
  • the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell.
  • introduction can be carried out by any method known in the art, including but not limited to, transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell mediated gene transfer, spheroplast fusion, etc.
  • Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, 1993, Meth. Enzymol. 217:599; Cohen et al., 1993, Meth. Enzymol.
  • the resulting recombinant cells can be delivered to a subject by various methods known in the art. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.
  • a delivery vehicle may target certain type of cells, e.g., by virtue of an innate feature of the vehicle, or by a moiety conjugated to (or otherwise associated with) the vehicle, which moiety specifically binds a particular subset of cells, e.g., by binding to a cell surface molecule characteristic of the subset of cells to be targeted.
  • a delivery vehicle of the invention targets cells expressing EphA2, and may preferably target cells expressing EphA2 or EphA4 not bound to a ligand over EphA2 or EphA4 bound to a ligand.
  • an EphA2 targeting moiety is attached to a delivery vehicle of the invention.
  • an EphA4 targeting moiety is attached to a delivery vehicle of the invention.
  • the delivery vehicle can be, for example, a peptide vector, a peptide-DNA aggregate, a liposome, a gas-filled microsome, an encapsulated macromolecule, a nanosuspension, and the like (see e.g., Torchilin, Drug Targeting. Eur. J. Phamaceutical Sciences: v. 11, pp. S81-S91 (2000); Gerasimov, Boomer, Quails, Thompson, Cytosolic drug delivery using pH- and light-sensitive liposomes, Adv. Drug Deliv. Reviews: v. 38, pp. 317-338 (1999); Hafez, Cullis, Roles of lipid polymo ⁇ hism in intracellular delivery, Adv. Drug Deliv.
  • the delivery vehicle is a viral vector.
  • a delivery vehicle can be, for example, an HVJ (Sendai virus)-liposome gene delivery system (see e.g., Kaneda et al, Ann. N.Y. Acad. Sci. 811 :299-308 (1997)); a "peptide vector” (see e.g., Vidal et al, CR Acad. Sci III 32:279-287 (1997)); a peptide-DNA aggregate (see e.g., Niidome et al, J. Biol. Chem.
  • lipidic vector systems see e.g., Lee et al, Crit Rev Ther Drug Carrier Syst. 14:173-206 (1997)); polymer coated liposomes (Marin et al, U.S. Pat. No. 5,213,804; Woodle et al, U.S. Pat. No. 5,013,556); cationic liposomes (Epand et al, U.S. Pat. No. 5,283,185; Jessee, J. A., U.S. Pat. No. 5,578,475; Rose et al, U.S. Pat. No. 5,279,833; Gebeyehu et al, U.S. Pat. No.
  • Methods of packaging the therapeutic or prophylactic agent(s) into a delivery vehicle depend on various factors, such as the type of the delivery vehicle being used, or the hydrophobic or hydrophilic nature of the agent(s). Any packaging method known in the art can be used in the present invention.
  • Viruses are attractive delivery vehicles for their natural ability to infect host cells and introduce foreign nucleic acids.
  • Viral vector systems useful in the practice of the instant invention include, for example, naturally occurring or recombinant viral vector systems.
  • viral vectors can be derived from the genome of human or bovine adenoviruses, vaccinia virus, he ⁇ es virus, adeno-associated virus (see e.g., Xiao et al, Brain Res. 756:76-83 (1997), minute virus of mice (MVM), HIV, HPV and HPV-like particles, Sindbis virus, and retroviruses (including but not limited to Rous sarcoma virus), and MoMLV, hepatitis B virus (see e.g., Ji et al, J. Viral Hepat.
  • genes of interest are inserted into such vectors to allow packaging of the gene construct, typically with accompanying viral DNA, followed by infection of a sensitive host cell and expression of the gene of interest.
  • a preferred recombinant viral vector is the adenoviral vector delivery system which has a deletion of the protein IX gene (see, International Patent Application WO 95/11984, which is herein inco ⁇ orated by reference in its entirety).
  • Another example of a preferred recombinant viral vector is the recombinant parainfluenza virus vector (recombinant PIV vectors, disclosed in e.g., Internation Patent Application Publication No.
  • WO 03/072720 Medlmmune Vaccines, Inc., inco ⁇ orated herein by reference in its entirety
  • a recombinant metapneumovirus vector recombinant MPV vectors, disclosed in e.g., International Patent Application Publication No. WO 03/072719, Medlmmune Vaccines, Inc., inco ⁇ orated herein by reference in its entirety.
  • vectors derived from a different species from that which is to be treated in order to avoid the preexisting immune response For example, equine he ⁇ es virus vectors for human gene therapy are described in WO 98/27216, published Aug. 5, 1998.
  • the vectors are described as useful for the treatment of humans as the equine virus is not pathogenic to humans.
  • ovine adenoviral vectors may be used in human gene therapy as they are claimed to avoid the antibodies against the human adenoviral vectors.
  • Such vectors are described in WO 97/06826, published April 10, 1997, which is inco ⁇ orated herein by reference.
  • the virus can be replication competent (e.g., completely wild-type or essentially wild-type such as Ad dl309 or Ad dl520), conditionally replicating (designed to replicate under certain conditions) or replication deficient (substantially incapable of replication in the absence of a cell line capable of complementing the deleted functions).
  • the viral genome can possess certain modifications to the viral genome to enhance certain desirable properties such as tissue selectivity. For example, deletions in the Ela region of adenovirus result in preferential replication and improved replication in tumor cells.
  • the viral genome can also modified to include therapeutic transgenes.
  • the virus can possess certain modifications to make it "selectively replicating," i.e. that it replicates preferentially in certain cell types or phenotypic cell states, e.g., cancerous.
  • a tumor or tissue specific promoter element can be used to drive expression of early viral genes resulting in a virus which preferentially replicates only in certain cell types.
  • a pathway-selective promoter active in a normal cell to drive expression of a repressor of viral replication.
  • Selectively replicating adenoviral vectors that replicate preferentially in rapidly dividing cells are described in International Patent Application Nos. WO 99/0021451 and WO 99/0021452, each of which is inco ⁇ orated herein by reference.
  • viral vectors that contain nucleic acid sequences that reduce EphA2 expression and/or function are used.
  • a retroviral vector can be used (see Miller et al, 1993, Meth. Enzymol. 217:581). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA.
  • the nucleic acid sequences to be used in accordance with the present invention are cloned into one or more vectors, which facilitates delivery of the nucleic acid into a subject.
  • retroviral vectors More detail about retroviral vectors can be found in Boesen et al, 1994, Biotherapy 6:291-302, which describes the use of a retroviral vector to deliver the mdr 1 gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy.
  • Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al, 1994, J. Clin. Invest. 93:644-651; Klein et al, 1994, Blood 83:1467- 1473; Salmons and Gunzberg, 1993, Human Gene Therapy 4:129-141; and Grossman and Wilson, 1993, Curr. Opin. in Genetics Devel. 3:110-114.
  • Adenoviruses are other viral vectors that can be used in delivering nucleic acid molecules of the invention. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson (1993, Current Opinion in Genetics Development 3:499) present a review of adenovirus-based gene therapy. Bout et al. (1994, Human Gene Therapy 5:3-10) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys.
  • adenovirus vectors are used.
  • Adeno-associated virus has also been proposed for use as a delivery vehicle (Walsh et al, 1993, Proc. Soc. Exp. Biol. Med. 204:289-300; and U.S. Patent No. 5,436,146).
  • viruses or virus-like particles such as human papilomavirus
  • can target certain cells without modification e.g., human papilomavirus target cervical cancer cells.
  • Such viruses or virus-like particles can be used to deliver the compositions of the invention directly to the desired sites.
  • an EphA2 or EphA4 targeting moiety e.g., an anti-
  • EphA2 or EphA4 antibody an EphA2 or EphA4 ligand, a peptide or other targeting moieties known in the art, is attached to the surface of the virus, and thus direct the virus to the cells that expressing EphA2 or EphA4.
  • Non-viral synthetic vectors can also be used as a delivery vehicle in accordance with the present invention.
  • a targeting moiety can be attached to a polycation (e.g., lipid or polymer) backbone.
  • the polycation backbone also forms a complex with the therapeutic or prophylactic agent (e.g., a nucleic acid molecule) to be delivered.
  • the therapeutic or prophylactic agent e.g., a nucleic acid molecule
  • a non-limiting example of such delivery vehicle is polylysine, which has been conjugated to a diverse set of ligands that selectively target particular receptors on certain cell types. See e.g., Cotton et al, Proc. Natl. Acad. Sci.
  • an EphA2 or EphA4 targeting moiety e.g., an anti-EphA2 or anti-EphA4 antibody, an EphA2 or EphA4 ligand, a peptide or other targeting moieties known in the art, is attached to the polycation backbone (e.g., polylysine), and thereby directs the therapeutic agent(s) to the cells that express EphA2 or Epha4.
  • Chimeric multi-domajn peptides can also be used as delivery vehicles in accordance with the present invention. See e.g., Fominaya et al., J. Biol. Chem.
  • Such carrier inco ⁇ orates targeting, endosomal escape, and DNA binding motifs into a single synthetic peptide molecule.
  • liposomes can be used as a delivery vehicle.
  • Liposomes are closed lipid vesicles used for a variety of therapeutic pu ⁇ oses, and in particular, for carrying therapeutic or prophylactic agents to a target region or cell by systemic administration of liposomes.
  • Liposomes are usually classified as small unilamellar vesicles (SUV), large unilamellar vesicles (LUV), or multi-lamellar vesicles (MLV).
  • SUVs and LUVs by definition, have only one bilayer, whereas MLVs contain many concentric bilayers.
  • Liposomes may be used to encapsulate various materials, by trapping hydrophilic molecules in the aqueous interior or between bilayers, or by trapping hydrophobic molecules within the bilayer. Gangliosides are believed to inhibit nonspecific adso ⁇ tion of serum proteins to liposomes, thereby prevent nonspecific recognition of liposomes by macrophages.
  • liposomes having a surface grafted with chains of water- soluble, biocompatible polymer, in particular polyethylene glycol have become important drug carries.
  • These liposomes offer an extended blood circulation lifetime over liposomes lacking the polymer coating.
  • the grafted polymer chains shield or mask the liposome, thus minimizing nonspecific interaction by plasma proteins. This in turn slows the rate at which the liposomes are cleared or eliminated in vivo since the liposome circulate unrecognized by macrophages and other cells of the reticuloendothelial system.
  • the liposomes tend to accumulate in sites of damaged or expanded vasculature, e.g., tumors, and sites of inflammation. [00231] It would be desirable to formulate a liposome composition having a long blood circulation lifetime and capable of retaining an entrapped drug for a desired time, yet able to release the drug on demand.
  • a liposome from a non-vesicle-forming lipid, such as dioleoylphosphatidylethanolamine (DOPE), and a lipid bilayer stabilizing lipid, such as methoxy-polyethylene glycol-distearoyl phosphatidylethanolamine (mPEG-DSPE) (Ki ⁇ otin et al, FEBS Lett. 388:115-118 (1996)).
  • DOPE dioleoylphosphatidylethanolamine
  • mPEG-DSPE methoxy-polyethylene glycol-distearoyl phosphatidylethanolamine
  • the mPEG is attached to the DSPE via a cleavable linkage. Cleavage of the linkage destabilizes the liposome for a quick release of the liposome contents.
  • Labile bonds for linking PEG polymer chains to liposomes have been described (U.S. Pat. Nos. 5,013,556, 5,891,468; WO 98/16201).
  • the labile bond in these liposome compositions releases the PEG polymer chains from the liposomes, for example, to expose a surface attached targeting ligand or to trigger fusion of the liposome with a target cell.
  • a therapeutic or prophylactic agent is entrapped during liposome formation and then administered to the patient to be treated. See e.g., U.S. Pat. Nos. 3,993,754, 4,145,410, 4,224,179, 4,356,167, and 4,377,567.
  • a liposome is preferably modified to have one or more EphA2 -targeting moieties (see Section 5.1 and 5.2., supra) on its surface.
  • Hybrid vectors exploit endosomal escape capabilities of viruses in combination with the flexibility of non- viral vectors.
  • Hybrid vectors can be divided into two subclasses: (1) membrane disrupting particles, either virus particles or other fusogenic peptides, added as separate entities in conjunction with non-viral vectors; and (2) such particles combined into a single complex with a traditional non-viral vector.
  • a hybrid vector may use adenovirus in trans with a targeted non-viral vector, for example, adenovirus together with complexes of transferrin/polylysine, antibody/polylysine, or asialoglycoprotein/polylysine.
  • targeted complex and virus particle can either be internalized in the same vesicle or into separate endosomes.
  • a viral particle is directly conjugated to a targeted vector. Inco ⁇ oration of viral particles into targeted complexes can be done, e.g., through streptavidin/biotinylation of adenovirus and polylysine, through antibodies pre-coupled to polylysine, or through direct chemical conjugation. See e.g., Verga et al., Biotechnology and Bioengineering 70(6): 593-605 (2000).
  • the present invention provides hybrid vectors comprising one or more EphA2 or EphA4 targeting moieties.
  • the present invention encompasses methods for treating, preventing, or managing a disease or disorder associated with overexpression of EphA2 or EphA4 and/or a cell hype ⁇ roliferative disorder, particularly cancer, in a subject comprising administering an effective amount of a composition that can target cells expressing EphA2 or EphA4, and inhibiting the EphA2 or EphA4 expression or function, and/or having therapeutic or prophylactic effects on the hype ⁇ roliferative cell disease.
  • the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety attached to a delivery vehicle, and a therapeutic or prophylactic agent against the hype ⁇ roliferative cell disease.
  • the method of the invention comprises administering to a subject a composition comprising a nucleic acid comprising a nucleotide sequence encoding an EphA2 or EphA4 targeting moiety and a nucleotide sequence encoding a therapeutic or prophylactic agent against the hype ⁇ roliferative disease.
  • the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety and a nucleic acid comprising a nucleotide sequence encoding a therapeutic or prophylactic agent against the hype ⁇ roliferative disease, wherein the targeting moiety is associated with the nucleic acid either directly or through a delivery vector for delivery to cells expressing EphA2 or EphA4.
  • an EphA2 or EphA4 targeting moiety also inhibits EphA2 or EphA4 expression or activity.
  • the present invention encompasses methods for treating, preventing, or managing a disease or disorder associated with overexpression of EphA2 or EphA4 and/or a cell hype ⁇ roliferative disorder, preferably cancer, in a subject comprising administering one or more antibodies that target EphA2 or EphA4 and/or inhibit EphA2 or EphA4 expression or activity, wherein said antibodies are EphA2 or EphA4 agonistic antibodies, EphA2 or EphA4 intrabodies, or EphA2 or EphA4 cancer cell phenotype inhibiting antibodies or exposed EphA2 or EphA4 epitope antibodies or EphA2 or EphA4 antibodies that bind EphA2 or EphA4 with a K 0ff less than 3 X 10 ' V 1 , preferably one or more monoclonal EphA2 or EphA4 agonistic antibodies, EphA2 or EphA4 intrabodies, BiTE molecules, or EphA2 or EphA
  • the disorder to be treated, prevented, or managed is malignant cancer.
  • the disorder to be treated, prevented, or managed is a pre-cancerous condition associated with cells that overexpress EphA2 or EphA4.
  • the pre-cancerous condition is high-grade prostatic intraepithelial neoplasia (PIN), fibroadenoma of the breast, fibrocystic disease, or compound nevi.
  • compositions of the invention can be administered in combination with one or more other therapeutic agents useful in the treatment, prevention or management of diseases or disorders associated with EphA2 or EphA4 overexpression, hype ⁇ roliferative disorders, and/or cancer.
  • one or more compositions of the invention are administered to a mammal, preferably a human, concurrently with one or more other therapeutic agents useful for the treatment of cancer.
  • compositions of the invention are administered to a subject in a sequence and within a time interval such that the compositions of the invention can act together with the other agent to provide an increased benefit than if they were administered otherwise.
  • each prophylactic or therapeutic agent may be administered at the same time or sequentially in any order at different points in time; however, if not administered at the same time, they should be administered sufficiently close in time so as to provide the desired therapeutic or prophylactic effect.
  • Each therapeutic agent can be administered separately, in any appropriate form and by any suitable route.
  • the compositions of the invention are administered before, concurrently to, or after surgery. Preferably the surgery completely removes localized tumors or reduces the size of large tumors. Surgery can also be done as a preventive measure or to relieve pain.
  • compositions of the invention comprise one or more EphA2 antibodies consisting of EA2-5, Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152, or any of the antibodies listed in Table 1, wherein said antibodies are used as EphA2-targeting moieties or agents against a hype ⁇ roliferative cell disease.
  • the compositions of the invention comprise antibodies consisting of EA2-5, Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152, or any of the antibodies listed in Table 1 that have been humanized.
  • compositions of the invention comprise one or more EphA4 antibodies consisting of EA44 (as disclosed, for example, in U.S. Non- Provisional Application Serial No. 10/863,729, filed June 7, 2004), wherein said antibodies are used as EphA4 targeting moieties or agents against a hype ⁇ roliferative cell disease.
  • the compositions of the invention comprise antibodies consisting of EA44 that have been humanized.
  • variants of EA44 e.g., with one or more amino acid substitutions, particularly in the variable domain, are provided that have increased activity, binding ability, etc., as compared to EA44.
  • the therapeutic and prophylactic methods of the invention comprise administration of an inhibitor of EphA2 or EphA4 expression, such as but not limited to, antisense nucleic acids specific for EphA2 or EphA4, double stranded EphA2 or EphA4 RNA that mediates RNAi, anti-EphA2 or anti-EphA4 ribozymes, an aptamer, or an agonist of EphA2 or EphA4 activity other than an EphA2 or EphA4 antibody, such as small molecule inhibitors or agonists of EphA2 or EphA4 activity.
  • an inhibitor of EphA2 or EphA4 expression such as but not limited to, antisense nucleic acids specific for EphA2 or EphA4, double stranded EphA2 or EphA4 RNA that mediates RNAi, anti-EphA2 or anti-EphA4 ribozymes, an aptamer, or an agonist of EphA2 or
  • the invention provides methods for treating, preventing, and managing a disease or disorder associated with EphA2 or EphA4 overexpression and/or hype ⁇ roliferative cell disease, particularly cancer, by administrating to a subject in need thereof a therapeutically or prophylactically effective amount of one or more compositions of the invention.
  • the compositions of the invention can be administered in combination with one or more other therapeutic agents.
  • the subject is preferably a mammal such as non-primate (e.g., cows, pigs, horses, cats, dogs, rats, etc.) and a primate (e.g., monkey, such as a cynomolgous monkey and a human).
  • the subject is a human.
  • the cancer is of an epithelial origin. Examples of such cancers are cancer of the lung, colon, prostate, breast, and skin. Other cancers include cancer of the bladder and pancreas and renal cell carcinoma and melanoma. Additional cancers are listed by example and not by limitation in the following section 5.4.1.1.
  • methods of the invention can be used to treat and/or prevent metastasis from primary tumors.
  • the methods and compositions of the invention comprise the administration of one or more compositions of the invention to subjects/patients suffering from or expected to suffer from cancer, e.g., have a genetic predisposition for a particular type of cancer, have been exposed to a carcinogen, or are in remission from a particular cancer.
  • cancer refers to primary or metastatic cancers. Such patients may or may not have been previously treated for cancer.
  • the methods and compositions of the invention may be used as a first line or second line cancer treatment. Included in the invention is also the treatment of patients undergoing other cancer therapies and the methods and compositions of the invention can be used before any adverse effects or intolerance of these other cancer therapies occurs.
  • the invention also encompasses methods for administering one or more compositions of the invention to treat or ameliorate symptoms in refractory patients.
  • that a cancer is refractory to a therapy means that at least some significant portion of the cancer cells are not killed or their cell division arrested.
  • the determination of whether the cancer cells are refractory can be made either in vivo or in vitro by any method known in the art for assaying the effectiveness of treatment on cancer cells, using the art-accepted meanings of "refractory" in such a context.
  • a cancer is refractory where the number of cancer cells has not been significantly reduced, or has increased.
  • the invention also encompasses methods for administering one or more EphA2 or EphA4 agonistic antibodies (use as a EphA2 or EphA4-targeting moiety and/or an agent against cancer) to prevent the onset or recurrence of cancer in patients predisposed to having cancer.
  • the monoclonal antibody is one or more of Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B- 233.152, or any of the antibodies listed in Table 1.
  • an EphA4 agonistic antibody for use in the compositions and methods of the invention is EA44.
  • compositions of the invention are administered to reverse resistance or reduced sensitivity of cancer cells to certain hormonal, radiation and chemotherapeutic agents thereby resensitizing the cancer cells to one or more of these agents, which can then be administered (or continue to be administered) to treat or manage cancer, including to prevent metastasis.
  • compositions of the invention are administered to patients with increased levels of the cytokine IL-6, which has been associated with the development of cancer cell resistance to different treatment regimens, such as chemotherapy and hormonal therapy.
  • compositions of the invention are administered to patients suffering from breast cancer that have a decreased responsiveness or are refractory to tamoxifen treatment.
  • compositions of the invention are administered to patients with increased levels of the cytokine IL-6, which has been associated with the development of cancer cell resistance to different treatment regimens, such as chemotherapy and hormonal therapy.
  • the invention provides methods for treating patients' cancer by administering one or more compositions of the invention in combination with any other treatment or to patients who have proven refractory to other treatments but are no longer on these treatments.
  • one or more of Eph099B-102.147, Eph099B- 208.261, Eph099B-210.248, Eph099B-233.152, any of the antibodies listed in Table 1, or EA44 are used in accordance with the present invention, either as an EphA2 or EphA4 targeting moiety or an anti-cancer agent.
  • the patients being treated by the methods of the invention are patients already being treated with chemotherapy, radiation therapy, hormonal therapy, or biological therapy/immunotherapy. Among these patients are refractory patients and those with cancer despite treatment with existing cancer therapies.
  • the patients have been treated and have no disease activity and one or more compositions of the invention are administered to prevent the recurrence of cancer.
  • the existing treatment is chemotherapy.
  • the existing treatment includes administration of chemotherapies including, but not limited to, methotrexate, taxol, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, etoposides, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, asparaginase, vinblastine, vincristine, vinorelbine, paclitaxel, docetaxel, etc.
  • chemotherapies including, but not limited to, methotrexate, taxol, mercaptopurine, thioguanine, hydroxyurea, cytarabine
  • the invention also encompasses methods for treating patients undergoing or having undergone radiation therapy.
  • patients being treated or previously treated with chemotherapy, hormonal therapy and/or biological therapy/immunotherapy.
  • patients who have undergone surgery for the treatment of cancer.
  • the invention encompasses methods for treating patients undergoing or having undergone hormonal therapy and/or biological therapy/immunotherapy. Among these are patients being treated or having been treated with chemotherapy and/or radiation therapy. Also among these patients are those who have undergone surgery for the treatment of cancer.
  • the invention also provides methods of treatment of cancer as an alternative to chemotherapy, radiation therapy, hormonal therapy, and/or biological therapy/immunotherapy where the therapy has proven or may prove too toxic, i.e., results in unacceptable or unbearable side effects, for the subject being treated.
  • the subject being treated with the methods of the invention may, optionally, be treated with other cancer treatments such as surgery, chemotherapy, radiation therapy, hormonal therapy or biological therapy, depending on which treatment was found to be unacceptable or unbearable.
  • the invention provides administration of one or more compositions of the invention without any other cancer therapies for the treatment of cancer, but who have proved refractory to such treatments.
  • patients refractory to other cancer therapies are administered one or more compositions of the invention in the absence of cancer therapies.
  • patients with a pre-cancerous condition associated with cells that overexpress EphA2 or EphA4 can be administered compositions of the invention to treat the disorder and decrease the likelihood that it will progress to malignant cancer.
  • the pre-cancerous condition is high-grade prostatic intraepithelial neoplasia (PIN), fibroadenoma of the breast, fibrocystic disease, or compound nevi.
  • the invention provides methods of treating, preventing and managing non-cancer hype ⁇ roliferative cell disorders, particularly those associated with overexpression of EphA2 or EphA4, including but not limited to, asthma, chromic obstructive pulmonary disorder (COPD), restenosis (smooth muscle and/or endothelial), psoriasis, etc.
  • COPD chromic obstructive pulmonary disorder
  • restenosis smooth muscle and/or endothelial
  • psoriasis etc.
  • cancers and related disorders that can be treated, prevented, or managed by methods and compositions of the present invention include but are not limited to cancers of an epithelial cell origin.
  • cancers include the following: leukemias, such as but not limited to, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemias, such as, myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia leukemias and myelodysplastic syndrome; chronic leukemias, such as but not limited to, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, hairy cell leukemia; polycythemia vera; lymphomas such as but not limited to Hodgkin's disease, non-Hodgkin's disease; multiple myelomas such as but not limited to smoldering multiple myeloma, nonsecretory mye
  • cancers include myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphangioendotheliosarcoma, mesothelioma, synovioma, hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma and papillary adenocarcinomas (for a review of such disorders, see Fishman et al., 1985, Medicine, 2d Ed., J.B. Lippincott Co., Philadelphia and Mu ⁇ hy et al., 1997, Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery, Viking Penguin, Penguin Books U.S.A., Inc., United States of America)
  • carcinoma including that of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid and skin; including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Burkitt's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyoscarcoma; other tumors, including melanoma, seminoma, tetratocarcinom
  • cancers caused by aberrations in apoptosis would also be treated by the methods and compositions of the invention.
  • Such cancers may include but not be limited to follicular lymphomas, carcinomas with p53 mutations, hormone dependent tumors of the breast, prostate and ovary, and precancerous lesions such as familial adenomatous polyposis, and myelodysplastic syndromes.
  • malignancy or dysproliferative changes such as metaplasias and dysplasias
  • hype ⁇ roliferative disorders are treated or prevented in the skin, lung, colon, breast, prostate, bladder, kidney, pancreas, ovary, or uterus.
  • sarcoma, melanoma, or leukemia is treated or prevented.
  • the cancer is malignant and overexpresses EphA2 or
  • the disorder to be treated is a pre-cancerous condition associated with cells that overexpress EphA2 or EphA4.
  • the pre-cancerous condition is high-grade prostatic intraepithelial neoplasia (PIN), fibroadenoma of the breast, fibrocystic disease, or compound nevi.
  • PIN prostatic intraepithelial neoplasia
  • fibroadenoma of the breast fibrocystic disease
  • compound nevi compound nevi.
  • the methods and compositions of the invention are used for the treatment and/or prevention of breast, colon, ovarian, lung, and prostate cancers and melanoma and are provided below by example rather than by limitation.
  • patients with breast cancer are administered an effective amount of one or more compositions of the invention.
  • the present invention provides a method of preventing, treating or managing a breast cancer comprising administering to the patient (a) a delivery vehicle conjugated to (or otherwise associated with) a moiety that binds EphA2 or EphA4, (b) one or more agents useful for breast cancer therapy, wherein said agents are contained within or associated with the delivery vehicle, and (c) a pharmaceutical acceptable carrier.
  • the compositions of the invention can be administered in combination with an effective amount of one or more other agents useful for breast cancer therapy.
  • Agents useful for breast cancer therapy include, but are not limited to: doxorubicin, epirubicin, the combination of doxorubicin and cyclophosphamide (AC), the combination of cyclophosphamide, doxorubicin and 5-fluorouracil (CAF), the combination of cyclophosphamide, epirubicin and 5-fluorouracil (CEF), herceptin, tamoxifen, the combination of tamoxifen and cytotoxic chemotherapy, taxanes (such as docetaxel and paclitaxel).
  • compositions of the invention may comprise or used in combination with taxanes plus standard doxorubicin and cyclophosphamide for adjuvant treatment of node-positive, localized breast cancer.
  • patients with pre-cancerous fibroadenoma of the breast or fibrocystic disease are administered a composition of the invention to treat the disorder and decrease the likelihood that it will progress to malignant breast cancer.
  • patients refractory to treatment particularly hormonal therapy, more particulatly tamoxifen therapy, are administered a composition of the invention to treat the cancer and/or render the patient non-refractory or responsive.
  • compositions of the invention comprise or used in combination with an effective amount of one or more other agents useful for colon cancer therapy, including but not limited to: the combination of 5-FU and leucovorin, the combination of 5-FU and levamisole, irinotecan (CPT-11) or the combination of irinotecan, 5-FU and leucovorin (IFL).
  • agents useful for colon cancer therapy including but not limited to: the combination of 5-FU and leucovorin, the combination of 5-FU and levamisole, irinotecan (CPT-11) or the combination of irinotecan, 5-FU and leucovorin (IFL).
  • compositions of the invention comprise or used in combination with an effective amount of one or more other agents useful for prostate cancer therapy, including but not limited to: external-beam radiation therapy, interstitial implantation of radioisotopes (i.e., I 125 , palladium, iridium), leuprolide or other LHRH agonists, non-steroidal antiandrogens (flutamide, nilutamide, bicalutamide), steroidal antiandrogens (cyproterone acetate), the combination of leuprolide and flutamide, estrogens such as DES, chlorotrianisene, ethinyl estradiol, conjugated estrogens U.S.P., DES-diphosphate, radioisotopes, such as strontium- 89, the combination of external-beam radiation therapy and strontium-89, second-
  • radioisotopes i.e., I 125 , palladium, iridium
  • patients with pre-cancerous high-grade prostatic intraepithelial neoplasia are administered a composition of the invention to treat the disorder and decrease the likelihood that it will progress to malignant prostate cancer.
  • compositions of the invention comprise or used in combination with an effective amount of one or more other agents useful for melanoma cancer therapy, including but not limited to: dacarbazine (DTIC), nitrosoureas such as carmustine (BCNU) and lomustine (CCNU), agents with modest single agent activity including vinca alkaloids, platinum compounds, and taxanes, the Dartmouth regimen (cisplatin, BCNU, and DTIC), interferon alpha (IFN- A), and interleukin-2 (IL-2).
  • DTIC dacarbazine
  • BCNU carmustine
  • CCNU lomustine
  • agents with modest single agent activity including vinca alkaloids, platinum compounds, and taxanes
  • the Dartmouth regimen cisplatin, BCNU, and DTIC
  • IFN- A interferon alpha
  • IL-2 interleukin-2
  • an effective amount of one or more agonistic monoclonal antibodies of the invention can be administered in combination with isolated hyperthermic limb perfusion (ILP) with melphalan (L-PAM), with or without tumor necrosis factor-alpha (TNF-alpha) to patients with multiple brain metastases, bone metastases, and spinal cord compression to achieve symptom relief and some shrinkage of the tumor with radiation therapy.
  • IRP isolated hyperthermic limb perfusion
  • L-PAM melphalan
  • TNF-alpha tumor necrosis factor-alpha
  • patients with pre-cancerous compound nevi are administered a composition of the invention to treat the disorder and decrease the likelihood that it will progress to malignant melanoma.
  • compositions of the invention comprise or used in combination with an effective amount of one or more other agents useful for ovarian cancer therapy including but not limited to: intraperitoneal radiation therapy, such as P 32 therapy, total abdominal and pelvic radiation therapy, cisplatin, the combination of paclitaxel (Taxol) or docetaxel (Taxotere) and cisplatin or carboplatin, the combination of cyclophosphamide and cisplatin, the combination of cyclophosphamide and carboplatin, the combination of 5-FU and leucovorin, etoposide, liposomal doxorubicin, gemcitabine or topotecan.
  • intraperitoneal radiation therapy such as P 32 therapy, total abdominal and pelvic radiation therapy
  • cisplatin the combination of paclitaxel (Taxol) or docetaxel (Taxotere) and cisplatin or carboplatin
  • an effective amount of one or more compositions of the invention are administered in combination with the administration Taxol for patients with platinum-refractory disease.
  • the treatment of patients with refractory ovarian cancer including administration of: ifosfamide in patients with disease that is platinum-refractory, hexamethylmelamine (HMM) as salvage chemotherapy after failure of cisplatin-based combination regimens, and tamoxifen in patients with detectable levels of cytoplasmic estrogen receptor on their tumors.
  • HMM hexamethylmelamine
  • compositions of the invention comprise or used in combination with an effective amount of one or more other agents useful for lung cancer therapy, including but not limited to: thoracic radiation therapy, cisplatin, vincristine, doxorubicin, and etoposide, alone or in combination, the combination of cyclophosphamide, doxorubicin, vincristine/etoposide, and cisplatin (CAV/EP), local palliation with endobronchial laser therapy, endobronchial stents, and/or brachytherapy.
  • agents useful for lung cancer therapy including but not limited to: thoracic radiation therapy, cisplatin, vincristine, doxorubicin, and etoposide, alone or in combination, the combination of cyclophosphamide, doxorubicin, vincristine/etoposide, and cisplatin (CAV/EP), local palliation with endobronchial laser therapy, endobronchial
  • patients with non-small lung cell cancer are administered an effective amount of one or more compositions of the invention in combination with an effective amount of one or more other agents useful for lung cancer therapy including but not limited to: palliative radiation therapy, the combination of cisplatin, vinblastine and mitomycin, the combination of cisplatin and vinorelbine, paclitaxel, docetaxel or gemcitabine, the combination of carboplatin and paclitaxel, interstitial radiation therapy for endobronchial lesions or stereotactic radiosurgery.
  • the present invention provides a method of preventing, treating or managing a hype ⁇ roliferative cell disease comprising administering to the patient (a) a delivery vehicle conjugated to (or otherwise associated with) a moiety that binds EphA2 or EphA4, (b) one or more prophylactic or therapeutic agents against the hype ⁇ roliferative cell disease, wherein said agents are contained within or associated with the delivery vehicle, and (c) a pharmaceutical acceptable carrier.
  • the present invention provides a method of preventing, treating or managing a hype ⁇ roliferative cell disease comprising administering one or more compositions of the invention in combination with the administration of one or more therapies such as, but not limited to, chemotherapies, radiation therapies, hormonal therapies, biological therapies/immunotherapies and/or surgery.
  • therapies such as, but not limited to, chemotherapies, radiation therapies, hormonal therapies, biological therapies/immunotherapies and/or surgery.
  • Prophylactic/therapeutic agents that can be used in accordance with the present invention include, but are not limited to, proteinaceous molecules, including, but not limited to, peptides, polypeptides, proteins, including post-translationally modified proteins, antibodies etc.; or small molecules (less than 1000 daltons), inorganic or organic compounds; or nucleic acid molecules including, but not limited to, double-stranded or single-stranded DNA, or double-stranded or single-stranded RNA, as well as triple helix nucleic acid molecules.
  • Prophylavtic/therapeutic agents can be derived from any known organism (including, but not limited to, animals, plants, bacteria, fungi, and protista, or viruses) or from a library of synthetic molecules.
  • prophylactic/therapeutic agents that can be used in accordance with the present invention are inhibitors of kinases such as, but are not limited to, ABL, ACK, AFK, AKT (e.g., AKT-1, AKT-2, and AKT-3), ALK, AMP-PK, ATM, Auroral, Aurora2, bARKl, bArk2, BLK, BMX, BTK, CAK, CaM kinase, CDC2, CDK, CK, COT, CTD, DNA-PK, EGF-R, ErbB-1, ErbB-2, ErbB-3, ErbB-4, ERK (e.g., ERK1, ERK2, ERK3, ERK4, ERK5, ERK6, ERK7), ERT-PK, FAK, FGR (e.g., FGF1R, FGF2R), FLT (e.g., FLT-1, FLT-2, FLT-3, FLT-4
  • one or more prophylactic/therapeutic agents that can be used in accordance with the present invention are inhibitors of Eph receptor kinases (e.g., EphA2, EphA4).
  • one or more prophylactic/therapeutic agents that can be used in accordance with the present invention are inhibitors of EphA2 or EphA4.
  • one or more prophylactic/therapeutic agents that can be used in accordance with the present invention are angiogenesis inhibitors such as, but not limited to: Angiostatin (plasminogen fragment); antiangiogenic antithrombin III; Angiozyme; ABT-627; Bay 12-9566; Benefin; Bevacizumab; BMS-275291; cartilage- derived inhibitor (CDI); CAI; CD59 complement fragment; CEP-7055; Col 3; Combretastatin A-4; Endostatin (collagen XVIII fragment); fibronectin fragment; Gro-beta; Halofuginone; Heparinases; Heparin hexasaccharide fragment; HMV833; Human chorionic gonadotropin (hCG); IM-862; Interferon alpha/beta/gamma; Interferon inducible protein (IP- 10); Interleukin- 12; Kringle 5 (plasminogen fragment); Marimastat
  • one or more prophylactic/therapeutic agents that can be used in accordance with the present invention are anti-cancer agents such as, but are not limited to: acivicin, aclarubicin, acodazole hydrochloride, acronine, adozelesin, aldesleukin, altretamine, ambomycin, ametantrone acetate, aminoglutethimide, amsacrine, anastrozole, anthramycin, asparaginase, asperlin, azacitidine, azetepa, azotomycin, batimastat, benzodepa, bicalutamide, bisantrene hydrochloride, bisnafide dimesylate, bizelesin, bleomycin sulfate, brequinar sodium, bropirimine, busulfan, cactinomycin, calusterone, caracemide, carbetimer, carboplatin
  • anti-cancer drugs include, but are not limited to: 20-epi-l,25 dihydroxyvitamin D3, 5-ethynyluracil, abiraterone, aclarubicin, acylfulvene, adecypenol, adozelesin, aldesleukin, ALL-TK antagonists, altretamine, ambamustine, amidox, amifostine, aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole, andrographolide, angiogenesis inhibitors, antagonist D, antagonist G, antarelix, anti-dorsalizing mo ⁇ hogenetic protein-1, antiandrogens, antiestrogens, antineoplaston, aphidicolin glycinate, apoptosis gene modulators, apoptosis regulators, apurinic acid, ara-CDP-DL-PTBA, arginine deaminase, asul
  • the present invention also comprises the administration of one or more compositions of the invention comprising or used in combination with one or more therapies such as, but are not limited to, anti-cancer agents such as those disclosed in Table 5, preferably for the treatment of breast, ovary, melanoma, prostate, colon and lung cancers as described above.
  • therapies such as, but are not limited to, anti-cancer agents such as those disclosed in Table 5, preferably for the treatment of breast, ovary, melanoma, prostate, colon and lung cancers as described above.
  • the invention also encompasses administration of the compositions of the invention in combination with radiation therapy comprising the use of x-rays, gamma rays and other sources of radiation to destroy the cancer cells.
  • the radiation treatment is administered as external beam radiation or teletherapy wherein the radiation is directed from a remote source.
  • the radiation treatment is administered as internal therapy or brachytherapy wherein a radioactive source is placed inside the body close to cancer cells or a tumor mass.
  • Cancer therapies and their dosages, routes of administration and recommended usage are known in the art and have been described in such literature as the Physician 's Desk Reference (58th ed., 2004).
  • a therapeutic or prophylactic agent of the invention is an EphA2 and/or an EphA4 vaccine.
  • EphA2 vaccine refers to any reagent that elicits or mediates an immune response against cells that overexpress EphA2, preferably associated with a hype ⁇ roliferative cell disorder.
  • an EphA2 vaccine is an EphA2 antigenic peptide, an expression vehicle (e.g., a naked nucleic acid or a viral or bacterial vector or a cell) for an EphA2 antigenic peptide (e.g., which delivers the EphA2 antigenic peptide), or T cells or antigen presenting cells (e.g., dendritic cells or macrophages) that have been primed with the EphA2 antigenic peptide of the invention.
  • an expression vehicle e.g., a naked nucleic acid or a viral or bacterial vector or a cell
  • an EphA2 antigenic peptide e.g., which delivers the EphA2 antigenic peptide
  • T cells or antigen presenting cells e.g., dendritic cells or macrophages
  • EphA2 antigenic peptide and “EphA2 antigenic polypeptide” refer to an EphA2 polypeptide, or a fragment, analog, or derivative thereof comprising one or more B cell epitopes or T cell epitopes of EphA2.
  • the EphA2 polypeptide may be from any species.
  • the EphA2 polypeptide may be from any species.
  • the human EphA2 sequence may be found in any publicly available data base, such as GenBank (Accession Nos. NM_004431.2 for the nucleotide sequence and NP_004422.2 for the amino acid sequence).
  • GenBank Accession Nos. NM_004431.2 for the nucleotide sequence and NP_004422.2 for the amino acid sequence.
  • an EphA2 polypeptide refers to the mature, processed form of EphA2.
  • an EphA2 polypeptide refers to an immature form of EphA2.
  • EphA2 vaccines see, e.g., U.S. Provisional Application Ser. No. 60/556,601, entitled "EphA2
  • therapeutic or prophylactic agent of the invention is an EphA4 Vaccine.
  • EphA4 vaccine refers to-any reagent that elicits or mediates an immune response against EphA4 on EphA4-expressing cells.
  • an EphA4 vaccine is an EphA4 antigenic peptide of the invention, an expression vehicle (e.g., a naked nucleic acid or a viral or bacterial vector or a cell) for an EphA4 antigenic peptide (e.g., which delivers the EphA4 antigenic peptide), or T cells or antigen presenting cells (e.g., dendritic cells or macrophages) that have been primed with the EphA4 antigenic peptide of the invention.
  • an expression vehicle e.g., a naked nucleic acid or a viral or bacterial vector or a cell
  • an EphA4 antigenic peptide e.g., which delivers the EphA4 antigenic peptide
  • T cells or antigen presenting cells e.g., dendritic cells or macrophages
  • EphA4 antigenic peptide and “EphA4 antigenic polypeptide” refer to an EphA4 polypeptide, or a fragment, analog, or derivative thereof comprising one or more B cell epitopes or T cell epitopes of EphA4.
  • the EphA4 polypeptide may be from any species.
  • the human EphA4 sequence may be found in any publicly available data base, such as GenBank (Accession Nos. NM_004438.3 for the nucleotide sequence and NP_004429.1 for the amino acid sequence).
  • GenBank GenBank
  • NP_004429.1 for the amino acid sequence
  • an EphA4 polypeptide refers to the mature, processed form of EphA4.
  • an EphA4 polypeptide refers to an immature form of EphA4.
  • the present invention thus provides therapeutic and/or prophylactic agents that are EphA2 or EphA4 vaccines.
  • a therapeutic and/or prophylactic agent is an EphA2- and/or EphA4 antigenic peptide expression vehicle expressing an EphA4 or an EphA4 antigenic peptide that can elicit or mediate a cellular immune response, a humoral response, or both, against cells that overexpress EphA2 or EphA4.
  • the immune response is a cellular immune response, it can be a Tc, Thl or a Th2 immune response.
  • the immune response is a Th2 cellular immune response.
  • an EphA2 or an EphA4 antigenic peptide expressed by an EphA2- or EphA4- antigenic peptide expression vehicle is an EphA2 or EphA4 antigenic peptide that is capable of eliciting an immune response against EphA2- and/or EphA4-expressing cells involved in an infection.
  • the EphA2- and/or EphA4 antigenic expression vehicle is a microorganism expressing an EphA2 and/or an EphA4 antigenic peptide.
  • the EphA2- and/or EphA4 antigenic expression vehicle is an attenuated bacteria.
  • Non-limiting examples of bacteria that can be utilized in accordance with the invention as an expression vehicle include Listeria monocytogenes, include but are not limited to Borrelia burgdorferi, Brucella melitensis, Escherichia coli, enteroinvasive Escherichia coli, Legionella pneumophila, Salmonella typhi, Salmonella typhimurium, Shigella spp., Streptococcus spp., Treponema pallidum, Yersinia enter ocohtica, Listeria monocytogenes, Mycobacterium avium, Mycobacterium bovis, Mycobacterium tuberculosis, BCG, Mycoplasma hominis, Rickettsiae quintana, Cryptococcus neoformans, Histoplasma capsulatum, Pneumocystis carnii, Eimeria acervulina, Neospora caninum, Plasmodium falciparum, Sar
  • an EphA2 EphA4 vaccine is a Xwter/ ⁇ -based vaccine expresses an EphA2 and/or an EphA4 antigenic peptide.
  • the Listeria-based vaccine expressing an EphA2- and/or an EphA4 antigenic peptide is attenuated.
  • an EphA2 or EphA4vaccine is not Lwtert ⁇ -based or is not EphA2- based.
  • the EphA2- and/or EphA4 antigenic peptide expression vehicle is a virus expressing an EphA2- and/or an EphA4 antigenic peptide.
  • viruses that can be utilized in accordance with the invention as an expression vehicle include RNA viruses (e.g., single stranded RNA viruses and double stranded RNA viruses), DNA viruses (e.g., double stranded DNA viruses), enveloped viruses, and non-enveloped viruses.
  • viruses useful as EphA2- and/or Ephrin Al antigenic peptide expression vehicles include retroviruses (including but not limited to lentiviruses), adenoviruses, adeno-associated viruses, or he ⁇ es simplex viruses.
  • retroviruses including but not limited to lentiviruses
  • adenoviruses including but not limited to adenoviruses
  • adeno-associated viruses he ⁇ es simplex viruses.
  • Preferred viruses for administration to human subjects are attenuated viruses.
  • a virus can be attenuated, for example, by exposing the virus to mutagens, such as ultraviolet inadiation or chemical mutagens, by multiple passages and/or passage in non- permissive hosts, and/or genetically altering the virus to reduce the virulence and pathogenicity of the virus.
  • Microorganisms can be produced by a number of techniques well known in the art. For example, antibiotic-sensitive strains of microorganisms can be selected, microorganisms can be mutated, and mutants that lack virulence factors can be selected, and new strains of microorganisms with altered cell wall lipopolysaccharides can be constructed.
  • the microorganisms can be attenuated by the deletion or disruption of DNA sequences which encode for virulence factors which insure survival of the microorganisms in the host cell, especially macrophages and neutrophils, by, for example, homologous recombination techniques and chemical or transposon mutagenesis.
  • Bacterial virulence factors include, for example: cytolysin; defensin resistance loci; DNA K; fimbriae; GroEL; inv loci; lipoprotein; LPS; lysosomal fusion inhibition; macrophage survival loci; oxidative stress response loci; pho loci (e.g., PhoP and PhoQ ); pho activated genes (pag; e.g., pagB and pagC); phoP and phoQ regulated genes (prg); porins; serum resistance peptide; virulence plasmids (such as spvB, traT and ty2).
  • cytolysin include, for example: cytolysin; defensin resistance loci; DNA K; fimbriae; GroEL; inv loci; lipoprotein; LPS; lysosomal fusion inhibition; macrophage survival loci; oxidative stress response loci; pho loci (e.g
  • Yet another method for the attenuation of the microorganisms is to modify substituents of the microorganism which are responsible for the toxicity of that microorganism.
  • lipopolysaccharide (LPS) or endotoxin is primarily responsible for the pathological effects of bacterial sepsis.
  • the component of LPS which results in this response is lipid A (LA).
  • LA lipid A
  • Rhodobacter (Rhodopseudomonas) sphaeroides and Rhodobacter capsulatus each possess a monophosphoryl lipid A (MLA) which does not elicit a septic shock response in experimental animals and, further, is an endotoxin antagonist.
  • MLA monophosphoryl lipid A
  • Gram negative bacteria other than Rhodobacter can be genetically altered to produce MLA, thereby reducing its potential of inducing septic shock.
  • the LPS pathway mutant is a firA mutant.
  • firA is the gene that encodes the enzyme UDP-3-O(R-30 hydroxymyristoyl)- glycocyamine N-acyltransferase, which regulates the third step in endotoxin biosynthesis (Kelley et al., 1993, J. Biol. Chem. 268:19866-19874).
  • the bacteria may be engineered such that it is attenuated in more than one manner, e.g., a mutation in the pathway for lipid A production and one or more mutations to auxotrophy for one or more nutrients or metabolites, such as uracil biosynthesis, purine biosynthesis, and arginine biosynthesis.
  • the EphA2 or EphA4 antigenic peptides are preferably expressed in a microorganism, such as bacteria, using a heterologous gene expression cassette.
  • a heterologous gene expression cassette is typically comprised of the following ordered elements: (1) prokaryotic promoter; (2) Shine-Dalgarno sequence; (3) secretion signal (signal peptide); and, (4) heterologous gene.
  • the heterologous gene expression cassette may also contain a transcription termination sequence, in constructs for stable integration within the bacterial chromosome. While not required, inclusion of a transcription termination sequence as the final ordered element in a heterologous gene expression cassette may prevent polar effects on the regulation of expression of adjacent genes, due to read-through transcription.
  • the expression vectors introduced into the microorganism EphA2 or EphA4 vaccines are preferably designed such that microorganism-produced EphA2 or EphA4 peptides and, optionally, prodrug converting enzymes, are secreted by microorganism.
  • a number of bacterial secretion signals are well known in the art and may be used in the compositions and methods of the present invention.
  • the bacterial EphA2 or EphA4 antigenic peptide expression vehicles are engineered to be more susceptible to an antibiotic and/or to undergo cell death upon administration of a compound.
  • the bacterial EphA2 or EphA4 antigenic peptide expression vehicles are engineered to deliver suicide genes to the target EphA2- or EphA4-expressing cells.
  • suicide genes include pro- drug converting enzymes, such as He ⁇ es simplex thymidine kinase (TK) and bacterial cytosine deaminase (CD).
  • TK phosphorylates the non-toxic substrates acyclovir and ganciclovir, rendering them toxic via their inco ⁇ oration into genomic DNA.
  • CD converts the non-toxic 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU), which is toxic via its inco ⁇ oration into RNA.
  • pro-drug converting enzymes encompassed by the present invention include cytochrome p450 NADPH oxidoreductase which acts upon mitomycin C and porfiromycin (Murray et al., 1994, J. Pharmacol. Exp. Therapeut. 270:645-649).
  • Other exemplary pro-drug converting enzymes that may be used include: carboxypeptidase; beta-glucuronidase; penicillin-V -amidase; penicillin-G- amidase; beta-lactamase; beta.-glucosidase; nitroreductase; and carboxypeptidase A.
  • Exemplary secretion signals that can be used with gram-positive microorganisms include SecA (Sadaie et al., 1991, Gene 98:101-105), SecY (Suh et al., 1990, Mol. Microbiol. 4:305-314), SecE (Jeong et al, 1993, Mol. Microbiol. 10:133-142), FtsY and FfH (PCT/NL 96/00278), and PrsA (International Publication No. WO 94/19471).
  • Exemplary secretion signals that may be used with gram-negative microorganisms include those of soluble cytoplasmic proteins such as SecB and heat shock proteins; that of the peripheral membrane-associated protein SecA; and those of the integral membrane proteins SecY, SecE, SecD and SecF.
  • the promoters driving the expression of the EphA2 or EphA4 antigenic peptides and, optionally, pro-drug converting enzymes may be either constitutive, in which the peptides or enzymes are continually expressed, inducible, in which the peptides or enzymes are expressed only upon the presence of an inducer molecule(s), or cell-type specific control, in which the peptides or enzymes are expressed only in certain cell types.
  • a suitable inducible promoter can be a promoter responsible for the bacterial "SOS" response (Friedberg et al, In: DNA Repair and Mutagenesis, pp. 407-455, Am. Soc. Microbiol. Press, 1995).
  • Such a promoter is inducible by numerous agents including chemotherapeutic alkylating agents such as mitomycin (Oda et al, 1985, Mutation Research 147:219-229; Nakamura et al, 1987, Mutation Res. 192:239-246; Shimda et al, 1994, Carcinogenesis 15:2523-2529) which is approved for use in humans.
  • chemotherapeutic alkylating agents such as mitomycin (Oda et al, 1985, Mutation Research 147:219-229; Nakamura et al, 1987, Mutation Res. 192:239-246; Shimda et al, 1994, Carcinogenesis 15:2523-2529) which is approved for use in humans.
  • Promoter elements which belong to this group include umuC, sulA and others (Shinagawa et al, 1983, Gene 23: 167-174; Schnan et ⁇ /., 1991, Biochemie 73:4
  • the sulA promoter includes the ATG of the sulA gene and the following 27 nucleotides as well as 70 nucleotides upstream of the ATG (Cole, 1983, Mol. Gen. Genet. 189:400-404). Therefore, it is useful both in expressing foreign genes and in creating gene fusions for sequences lacking initiating codons.
  • an EphA2 or EphA4 vaccine does not comprise a microorganism.
  • any antibody that immunospecifically binds to EphA2 or EphA4 can be used as an EphA2 or EphA4 targeting moiety.
  • an antibody that immunospecifically binds to EphA2 or EphA4 also inhibits EphA2 or EphA4 activity or expression and/or cancer cell development.
  • Antibodies of the invention may preferably agonize (i.e., elicit EphA2 or
  • EphA4 phosphorylation as well as immunospecifically bind to the EphA2 or EphA4 receptor.
  • EphA2 or EphA4 becomes phosphorylated and then subsequently degraded.
  • Any method known in the art to assay either the level of EphA2 or EphA4 phosphorylation, activity, or expression can be used to assay candidate EphA2 or EphA4 antibodies to determine their agonistic activity (see, e.g., Section 6.2 infra).
  • Antibodies of the invention may preferably bind to EphA2 or EphA4 epitopes exposed on cancer cells (e.g., cells overexpressing EphA2 or EphA4 and/or cells with substantial EphA2 or EphA4 that is not bound to ligand) but not non-cancer cells or cell where EphA2 or EphA4 is bound to ligand.
  • antibodies of the invention are antibodies directed to an EphA2 or EphA4 epitope not exposed on non-cancer cells but exposed on cancer cells (see, e.g., Section 6.8 infra).
  • EphA2 or EphA4 membrane distribution between non-cancer cells and cancer cells expose certain epitopes on cancer cells that are not exposed on non-cancer cells.
  • EphA2 or EphA4 is bound to its ligand, Ephrin Al, and localizes at areas of cell-cell contacts.
  • cancer cells generally display decreased cell-cell contacts as well as overexpress EphA2 or EphA4 in excess of its ligand.
  • an antibody that preferentially binds unbound, unlocalized EphA2 or EphA4 is an antibody of the invention.
  • antibodies of the invention may preferably bind to
  • EphA2 or EphA4 epitopes exposed on cancer cells e.g., cells overexpressing EphA2 or EphA4 and/or cells with substantial EphA2 or EphA4 that is not bound to ligand
  • cancer cells e.g., cells overexpressing EphA2 or EphA4 and/or cells with substantial EphA2 or EphA4 that is not bound to ligand
  • any method known in the art to determine candidate EphA2 or EphA4 antibody binding/localization on a cell can be used to screen candidate antibodies for desirable binding properties.
  • immunofluorescence microscopy is used to determine the binding characteristics of an antibody.
  • Standard techniques can be used to compare the binding of an antibody binding to cells grown in vitro.
  • antibody binding to cancer cells is compared to antibody binding to non- cancer cells.
  • An exposed EphA2 or EphA4 epitope antibody binds poorly to non-cancer cells but binds well to cancer cells.
  • antibody binding to non-cancer dissociated cells is compared to antibody binding to non-cancer cells that have not been dissociated.
  • An exposed EphA2 or EphA4 epitope antibody binds poorly non-cancer cells that have not been dissociated but binds well to dissociated non-cancer cells.
  • flow cytometry is used to determine the binding characteristics of an antibody.
  • EphA2 or EphA4 may or may not be crosslinked to its ligand, Ephrin Al .
  • EphA2 or EphA4 epitope antibody binds poorly crosslinked EphA2 or EphA4 but binds well to uncrosslinked EphA2 or EphA4.
  • cell-based or immunoassays are used to determine the binding characteristics of an antibody.
  • antibodies that can compete with an EphA2 or EphA4 ligand e.g., Ephrin Al
  • EphA2 or EphA4 ligand used in this assay can be soluble protein (e.g., recombinantly expressed) or expressed on a cell so that it is anchored to the cell.
  • Antibodies of the invention may preferably inhibit (and preferably reduce) cancer cell colony formation in, for example, soft agar, or tubular network formation in a three-dimensional basement membrane or extracellular matrix preparation as well as immunospecifically bind to the EphA2 or EphA4 receptor.
  • One of skill in the art can assay candidate EphA2 or EphA4 antibodies for their ability to inhibit such behavior (see, e.g., Section 6.2 infra). Metastatic tumor cells suspended in soft agar form colonies while benign tumors cells do not. Colony formation in soft agar can be assayed as described in Zelinski et al. (2001, Cancer Res.
  • Antibodies to be assayed for agonistic activity can be included in bottom and top agar solutions.
  • Metastatic tumor cells can be suspended in soft agar and allowed to grow.
  • EphA2 or EphA4 cancer cell phenotype inhibiting antibodies will inhibit colony formation.
  • Another behavior specific to metastatic cells that can be used to identify cancer cell phenotype inhibiting antibodies is tubular network formation within a three- dimensional microenvironment, such as MATRIGELTM. Normally, cancer cells quickly assemble into tubular networks that progressively invade all throughout the MATRIGELTM.
  • EphA2 or EphA4 cancer cell phenotype inhibiting antibodies can be identified by their ability to inhibit tubular network formation of cancer cells.
  • Any other method that detects an increase in contact inhibition of cell proliferation e.g., reduction of colony formation in a monolayer cell culture may also be used to identify cancer cell phenotype inhibiting antibodies.
  • cancer cell phenotype inhibiting antibodies may also cause a reduction or elimination of colonies when added to already established colonies of cancer cells by cell killing, e.g., by necrosis or apoptosis. Methods for assaying for necrosis and apoptosis are well known in the art.
  • EphA4 or a fragment thereof and the off-rate of a monoclonal antibody-EphA2 or EphA4 interaction can be determined by competitive binding assays.
  • a competitive binding assay is a radioimmunoassay comprising the incubation of labeled EphA2 or EphA4 (e.g., 3 H or I25 I) with the monoclonal antibody of interest in the presence of increasing amounts of unlabeled EphA2 or EphA4, and the detection of the monoclonal antibody bound to the labeled EphA2 or EphA4.
  • the affinity of a monoclonal antibody for an EphA2 or EphA4 and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second monoclonal antibody can also be determined using radioimmunoassays.
  • EphA2 or EphA4 is incubated with a monoclonal antibody conjugated to a labeled compound (e.g. , H or I) in the presence of increasing amounts of a second unlabeled monoclonal antibody.
  • a labeled compound e.g. , H or I
  • a candidate EphA2 or EphA4 antibody may be assayed using any surface plasmon resonance based assays known in the art for characterizing the kinetic parameters of the EphA2-EphA2 or EphA4-EphA4 antibody interaction.
  • SPR instrument commercially available including, but not limited to, BIACORE Instruments, available from Biacore AB (Uppsala, Sweden); IAsys instruments available form Affinity Sensors (Franklin, MA.); IBIS system available from Windsor Scientific Limited (Berks, UK), SPR-CELLIA systems available from Nippon Laser and Electronics Lab (Hokkaido, Japan), and SPR Detector Spreeta available from Texas Instruments (Dallas, TX) can be used in the instant invention.
  • BIACORE Instruments available from Biacore AB (Uppsala, Sweden
  • IAsys instruments available form Affinity Sensors (Franklin, MA.)
  • IBIS system available from Windsor Scientific Limited (Berks, UK)
  • SPR-CELLIA systems available from Nippon Laser and Electronics Lab (Hokkaido, Japan)
  • SPR Detector Spreeta available from Texas Instruments (Dallas, TX)
  • SPR based assays involve immobilizing a member of a binding pair on a surface, and monitoring its interaction with the other member of the binding pair in solution.
  • SPR is based on measuring the change in refractive index of the solvent near the surface that occurs upon complex formation or dissociation.
  • the surface onto which the immobilization occur is the sensor chip, which is at the heart of the SPR technology; it consists of a glass surface coated with a thin layer of gold and forms the basis for a range of specialized surfaces designed to optimize the binding of a molecule to the surface.
  • a variety of sensor chips are commercially available especially from the companies listed supra, all of which may be used in the methods of the invention.
  • sensor chips examples include those available from BIAcore AB, Inc., e.g., Sensor Chip CM5, SA, NTA, and HPA.
  • a molecule of the invention may be immobilized onto the surface of a sensor chip using any of the immobilization methods and chemistries known in the art, including but not limited to direct covalent coupling via amine groups, direct covalent coupling via sulfhydryl groups, biotin attachment to avidin coated surface, aldehyde coupling to carbohydrate groups and attachment through the histidine tag with NTA chips.
  • BIACORETM kinetic analysis is used to determine the binding on and off rates of monoclonal antibodies to EphA2 or EphA4 (see, e.g., Section 6.7 infra).
  • BIACORETM kinetic analysis comprises analyzing the binding and dissociation of a monoclonal antibody from chips with immobilized EphA2 or EphA4 or fragment thereof on their surface.
  • the resulting binding curves are globally fitted using computer algorithms supplied by the manufacturer, BIAcore, Inc. (Piscataway, NJ). These algorithms calculate both the K on and K 0ff , from which the apparent equilibrium binding constant, K D is deduced as the ratio of the two rate constants (i.e., K 0ff /K on ). More detailed treatments of how the individual rate constants are derived can be found in the BIAevaluaion Software Handbook (BIAcore, Inc., Piscataway, NJ). The analysis of the generated data may be done using any method known in the art.
  • EphA2 or EphA4 and preferably have a K 0ff rate (antibody (Ab) + antigen (Ag) ⁇ off Ab- Ag) of less than 3 X 10 "3 s "1 , more preferably less than 1 X 10 "3 s "1 .
  • the antibodies of the invention immunospecifically bind to EphA2 or EphA4 and have a K 0f r of less than 5 X 10 "3 s “1 , less than 10 "3 s “1 , less than 8 X 10 "4 s “1 , less than 5 X 10 "4 s “1 , less than 10 “4 s “1 , less than 9 X 10 "5 s “1 , less than 5 X 10 "5 s “1 , less than 10 "5 s “1 , less than 5 X 10 "6 s “1 , less than 10 '6 s “1 , less than 5 X 10 "7 s “1 , less than 10 "7 s “1 , less than 5 X 10 "8 s “1 , less than 10 “8 s “1 , less than 5 X 10 "9 s '1 , less than 10 "9 s " ⁇ or less than 10 "10 s “1 .
  • the invention provides methods of assaying and screening for EphA2 or EphA4 antibodies of the invention by incubating antibodies that specifically bind EphA2 or EphA4, particularly that bind the extracellular domain of EphA2 or EphA4, with cells that express EphA2 or EphA4, particularly cancer cells, preferably metastatic cancer cells, that overexpress EphA2 or EphA4 (relative to non-cancer cells of the same cell type) and then assaying for an increase in EphA2 or EphA4 phosphorylation and/or EphA2 or EphA4 degradation (for agonistic antibodies), or reduction in colony formation in soft agar or tubular network formation in three-dimensional basement membrane or extracellular matrix preparation (for cancer cell phenotype inhibiting antibodies), or increased antibody binding to cancer cells as compared to non-cancer cells by e.g., immunofluorescence (for exposed EphA2 or EphA4 epitope antibodies) thereby identifying an EphA2 or Ep
  • nucleic acid molecules specific for EphA2 or EphA4 can also be used to decrease EphA2 or EphA4 expression and, therefore, be used in methods of the invention.
  • the present invention encompasses antisense nucleic acid molecules, i.e., molecules which are complementary to all or part of a sense nucleic acid encoding EphA2 or EphA4, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid.
  • the antisense nucleic acid can be complementary to an entire coding strand, or to only a portion thereof, e.g., all or part of the protein coding region (or open reading frame).
  • An antisense nucleic acid molecule can be antisense to all or part of a non-coding region of the coding strand of a nucleotide sequence encoding a polypeptide of the invention.
  • the non-coding regions (“5' and 3' untranslated regions") are the 5' and 3' sequences which flank the coding region and are not translated into amino acids.
  • Antisense nucleic acid molecules may be determined by any method known in the art, using the nucleotide sequences in publicly available databases such as GenBank. For example, using the nucleotide sequence of human EphA2 (GenBank accession no. NM_004431.2) or the nucleotide sequence of human EphA4 (GenBank accession no. NM_004438.3).
  • the antisense nucleic acid molecule is [00313] 5'- CCAGCAGTACCGCTTCCTTGCCCTGCGGCCG-3' (SEQ ID NO: 104) (see, e.g., Section 6.6 infra).
  • an EphA2 antisense nucleic acid molecule is not 5'-CCAGCAGTACCACTTCCTTGCCCTGCGCCG-3' (SEQ ID NO: 105) and/or 5'- GCCGCGTCCCGTTCCTTCACCATGACGACC-3' (SEQ ID NO: 106).
  • an EphA2 antisense nucleic acid moleucle is not 5'- CCAGCAGTACCGCTTCCTTGCCCTGCGGCCG-3' (SEQ ID NO: 107) and/or 5'- GCCGCGTCCCGTTCCTTCACCATGACGACC-3' (SEQ ID NO: 108).
  • an EphA2 or EphA4 binding moiety of the invention is not an EphA2 antisense nucleic acid molecule.
  • An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length.
  • an antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art.
  • an antisense nucleic acid e.g., an antisense oligonucleotide
  • an antisense nucleic acid can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used.
  • modified nucleotides which can be used to generate the antisense nucleic acid include 5- fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4- acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2- thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, ⁇ -D-galactosylqueosine, " inosine, N6-isopentenyladenine, 1 -methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7- methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, ⁇ -D- mannosylqueosine,
  • the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, i.e., EphA2 or EphA4).
  • an antisense orientation i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, i.e., EphA2 or EphA4
  • the antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a selected polypeptide of the invention to thereby inhibit expression, e.g., by inhibiting transcription and/or translation.
  • the hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix.
  • An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site.
  • antisense nucleic acid molecules can be modified to target selected cells and then administered systemically.
  • antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g. , by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens.
  • the antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are prefened.
  • An antisense nucleic acid molecule of the invention can be an ⁇ -anomeric nucleic acid molecule.
  • An ⁇ -anomeric nucleic acid molecule forms specific double- stranded hybrids with complementary RNA in which, contrary to the usual ⁇ -units, the strands run parallel to each other (Gaultier et al., 1987, Nucleic Acids Res. 15:6625).
  • the antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue et al., 1987, Nucleic Acids Res. 15:6131) or a chimeric RNA-DNA analogue (Inoue et al., 1987, FEBSLett. 215:327).
  • Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region.
  • ribozymes e.g., hammerhead ribozymes; described in Haselhoff and Gerlach, 1988, Nature 334:585-591
  • a ribozyme having specificity for a nucleic acid molecule encoding EphA2 or EphA4 can be designed based upon the nucleotide sequence of EphA2 or EphA4.
  • a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in U.S. Patent Nos. 4,987,071 and 5,116,742.
  • an mRNA encoding a polypeptide of the invention can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel and Szostak, 1993, Science 261 : 1411.
  • RNA interference is defined as the ability of double-stranded RNA (dsRNA) to suppress the expression of a gene conesponding to its own sequence. RNAi is also called post-transcriptional gene silencing or PTGS. Since the only RNA molecules normally found in the cytoplasm of a cell are molecules of single- stranded mRNA, the cell has enzymes that recognize and cut dsRNA into fragments containing 21-25 base pairs (approximately two turns of a double helix).
  • the antisense strand of the fragment separates enough from the sense strand so that it hybridizes with the complementary sense sequence on a molecule of endogenous cellular mRNA. This hybridization triggers cutting of the mRNA in the double-stranded region, thus destroying its ability to be translated into a polypeptide. Introducing dsRNA corresponding to a particular gene thus knocks out the cell's own expression of that gene in particular tissues and/or at a chosen time.
  • Double-stranded (ds) RNA can be used to interfere with gene expression in mammals (Wianny & Zernicka-Goetz, 2000, Nature Cell Biology 2: 70-75; inco ⁇ orated herein by reference in its entirety).
  • dsRNA is used as inhibitory RNA or RNAi of the function of EphA2 or EphA4 to produce a phenotype that is the same as that of a null mutant of EphA2 or EphA4 (Wianny & Zernicka-Goetz, 2000, Nature Cell Biology 2: 70- 75).
  • the invention provides aptamers of EphA2 and
  • aptamers are macromolecules composed of nucleic acid (e.g., RNA, DNA) that bind tightly to a specific molecular target (e.g., EphA2 or EphA4 proteins, EphA2 or EphA4 polypeptides and/or EphA2 or EphA4 epitopes as described herein).
  • a particular aptamer may be described by a linear nucleotide sequence and is typically about 15-60 nucleotides in length.
  • the chain of nucleotides in an aptamer form intramolecular interactions that fold the molecule into a complex three-dimensional shape, and this three-dimensional shape allows the aptamer to bind tightly to the surface of its target molecule.
  • aptamers may be obtained for a wide array of molecular targets, including proteins and small molecules.
  • aptamers have very high affinities for their targets (e.g., affinities in the picomolar to low nanomolar range for proteins).
  • Aptamers are chemically stable and can be boiled or frozen without loss of activity. Because they are synthetic molecules, they are amenable to a variety of modifications, which can optimize their function for particular applications. For in vivo applications, aptamers can be modified to dramatically reduce their sensitivity to degradation by enzymes in the blood. In addition, modification of aptamers can also be used to alter their biodistribution or plasma residence time.
  • aptamers that can bind to EphA2 or EphA4 or a fragment thereof can be achieved through methods known in the art.
  • aptamers can be selected using the SELEX (Systematic Evolution of Ligands by Exponential Enrichment) method (Tuerk and Gold, 1990, Science 249:505-510, which is inco ⁇ orated by reference herein in its entirety).
  • a large library of nucleic acid molecules (e.g., 10 15 different molecules) is produced and/or screened with the target molecule (e.g., EphA2 or EphA4 proteins, EphA2 or EphA4 polypeptides and/or EphA2 or EphA4 epitopes or fragments thereof as described herein).
  • the target molecule e.g., EphA2 or EphA4 proteins, EphA2 or EphA4 polypeptides and/or EphA2 or EphA4 epitopes or fragments thereof as described herein.
  • the target molecule is allowed to incubate with the library of nucleotide sequences for a period of time.
  • Several methods can then be used to physically isolate the aptamer target molecules from the unbound molecules in the mixture and the unbound molecules can be discarded.
  • the aptamers with the highest affinity for the target molecule can then be purified away from the target molecule and amplified enzymatically to produce a new library of molecules that is substantially enriched for aptamers that can bind the target molecule.
  • the enriched library can then be used to initiate a new cycle of selection, partitioning, and amplification. After 5-15 cycles of this selection, partitioning and amplification process, the library is reduced to a small number of aptamers that bind tightly to the target molecule.
  • Individual molecules in the mixture can then be isolated, their nucleotide sequences determined, and their properties with respect to binding affinity and specificity measured and compared.
  • Isolated aptamers can then be further refined to eliminate any nucleotides that do not contribute to target binding and/or aptamer structure (i.e., aptamers truncated to their core binding domain). See, e.g., Jayasena, 1999, Clin. Chem. 45:1628-1650 for review of aptamer technology, the entire teachings of which are inco ⁇ orated herein by reference).
  • the aptamers of the invention have the binding specificity and/or functional activity described herein for the antibodies of the invention.
  • the present invention is drawn to aptamers that have the same or similar binding specificity as described herein for the antibodies of the invention (e.g., binding specificity for EphA2 or EphA4 polypeptide, fragments of vertebrate EphA2 or EphA4 polypeptides, epitopic regions of vertebrate EphA2 or EphA4 polypeptides (e.g., epitopic regions of EphA2 or EphA4 that are bound by the antibodies of the invention).
  • the aptamers of the invention can bind to an EphA2 or EphA4 polypeptide and inhibit one or more activities of the EphA2 or EphA4 polypeptide.
  • nucleic acids that reduce EphA2 or EphA4 expression are administered to treat, prevent or manage a hype ⁇ roliferative disease, particular cancer, by way of gene therapy.
  • Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid.
  • the antisense nucleic acids are produce and mediate a prophylactic or therapeutic effect.
  • Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below. [00326] For general reviews of the methods of gene therapy, see Goldspiel et al.,
  • composition of the invention comprises EphA2 or
  • EphA4 nucleic acids that reduce EphA2 or EphA4 expression, said nucleic acids being part of an expression vector that expresses the nucleic acid in a suitable host.
  • nucleic acids have promoters, preferably heterologous promoters, said promoter being inducible or constitutive, and, optionally, tissue-specific.
  • nucleic acid molecules are used in which the nucleic acid that reduces EphA2 or EphA4 expression and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the nucleic acids that reduce EphA2 or EphA4 expression (Koller and Smithies, 1989, PNAS 86:8932; Zijlstra et al., 1989, Nature 342:435).
  • Delivery of the nucleic acids into a subject may be either direct, in which case the subject is directly exposed to the nucleic acid or nucleic acid-carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the subject. These two approaches are known, respectively, as in vivo or ex vivo gene therapy. For detailed description of delivery methods, see Section 5.3., supra.
  • kinase inhibitors that are capable of inhibiting or reducing the expression of EphA2 or EphA4 can be used in methods of the invention.
  • kinase inhibitors include, but are not limited to, inhibitors of Ras, and inhibitors of certain other oncogenic receptor tyrosine kinases such as EGFR and HER2.
  • Non-limiting examples of such inhibitors are disclosed in U.S. Patent Nos.
  • the kinase inhibitors inhibit or reduce EphA2 and/or EphA4 expression by at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%, or at least 1.5 fold, at least 2 fold, at least 2.5 fold, at least 3 fold, at least 3.5 fold, at least 4 fold, at least 4.5, at least 5 fold, at least 7 fold or at least 10 fold relative to a control (e.g., phosphate buffered saline) in an assay described herein or known in the art (e.g., RT- PCR, a Northern blot or an immunoassay such as an ELISA, Western blot).
  • a control e.g., phosphate buffered saline
  • an assay described herein or known in the art e.g.,
  • Toxicity and efficacy of the prophylactic and/or therapeutic protocols of the instant invention can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD 0 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD 5 o/ED 0 .
  • Prophylactic and/or therapeutic agents that exhibit large therapeutic indices are preferred. While prophylactic and/or therapeutic agents that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such agents to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
  • the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage of the prophylactic and/or therapeutic agents for use in humans.
  • the dosage of such agents lies preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
  • the therapeutically effective dose can be estimated initially from cell culture assays.
  • a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 50 (i.e., the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture.
  • IC 50 i.e., the concentration of the test compound that achieves a half-maximal inhibition of symptoms
  • levels in plasma may be measured, for example, by high performance liquid chromatography.
  • the anti-cancer activity of the therapies used in accordance with the present invention also can be determined by using various experimental animal models for the study of cancer such as the SCID mouse model or transgenic mice where a mouse EphA2 or EphA4 is replaced with the human EphA2 or EphA4, nude mice with human xenografts, animal models described in Section 6 infra, or any animal model (including hamsters, rabbits, etc.) known in the art and described in Relevance of Tumor Models for Anticancer Drug Development (1999, eds. Fiebig and Burger); Contributions to Oncology (1999, Karger); The Nude Mouse in Oncology Research (1991, eds.
  • in vitro assays which can be used to determine whether administration of a specific therapeutic protocol is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a protocol, and the effect of such protocol upon the tissue sample is observed, e.g., increased phosphorylation degradation of EphA2 or EphA4, inhibition of or decrease in growth and/or colony formation in soft agar or tubular network formation in three- dimensional basement membrane or extracellular matrix preparations.
  • a lower level of proliferation or survival of the contacted cells indicates that the therapeutic agent is effective to treat the condition in the patient.
  • therapeutic agents and methods may be screened using cells of a tumor or malignant cell line.
  • cell proliferation can be assayed by measuring 3 H-thymidine inco ⁇ oration, by direct cell count, by detecting changes in transcriptional activity of known genes such as proto-oncogenes (e.g., fos, myc) or cell cycle markers; cell viability can be assessed by trypan blue staining, differentiation can be assessed visually based on changes in mo ⁇ hology, increased phosphorylation/degradation of EphA2 or EphA4, decreased growth and/or colony formation in soft agar or tubular network formation in three-dimensional basement membrane or extracellular matrix preparation, etc.
  • proto-oncogenes e.g., fos, myc
  • cell cycle markers e.g., cell cycle markers
  • cell viability can be assessed by trypan blue staining
  • differentiation can be assessed visually based on changes in mo ⁇ hology, increased phosphorylation/degradation of EphA2 or EphA4, decreased growth and/or colony formation in soft agar or tubular network formation in three-dimensional basement membrane
  • Compounds for use in therapy can be tested in suitable animal model systems prior to testing in humans, including but not limited to in rats, mice, chicken, cows, monkeys, rabbits, hamsters, etc., for example, the animal models described above. The compounds can then be used in the appropriate clinical trials.
  • any assays known to those skilled in the art can be used to evaluate the prophylactic and/or therapeutic utility of the combinatorial therapies disclosed herein for treatment or prevention of cancer.
  • compositions of the invention include bulk drug compositions useful in the manufacture of pharmaceutical compositions (e.g., impure or non-sterile compositions) and pharmaceutical compositions (i.e., compositions that are suitable for administration to a subject or patient) which can be used in the preparation of unit dosage forms.
  • Such compositions comprise a prophylactically or therapeutically effective amount of a therapy (e.g., prophylactic and/or therapeutic agent) disclosed herein or a combination of those agents and a pharmaceutically acceptable canier.
  • compositions of the invention comprise a prophylactically or therapeutically effective amount of one or more EphA2 or EphA4 antibodies of the invention and a pharmaceutically acceptable carrier or an agent that reduces EphA2 or EphA4 expression (e.g., antisense oligonucleotides) and a pharmaceutically acceptable carrier.
  • the composition of the invention further comprises an additional therapeutic, e.g., anti-cancer, agent.
  • pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • carrier refers to a diluent, adjuvant (e.g., Freund's adjuvant (complete and incomplete) or, more preferably, MF59C.1 adjuvant available from Chiron, Emeryville, CA), excipient, or vehicle with which the therapeutic is administered.
  • adjuvant e.g., Freund's adjuvant (complete and incomplete) or, more preferably, MF59C.1 adjuvant available from Chiron, Emeryville, CA
  • Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred canier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid caniers, particularly for injectable solutions.
  • Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • the composition if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like.
  • compositions of the invention are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
  • a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
  • the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline.
  • an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
  • the compositions of the invention can be formulated as neutral or salt forms.
  • Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.
  • compositions of the invention e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the antibody or antibody fragment, receptor-mediated endocytosis (see, e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432), construction of a nucleic acid as part of a retroviral or other vector, etc.
  • Methods of administering a prophylactic or therapeutic agent of the invention include, but are not limited to, parenteral administration (e.g., intradermal, intramuscular, intraperitoneal, intravenous and subcutaneous), epidural, and mucosal (e.g., intranasal, inhaled, and oral routes).
  • parenteral administration e.g., intradermal, intramuscular, intraperitoneal, intravenous and subcutaneous
  • epidural e.g., epidural, and mucosal (e.g., intranasal, inhaled, and oral routes).
  • mucosal e.g., intranasal, inhaled, and oral routes.
  • prophylactic or therapeutic agents of the invention are administered intramuscularly, intravenously, or subcutaneously.
  • the prophylactic or therapeutic agents may be administered by any convenient route, for example by infusion or bolus injection, by abso ⁇ tion through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local.
  • compositions of the invention can be delivered in a controlled release or sustained release system.
  • a pump may be used to achieve controlled or sustained release (see Langer, supra; Sefton, 1987, CRC Crit. Ref Biomed. Eng. 14:20; Buchwald et al., 1980, Surgery 88:507; Saudek et al., 1989, N. Engl. J. Med. 321 :574).
  • polymeric materials can be used to achieve controlled or sustained release of the compositions of the invention (see e.g., Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, J. Macromol Sci. Rev. Macromol Chem. 23:61; see also Levy et al., 1985, Science 228:190; During et al., 1989, Ann. Neurol. 25:351 ; Howard et al, 1989, J. Neurosurg. 1 1 :105); U.S.
  • polymers used in sustained release formulations include, but are not limited to, poly(2-hydroxy ethyl methacrylate), poly(methyl methacrylate), poly(acrylic acid), poly(ethylene-co-vinyl acetate), poly(methacrylic acid), polyglycohdes (PLG), polyanhydrides, poly(N-vinyl pyrrolidone), poly(vinyl alcohol), polyacrylamide, poly(ethylene glycol), polylactides (PLA), poly(lactide-co-glycolides) (PLGA), and polyorthoesters.
  • the polymer used in a sustained release formulation is inert, free of leachable impurities, stable on storage, sterile, and biodegradable.
  • a controlled or sustained release system can be placed in proximity of the prophylactic or therapeutic target, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)).
  • compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable caniers or excipients.
  • compositions of the invention and their physiologically acceptable salts and solvates may be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or oral, parenteral or mucosal (such as buccal, vaginal, rectal, sublingual) administration.
  • parenteral or mucosal such as buccal, vaginal, rectal, sublingual
  • local or systemic parenteral administration is used.
  • the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate).
  • binding agents e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate
  • lubricants e.g., magnesium stearate, talc or silica
  • disintegrants e.g., potato starch
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid).
  • the preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.
  • Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
  • compositions may take the form of tablets or lozenges formulated in conventional manner.
  • the prophylactic or therapeutic agents for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the prophylactic or therapeutic agents may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • the prophylactic or therapeutic agents may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
  • the prophylactic or therapeutic agents may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the prophylactic or therapeutic agents may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the invention also provides that a prophylactic or therapeutic agent is packaged in a hermetically sealed container such as an ampoule or sachette indicating the quantity.
  • a prophylactic or therapeutic agent is supplied as a dry sterilized lyophilized powder or water free concentrate in a hermetically sealed container and can be reconstituted, e.g., with water or saline to the appropriate concentration for administration to a subject.
  • the therapeutic agents of the invention can be formulated and supplied as provided in Table
  • radiation therapy agents such as radioactive isotopes can be given orally as liquids in capsules or as a drink. Radioactive isotopes can also be formulated for intravenous injections. The skilled oncologist can determine the prefened formulation and route of administration.
  • compositions of the invention are formulated at
  • compositions may, if desired, be presented in a pack or dispenser device that may contain one or more unit dosage forms containing the active ingredient.
  • the pack may for example comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration.
  • the amount of a therapy e.g., prophylactic or therapeutic agent
  • a composition of the invention which will be effective in the prevention, treatment, management, and/or amelioration of a hype ⁇ roliferative disease or one or more symptoms thereof can be determined by standard clinical methods.
  • the frequency and dosage will vary also according to factors specific for each patient depending on the specific therapies (e.g., the specific therapeutic or prophylactic agent or agents) administered, the severity of the disorder, disease, or condition, the route of administration, as well as age, body, weight, response, and the past medical history of the patient.
  • the dosage of a prophylactic or therapeutic agent or a composition of the invention which will be effective in the treatment, prevention, management, and/or amelioration of an hyperproliferative disease or one or more symptoms thereof can be determined by administering the composition to an animal model such as, e.g., the animal models disclosed herein or known in to those skilled in the art.
  • an animal model such as, e.g., the animal models disclosed herein or known in to those skilled in the art.
  • in vitro assays may optionally be employed to help identify optimal dosage ranges. Suitable regimens can be selected by one skilled in the art by considering such factors and by following, for example, dosages are reported in literature and recommended in the Physician 's Desk Reference (58th ed., 2004).
  • the therapies are administered less than 1 hour apart, at about 1 hour apart, at about 1 hour to about 2 hours apart, at about 2 hours to about 3 hours apart, at about 3 hours to about 4 hours apart, at about 4 hours to about 5 hours apart, at about 5 hours to about 6 hours apart, at about 6 hours to about 7 hours apart, at about 7 hours to about 8 hours apart, at about 8 hours to about 9 hours apart, at about 9 hours to about 10 hours apart, at about 10 hours to about 11 hours apart, at about 11 hours to about 12 hours apart, no more than 24 hours apart or no more than 48 hours apart.
  • two or more components are administered within the same patient visit.
  • the dosage amounts and frequencies of administration provided herein are encompassed by the terms therapeutically effective and prophylactically effective.
  • the dosage and frequency further will typically vary according to factors specific for each patient depending on the specific therapeutic or prophylactic agents administered, the severity and type of cancer, the route of administration, as well as age, body weight, response, and the past medical history of the patient. Suitable regimens can be selected by one skilled in the art by considering such factors and by following, for example, dosages reported in the literature and recommended in the Physician 's Desk Reference (58 th ed., 2004).
  • Exemplary doses of a small molecule include milligram or microgram amounts of the small molecule per kilogram of subject or sample weight (e.g., about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram).
  • the dosage administered to a patient is typically 0.0001 mg/kg to 100 mg/kg of the patient's body weight.
  • the dosage administered to a patient is between 0.0001 mg/kg and 20 mg/kg, 0.0001 mg/kg and 10 mg/kg, 0.0001 mg/kg and 5 mg/kg, 0.0001 and 2 mg/kg, 0.0001 and 1 mg/kg, 0.0001 mg/kg and 0.75 mg/kg, 0.0001 mg/kg and 0.5 mg/kg, 0.0001 mg/kg to 0.25 mg/kg, 0.0001 to 0.15 mg/kg, 0.0001 to 0.10 mg/kg, 0.001 to 0.5 mg/kg, 0.01 to 0.25 mg/kg or 0.01 to 0.10 mg/kg of the patient's body weight.
  • human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention or fragments thereof may be reduced by enhancing uptake and tissue penetration of the antibodies by modifications such as, for example, lipidation.
  • the dosage of EphA2 and/or EphA4 binding moieties (e.g., antibodies, compositions, or combination therapies of the invention) administered to prevent, treat, manage, and/or ameliorate a hype ⁇ roliferative disease or one or more symptoms thereof in a patient is 150 ⁇ g/kg or less, preferably 125 ⁇ g/kg or less, 100 ⁇ g/kg or less, 95 ⁇ g/kg or less, 90 ⁇ g/kg or less, 85 ⁇ g/kg or less, 80 ⁇ g/kg or less, 75 ⁇ g/kg or less, 70 ⁇ g/kg or less, 65 ⁇ g/kg or less, 60 ⁇ g/kg or less, 55 ⁇ g/kg or less, 50 ⁇ g/kg or less, 45 ⁇ g/kg or less, 40 ⁇ g/kg or less, 35 ⁇ g/kg or less, 30 ⁇ g/kg or less, 25 ⁇ g/kg or less, 20 ⁇ g/kg or less, 15
  • the dosage of the EphA2 and/or EphA4 binding moieties or combination therapies of the invention administered to prevent, treat, manage, and/or ameliorate a hype ⁇ roliferative disease, or one or more symptoms thereof in a patient is a unit dose of 0.1 mg to 20 mg, 0.1 mg to 15 mg, 0.1 mg to 12 mg, 0.1 mg to 10 mg, 0.1 mg to 8 mg, 0.1 mg to 7 mg, 0.1 mg to 5 mg, 0.1 to 2.5 mg, 0.25 mg to 20 mg, 0.25 to 15 mg, 0.25 to 12 mg, 0.25 to 10 mg, 0.25 to 8 mg, 0.25 mg to 7m g, 0.25 mg to 5 mg, 0.5 mg to 2.5 mg, 1 mg to 20 mg, 1 mg to 15 mg, 1 mg to 12 mg, 1 mg to 10 mg, 1 mg to 8 mg, 1 mg to 7 mg, 1 mg to 5 mg, or 1 mg to 2.5 mg.
  • a subject is administered one or more doses of an effective amount of one or therapies (e.g., therapeutic or prophylactic agents) of the invention, wherein the dose of an effective amount achieves a serum titer of at least 0.1 ⁇ g/ml, at least 0.5 ⁇ g/ml, at least 1 ⁇ g/ml, at least 2 ⁇ g/ml, at least 5 ⁇ g/ml, at least 6 ⁇ g/ml, at least 10 ⁇ g/ml, at least 15 ⁇ g/ml, at least 20 ⁇ g/ml, at least 25 ⁇ g/ml, at least 50 ⁇ g/ml, at least 100 ⁇ g/ml, at least 125 ⁇ g/ml, at least 150 ⁇ g/ml, at least 175 ⁇ g/ml, at least 200 ⁇ g/ml, at least 225 ⁇ g/ml, at least 250 ⁇ g/ml, at least 275 ⁇ g
  • a subject is administered a dose of an effective amount of one or more EphA2 or EphA4 binding moieties of the invention to achieve a serum titer of at least 0.1 ⁇ g/ml, at least 0.5 ⁇ g/ml, at least 1 ⁇ g/ml, at least, 2 ⁇ g/ml, at least 5 ⁇ g/ml, at least 6 ⁇ g/ml, at least 10 ⁇ g/ml, at least 15 ⁇ g/ml, at least 20 ⁇ g/ml, at least 25 ⁇ g/ml, at least 50 ⁇ g/ml, at least 100 ⁇ g/ml, at least 125 ⁇ g/ml, at least 150 ⁇ g/ml, at least 175 ⁇ g/ml, at least 200 ⁇ g/ml, at least 225 ⁇ g/ml, at least 250 ⁇ g/ml, at least 275 ⁇ g/ml, at least 300 ⁇ g/ml,
  • a subject may be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12 or more subsequent doses.
  • the invention provides methods of preventing, treating, managing, or ameliorating a hype ⁇ roliferative disease or one or more symptoms thereof, said method comprising administering to a subject in need thereof a dose of at least 10 ⁇ g, preferably at least 15 ⁇ g, at least 20 ⁇ g, at least 25 ⁇ g, at least 30 ⁇ g, at least 35 ⁇ g, at least 40 ⁇ g, at least 45 ⁇ g, at least 50 ⁇ g, at least 55 ⁇ g, at least 60 ⁇ g, at least 65 ⁇ g, at least 70 ⁇ g, at least 75 ⁇ g, at least 80 ⁇ g, at least 85 ⁇ g, at least 90 ⁇ g, at least 95 ⁇ g, at least 100 ⁇ g, at least 105 ⁇ g, at least 110 ⁇ g, at least 115 ⁇ g, or at least 120 ⁇
  • the invention provides a method of preventing, treating, managing, and or ameliorating a hype ⁇ roliferative disease or one or more symptoms thereof, said methods comprising administering to a subject in need thereof a dose of at least 10 ⁇ g, preferably at least 15 ⁇ g, at least 20 ⁇ g, at least 25 ⁇ g, at least 30 ⁇ g, at least 35 ⁇ g, at least 40 ⁇ g, at least 45 ⁇ g, at least 50 ⁇ g, at least 55 ⁇ g, at least 60 ⁇ g, at least 65 ⁇ g, at least 70 ⁇ g, at least 75 ⁇ g, at least 80 ⁇ g, at least 85 ⁇ g, at least 90 ⁇ g, at least 95 ⁇ g, at least 100 ⁇ g, at least 105 ⁇ g, at least 110 ⁇ g, at least 1 15 ⁇ g, or at least 120 ⁇ g of one or more EphA2 and/or EphA4 binding moieties, combination therapies, or compositions of the invention once every 3 days,
  • the present invention provides methods of preventing, treating, managing, or preventing a hype ⁇ roliferative disease or one or more symptoms thereof, said method comprising: (a) administering to a subject in need thereof one or more doses of a prophylactically or therapeutically effective amount of one or more EphA2 and/or EphA4 binding moieties, combination therapies, or compositions of the invention; and (b) monitoring the plasma level/concentration of the said administered EphA2 and/or EphA4 binding moieties in said subject after administration of a certain number of doses of the said therapies (e.g., therapeutic or prophylactic agents).
  • said certain number of doses is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 doses of a prophylactically or therapeutically effective amount one or more EphA2 or EphA4and/or binding moieties, compositions, or combination therapies of the invention.
  • the invention provides a method of preventing, treating, managing, and/or ameliorating a hype ⁇ roliferative disease or one or more symptoms thereof, said method comprising: (a) administering to a subject in need thereof a dose of at least 10 ⁇ g (preferably at least 15 ⁇ g, at least 20 ⁇ g, at least 25 ⁇ g, at least 30 ⁇ g, at least 35 ⁇ g, at least 40 ⁇ g, at least 45 ⁇ g, at least 50 ⁇ g, at least 55 ⁇ g, at least 60 ⁇ g, at least 65 ⁇ g, at least 70 ⁇ g, at least 75 ⁇ g, at least 80 ⁇ g, at least 85 ⁇ g, at least 90 ⁇ g, at least 95 ⁇ g, or at least 100 ⁇ g) of one or more therapies (e.g., therapeutic or prophylactic agents) of the invention; and (b) administering one or more subsequent doses to said subject when the plasma level of the EphA2 and/or EphA
  • the invention provides a method of preventing, treating, managing, and/or ameliorating a hype ⁇ roliferative disease or one or more symptoms thereof, said method comprising: (a) administering to a subject in need thereof one or more doses of at least 10 ⁇ g (preferably at least 15 ⁇ g, at least 20 ⁇ g, at least 25 ⁇ g, at least 30 ⁇ g, at least 35 ⁇ g, at least 40 ⁇ g, at least 45 ⁇ g, at least 50 ⁇ g, at least 55 ⁇ g, at least 60 ⁇ g, at least 65 ⁇ g, at least 70 ⁇ g, at least 75 ⁇ g, at least 80 ⁇ g, at least 85 ⁇ g, at least 90 ⁇ g, at least 95 ⁇ g, or at least 100 ⁇ g) of one or more antibodies of the invention; (b) monitoring the plasma level of the administered EphA2 and/or EphA4 binding moieties of the invention in said subject after the administration of a certain number of doses; and (c) administering
  • Therapies e.g., prophylactic or therapeutic agents
  • other than the EphA2 and/or EphA4 binding moieties of the invention which have been or are cunently being used to prevent, treat, manage, and/or ameliorate a hype ⁇ roliferative disease or one or more symptoms thereof can be administered in combination with one or more EphA2 and/or EphA4 binding moieties according to the methods of the invention to treat, manage, prevent, and/or ameliorate a hype ⁇ roliferative disease or one or more symptoms thereof.
  • the dosages of prophylactic or therapeutic agents used in combination therapies of the invention are lower than those which have been or are cunently being used to prevent, treat, manage, and/or ameliorate a hyperproliferative disease or one or more symptoms thereof.
  • the recommended dosages of agents currently used for the prevention, treatment, management, or amelioration of a hype ⁇ roliferative disease or one or more symptoms thereof can be obtained from any reference in the art including, but not limited to, Hardman et al, eds., 2001, Goodman & Gilman's The Pharmacological Basis Of Basis Of Therapeutics, 10th ed., Mc-Graw-Hill, New York; Physician's Desk Reference (PDR) 58th ed., 2004, Medical Economics Co., Inc., Montvale, NJ, which are inco ⁇ orated herein by reference in its entirety.
  • the therapies are administered less than 5 minutes apart, less than 30 minutes apart, 1 hour apart, at about 1 hour apart, at about 1 to about 2 hours apart, at about 2 hours to about 3 hours apart, at about 3 hours to about 4 hours apart, at about 4 hours to about 5 hours apart, at about 5 hours to about 6 hours apart, at about 6 hours to about 7 hours apart, at about 7 hours to about 8 hours apart, at about 8 hours to about 9 hours apart, at about 9 hours to about 10 hours apart, at about 10 hours to about 1 1 hours apart, at about 1 1 hours to about 12 hours apart, at about 12 hours to 18 hours apart, 18 hours to 24 hours apart, 24 hours to 36 hours apart, 36 hours to 48 hours apart, 48 hours to 52 hours apart, 52 hours to 60 hours apart, 60 hours to 72 hours apart, 72 hours to 84 hours apart, 84 hours to 96 hours apart, or 96 hours to 120 hours part.
  • two or more therapies are administered within the same patient visit
  • one or more antibodies of the invention and one or more other therapies are cyclically administered. Cycling therapy involves the administration of a first therapy (e.g., a first prophylactic or therapeutic agent) for a period of time, followed by the administration of a second therapy (e.g., a second prophylactic or therapeutic agent) for a period of time, optionally, followed by the administration of a third therapy (e.g., prophylactic or therapeutic agent) for a period of time and so forth, and repeating this sequential administration, i.e., the cycle in order to reduce the development of resistance to one of the therapies, to avoid or reduce the side effects of one of the therapies, and/or to improve the efficacy of the therapies.
  • a first therapy e.g., a first prophylactic or therapeutic agent
  • a second therapy e.g., a second prophylactic or therapeutic agent
  • a third therapy e.g., prophylactic or therapeutic agent
  • EphA4 binding moiety of the invention may be repeated and the administrations may be separated by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or at least 6 months.
  • the administration of the same therapy (e.g., prophylactic or therapeutic agent) other than an EphA2 and/or EphA4 binding moieties of the invention may be repeated and the administration may be separated by at least at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or at least 6 months.
  • the EphA2 or EphA4 antigenic peptides and anti- idiotypic antibodies of the invention are formulated at 1 mg/ml, 5 mg/ml, 10 mg/ml, and 25 mg/ml for intravenous injections and at 5 mg/ml, 10 mg/ml, and 80 mg/ml for repeated subcutaneous administration and intramuscular injection.
  • the vaccine can be formulated at amounts ranging between approximately lxlO 2 CFU/ml to approximately lxlO 12 CFU/ml, for example at lxlO 2 CFU/ml, 5xl0 2 CFU/ml, lxlO 3 CFU/ml, 5xl0 3 CFU/ml, lxlO 4 CFU/ml, 5xl0 4 CFU/ml, lxlO 5 CFU/ml, 5xl0 5 CFU/ml, lxlO 6 CFU/ml, 5xl0 6 CFU/ml, lxl 0 7 CFU/ml, 5xl0 7 CFU/ml, lxl 0 8 CFU/ml, 5xl0 8 CFU/ml, lxlO 9 CFU/ml, 5xl0 9 CFU/ml, lxlO
  • the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight.
  • the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight.
  • the dosage is based on the amount colony forming units (c.f.u.).
  • the dosage ranges are from about 1.0 c.f.u./kg to about 1 x 10 10 c.f.u./kg; from about 1.0 c.f.u./kg to about 1 x 10 c.f.u./kg; from about 1 x 10 c.f.u./kg to about 1 x 10 8 c.f.u./kg; and from about 1 x 10 4 c.f.u./kg to about 1 x 10 8 c.f.u./kg.
  • Effective doses may be extrapolated from dose-response curves derived animal model test systems.
  • the dosage ranges are 0.001 -fold to 10, 000-fold of the murine LD 50 , 0.01-fold to 1, 000-fold of the murine LD 50 , 0.1 -fold to 500-fold of the murine LD 50 , 0.5-fold to 250-fold of the murine LD 50 , 1-fold to 100-fold of the murine LD 0 , and 5- fold to 50-fold of the murine LD 50 .
  • the dosage ranges are 0.00.1-fold, 0.01-fold, 0.1 -fold, 0.5-fold, 1-fold, 5-fold, 10-fold, 50-fold, 100-fold, 200-fold, 500-fold, 1,000-fold, 5,000-fold or 10,000-fold of the murine LD 50 .
  • the invention provides a pharmaceutical pack or kit comprising one or more containers filled with a composition of the invention. Additionally, one or more other prophylactic or therapeutic agents useful for the treatment of a cancer can also be included in the pharmaceutical pack or kit.
  • the invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
  • Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
  • the present invention provides kits that can be used in the above methods.
  • a kit comprises one or more compositions of the invention.
  • a kit further comprises one or more other prophylactic or therapeutic agents useful for the treatment of cancer, in one or more containers.
  • the monoclonal antibody of the invention EA2-5, Eph099B-102.147, Eph099B-208.261, Eph099B-210.248, Eph099B-233.152, any of the antibodies listed in Table 1 or EA44 is used in accordance with the present invention.
  • the other prophylactic or therapeutic agent is a chemotherapeutic.
  • the prophylactic or therapeutic agent is a biological or hormonal therapeutic.
  • EphA2-Fc Monoclonal antibodies against the extracellular domain of EphA2 were generated using the fusion protein EphA2-Fc.
  • This fusion protein consisted of the extracellular domain of human EphA2 linked to human immunoglobulin to facilitate secretion of the fusion protein.
  • mice Two groups of 5 mice each (either Balb/c mice (group A) or S JL mice
  • EphA2 antibodies promoted tyrosine phosphorylation and degradation of
  • EphA2 in MDA-MB-231 cells Monolayers of cells were incubated in the presence of EphA2 agonistic antibodies or control at 37°C. Cell lysates were then immunoprecipitated with an EphA2-specific antibody (D7, purchased from Upstate Biologicals, Inc., Lake Placid, NY and deposited with the American Type Tissue Collection on December 8, 2000, and assigned ATCC number PTA 2755), resolved by SDS-PAGE and subjected to Western blot analysis with a phosphotyrosine-specific antibody (PY20 or 4G10, purchased from Upstate Biologicals, Inc., Lake Placid, NY). Eph099B-208.261, EA2 (FIGS.
  • Eph099B-233.152 increased EphA2 phosphorylation.
  • Some membranes were stripped and re-probed with the EphA2-specific antibody used in the immunoprecipitation (D7) as a loading control (FIGS. 2C-2D).
  • EphA2 antibodies of the invention were also found to increase EphA2 phosphorylation (Table 9, column 5) including Eph099B-102.147 and Eph099B-210.248 (data not shown).
  • EphA2 agonistic antibodies at 37°C Cell lysates were then resolved by SDS-PAGE and subjected to Western blot analysis with an EphA2-specific antibody (D7).
  • Eph099B- 208.261, EA2 FIGS. 3A-3B
  • Eph099B-233.152 FIG. 4B
  • EphA2 protein level Some membranes were stripped and re-probed with a ⁇ -catenin-specific antibody as a loading control (FIGS. 3C-3D).
  • EphA2 antibodies of the invention were also found to decrease EphA2 protein levels 4 hours and/or 24 hours after antibody treatment (Table 9, columns 6 and 7) including Eph099B-102.147 and Eph099B-210.248 (data not shown). Decreased EphA2 expression is due, in part, to deceased mRNA expression levels in response to EphA2 protein degradation caused by agonistic antibody binding (data not shown).
  • MATRIGELTM can reliably predict the differentiation state and aggressiveness of breast epithelial cells.
  • Monolayer cultures of benign (MCF-10A) or malignant (MDA-MB-231) breast epithelial cells are incubated on MATRIGELTM in the presence of EphA2 antibodies (10 ⁇ g/ml) or control solution (PBS).
  • EphA2 antibodies (10 ⁇ g/ml) or control solution (PBS).
  • PBS control solution
  • tissue culture dishes are coated with MATRIGELTM (Collaborative Biomedical Products, Bedford, MA) at 37°C before adding 1 x 10 5 MDA-MB-231 or MCF-10A cells previously incubated on ice for 1 hour with the EphA2 antibody or control solution (PBS).
  • PBS EphA2 antibody or control solution
  • Cells are incubated on MATRIGELTM for 24 hours at 37°C, and cell behavior is assessed using an Olympus IX-70 inverted light microscope. All images are recorded onto 35 mm film (T-Max-400. Kodak, Rochester, NY).
  • Eph099B-233.152 can inhibit tumor cell growth in vivo and extend survival time of tumor-bearing mice. Briefly, 5xl0 6 MDA-MB-231 breast cancer cells were implanted subcutaneously into athymic mice. After the tumors had grown to an average volume of 100mm 3 , mice were administered 6mg/ml Eph099B-233.152 or PBS control intraperitoneally twice a week for 3 weeks. Tumor growth was assessed and expressed as a ratio of the tumor volume divided by initial tumor volume (100 mm 3 ).
  • mice administered Eph099B-233.152 had smaller tumors than mice administered PBS (FIG. 6A). Tumor growth was allowed to proceed until tumor volume reached 1000mm 3 . Survival of the mice was assessed by scoring the percent of mice living each day post treatment. A greater percentage of mice survived at each time point examined in the group administered Eph099B-233.152 (FIG. 6B). By day 36, all of the mice in the control group had died in contrast with only 70% of the mice admixture Eph099B-233.152. [00389] Additionally, EA2 and Eph099B-208.261 can also inhibit tumor cell growth in vivo.
  • mice 5xl0 6 MDA-MB-231 breast cancer cells were implanted orthotopically or subcutaneously and 5xl0 6 A549 lung cancer cells were implanted subcutaneously into athymic mice. After the tumors had grown to an average volume of 100mm 3 , mice were administered 6mg/kg of an EphA2 agonistic antibody or negative control (PBS or 1A7 antibody) intraperitoneally twice a week for 3 weeks. Animals were generally sacrificed at least two weeks after the last treatment or when tumors exceeded 2000 mm . Tumor growth was assessed and expressed either as a ratio of the tumor volume divided by initial tumor volume (100 mm 3 ) or as total tumor volume.
  • PBS or 1A7 antibody EphA2 agonistic antibody or negative control
  • Estrogen-sensitive breast cancer cells MCF-7 cells
  • MCF-7 EphA2 human EphA2
  • pNeoMSV-EphA2 provided by Dr. T. Hunter, Scripps Institute
  • Western blot analyses confirmed the ectopic overexpression of EphA2 in transfected cells relative to matched controls (data not shown).
  • EphA2 overexpression increased malignant growth (FIGS. 8A-8B). Growth assays were conducted as follows. MCF-7 neo (control cells) or MCF7 EphA2 cells were seeded in 96-well plates.
  • MCF-7 control cells were largely unable to colonize soft agar (an average of 0.1 colony/field)
  • MCF-7 Eph ⁇ 2 cells formed larger and more numerous colonies (4.7 colonies/field; P ⁇ 0.01) that persisted for at least three weeks (FIG. 8A and data not shown).
  • the growth of MCF-7 EphA2 cells in monolayer culture did not differ from matched controls (FIG. 8B), thus indicating that the growth promoting activities of EphA2 were most apparent using experimental conditions that model anchorage-independent (malignant) cell growth.
  • MCF-7 EphA2 cells formed larger, more rapidly growing tumors in vivo.
  • Six to eight week- old athymic (nu/nu) mice were purchased from Harlan Sprague Dawley (Indianapolis, IN).
  • a controlled release estradiol pellet (0.72 mg 17 ⁇ -estradiol, 60-day formulation) was injected subcutaneously via a sterile 14-gauge trocar 24 hours prior to tumor implantation and pellets were replaced every 60 days for those experiments spanning > 60 days in duration.
  • lxlO 6 MCF-7 neo or MCF7 EphA2 cells were injected into the mammary fat pad under direct visualization.
  • tamoxifen (1 mg) was administered by oral gavage 6 days per week.
  • EphA2-overexpressing tumors differed phenotypically from control tumors in that they were more vascular and locally invasive at the time of resection (data not shown).
  • EphA2-specif ⁇ c antibodies FIG. 9B
  • the membranes were then stripped and reprobed with ⁇ -catenin antibodies to verify equal sample loading.
  • the relative amount of EphA2 was higher in tumor samples than in the input cells (prior to implantation), suggesting that tumors arose from cells with high levels of EphA2. Comparable findings with in vitro and in vivo models indicate that EphA2 overexpression results in a more aggressive phenotype. [00395] Parallel studies were performed in the absence of exogenous estrogen.
  • MCF-7 EphA2 cells were less sensitive to tamoxifen as compared with control (MCF-7 neo ) cells (FIG. 1 IB).
  • MCF-7 neo control cells
  • FIG. 1 IB Western blot analyses revealed comparable levels of ER ⁇ and ER ⁇ in control and MCF-7 EphA2 cells (FIGS. 12A-12B) (ER ⁇ and ER ⁇ antibodies were purchased from Chemicon, Temecula, CA).
  • Estrogen receptor activity was measured using ERE-TK-CAT vector (which encodes a single ERE; a generous gift from Dr. Nakshatri, Indiana University School of Medicine) in the unstimulated state, after estradiol (10 "8 M) stimulation and tamoxifen (10 '6 M) inhibition.
  • ERE-TK-CAT vector which encodes a single ERE; a generous gift from Dr. Nakshatri, Indiana University School of Medicine
  • the ⁇ - galactosidase expression vector RSV/ ⁇ -galactosidase (2 ⁇ g, Dr. Nakshatri's gift) was cotransfected as a control. Fresh media including the appropriate selection drugs were added 24 hours after transfection. Cells were harvested after 24 hours and CAT activity was evaluated as described (Nakshatri et al., 1997, Mol Cell. Biol. 17:3629-39). These results indicate that the estrogen receptor in MCF-7 EphA2 cells is expressed and remains sensitive to tamoxifen, thus suggesting that the defect which renders MCF-7 EphA2 less dependent on estrogen lies downstream of estrogen signaling.
  • the MCF-7 EphA2 cells were less sensitive to tamoxifen (25% inhibition by tamoxifen) as compared to the matched controls (75% inhibition by tamoxifen). Whereas EA2 decreased soft agar colonization (by 19%), the combination of EA2 and tamoxifen caused a much more dramatic (>80%) decrease in soft agar colonization. Thus, EA2 treatment restored a phenotype that was comparable to control MCF-7 cells.
  • EphA2 immunoreactivity distinguished neoplastic prostatic epithelial cells from their non-neoplastic counte ⁇ arts.
  • Grading of the primary tumor from radical prostatectomy specimens was performed according to the Gleason system (Bostwick "Neoplasms of the prostate" in Bostwick and Eble, eds., 1997, Urologic Surgical Pathology St. Louis:Mosby page 343-422; Gleson and Mellinger, 1974, J.
  • Urol 111 :58-64 The Gleason grade ranged from 4 to 10.
  • Tissue sections were then incubated with a mouse monoclonal antibody against human EphA2 (IgGi , 1 :100 dilution) overnight at room temperature, followed by biotinylated secondary antibody (DAKO co ⁇ oration, Ca ⁇ intera, CA) and peroxidase-labeled streptavidin, and 3,3-diaminobenzidine was used as the chromogen in the presence of hydrogen peroxide. Positive and negative controls were run in parallel with each batch.
  • DAKO co ⁇ oration Ca ⁇ intera, CA
  • EphA2 immunoreactivity was observed in all cases of high-grade prostatic intraepithelial neoplasia (PIN) and cancers but not in benign epithelial cells.
  • EphA2 expression both the mean percentage of immunoreactive cells and staining intensity
  • EphA2 immunoreactivity was increased in prostatic carcinomas compared with high-grade PIN (Tables 6 and 7). This immunoreactivity was evident at the membrane and cytoplasm of the neoplastic epithelial cells (data not shown).
  • EphA2 Although high levels of EphA2 could distinguish neoplastic from benign prostatic epithelial cells, EphA2 did not conelate with other histologic and pathologic parameters of disease severity. For example, high levels of EphA2 were observed in most prostatic carcinomas and did not relate to Gleason grade, pathologic stage, lymph node metastasis, extraprostatic extension, surgical margins, vascular invasion, perineural invasion or the presence of other areas of the prostate with high-grade PIN (Table 8).
  • a study is designed to assess pharmacokinetics and safety of monoclonal antibodies of the invention in patients with metastatic breast cancer. Cancer patients currently receive Taxol or Taxotere. Patients currently receiving treatment are permitted to continue these medications. [00407] Patients are administered a single IV dose of a monoclonal antibody of the invention and then, beginning 4 weeks later, are analyzed following administration of repeated weekly IV doses at the same dose over a period of 12 weeks. The safety of treatment with the monoclonal antibody of the invention is assessed as well as potential changes in disease activity over 26 weeks of IV dosing. Different groups of patients are treated and evaluated similarly but receive doses of 1 mg/kg, 2 mg/kg, 4 mg/kg, or 8 mg/kg.
  • Monoclonal antibodies of the invention are formulated at 5 mg/ml and 10 mg/ml for IV injection. A formulation of 80 mg/ml is required for repeated subcutaneous administration. The monoclonal antibodies of the invention are also formulated at 100 mg/ml for administration for the pu ⁇ oses of the study. [00409] Changes are measured or determined by the progression of tumor growth.
  • EphA2 Antisense Oligonucleotides 6.6 Decreased EphA2 Levels Using EphA2 Antisense Oligonucleotides
  • An antisense oligonucleotide-based approach that decreased EphA2 expression in tumor cells independent of EphA2 activation was developed.
  • MDA-MB-231 breast carcinoma cells were transiently transfected with phosphorothioate-modified antisense oligonucleotides that conesponded to a sequence that was found to be unique to EphA2 as determined using a sequence evaluation of GenBank (5'-CCAGCAGTACCGCTTCCTTGCCCTGCGGCCG-3'; SEQ ID NO: 104).
  • Inverted antisense oligonucleotides (5'-GCCGCGTCCCGTTCCTTCACCATGACGACC- 3'; SEQ ID NO: 109) provided a control.
  • the cells were transfected with oligonucleotides (2 ⁇ g/ml) using Lipofectamine PLUS Reagent (Life Technologies, Inc.) according to the manufacturer's protocol. Twenty- four hours post- transfection, the cells were divided. Half of the cells were seeded into soft agar, and the remaining cells were extracted and subjected to Western blot analysis.
  • EphA2 antisense oligonucleotides decreased soft agar colonization by at least 60% as compared to matched controls (FIG. 14C). Consistent results with EphA2 antibodies and antisense oligonucleotides thus indicate that decreased EphA2 expression is sufficient to decrease tumor cell growth.
  • the surface plasmon resonance-based BIACORETM assay was used to measure the K 0ff rates of the monoclonal antibodies of the invention. IgG present in the hybridoma supernatant was used for measurement.
  • Antibodies with K 0f f rates of "X 1 approximately less than 3 X 10 " s " have slow K 0 f f rates.
  • Antibodies with K 0ff rates of approximately 8 X 10 "4 s "1 or less have very slow K 0ff rates.
  • Antibodies with K 0t r rates of approximately 9 X 10 "5 s "1 or less have ultra slow K 0 f f rates.
  • EphA2-Fc was immobilize to a surface on a CM5 sensorchip using a standard amine (70 ⁇ l of a 1 :1 mix of NHS/EDC) coupling chemistry. Briefly, a 400nM solution of EphA2-Fc in lOmM NaOAc, pH4, was then injected over the activated surface to a density of 1000-1100 RU's. Unused reactive esters were subsequently "capped” with a 70 ⁇ l injection of IM Et-NH2. Similarly, an activated and "capped” control surface was prepared on the same sensor chip without protein to serve as a reference surface.
  • EphA2 hybridoma supematants were made over both the EphA2-Fc and control surfaces, and the binding responses were recorded. These supematants were used undiluted. Following each injection, at least 10 min. of dissociation phase data was collected. Purified EphA2 monoclonal antibody EA2 was prepared to serve as a positive control (at l ⁇ g, 5 ⁇ g and 25 ⁇ g per 250 ⁇ l of growth medium). A negative control monoclonal antibody that does not bind EphA2 was also prepared at 5 ⁇ g/250 ⁇ l growth medium. Control injections of growth medium across these surfaces were also made. Following each binding cycle, the EphA2-Fc surface was regenerated with a single 1 min. pulse (injection) of IM NaCl-50mM NaOH.
  • Eph099B-208.261 and Eph099B-233.152 have slower K off rates than EA2 (FIG. 15). Additionally, other antibodies of the invention have slow K 0ff rates (Table 6, column 8) including Eph099B-102.147 and Eph099B-210.248 (data not shown). [00419] Table 9 summarizes the characterization of EphA2 monoclonal antibodies as described herein.
  • EphA2 Antibodies [00420] The epitopes of EphA2 antibodies were characterized. Non-transformed
  • MCF-10A cells or transformed MDA-MB-231 cells were incubated with 10 ⁇ g/ml Eph099B-233.152 or EA2 at 4°C for 30 min. prior to fixation in a 3% formalin solution and immunolabeling with fluorophore-conjugated anti-mouse IgG.
  • EA2 preferentially binds EphA2 on transformed cells (FIG. 16D).
  • Eph099B-233.152 binds EphA2 expressed on both transformed and non-transformed cells (FIGS. 16A-16B).
  • Treatment of non-transformed MCF-10A cells with 4mM EGTA for 20 min. dissociated the cells.
  • EA2 bound EphA2 on the EGTA dissociated cells but not the untreated cells (FIGS. 17A-17B).
  • Control cells were incubated only with secondary antibody (fluorophore-labeled donkey anti-mouse IgG) in the absence of primary antibody (EA2) (bottom panel). The samples were then evaluated using flow cytometry (Becton Dickinson FACStar Plus). EGTA treatment did not affect EA2 binding to transformed cells (FIG. 17D, top and middle panels). In contrast, EA2 binding to non-transformed cells was increased by incubation in EGTA (FIG. 17C, top and middle panels). [00422] A microtiter plate was coated with 10 mg/ml Ephrin Al-F c overnight at 4°C.
  • EphA2-Ephrin Al-F c A fusion protein consisting of the extracellular domain of EphA2 linked to human IgGi constant region (EphA2-F c ) was incubated with and bound to the immobilized Ephrin Al- F c Biotinylated Ephrin Al-F c , EA2, or Eph099B-233.152 was incubated with the EphA2- Ephrin Al-F c complex and amount of binding was measured. Very little additional Ephrin Al-F c bound the EphA2-Ephrin Al-F c complex while, in contrast, considerable levels of EA2 and Eph099B-233.152 bound the EphA2-Ephrin Al- F c complex (FIG. 18A). [00423] The EphA2-Ephrin Al-F c complex was prepared as described above.
  • Biotinylated EA2 (10 ⁇ g/ml) was then incubated with the complex for 30 min. Unlabeled competitor was incubated with EphA2-Ephrin A1-F C -EA2 complex in the indicated amount. Unlabeled EA2 could displace the labeled EA2 at concentrations of 100 ng/ml or greater. Unlabeled Eph099B-233.152 and Ephrin Al-F c were similar in their ability to displace labeled EA2 (FIG 18B). - 163.1- International Application No: PCT/ / MICROORGANISMS

Abstract

La présente invention concerne des procédés et des compositions destinés au traitement, à la gestion ou à la prévention d'une maladie cellulaire hyperproliférative, notamment du cancer. Les procédés selon l'invention consistent à administrer une quantité efficace d'une composition ciblant des cellules exprimant une tyrosine kinase réceptrice de la famille Eph, telle que EphA2 ou EphA4, pour le traitement, la gestion ou la prévention de maladies hyperprolifératives, notamment du cancer. Dans un mode de réalisation, le procédé selon l'invention consiste à administrer à un sujet une composition contenant un groupe fonctionnel liant EphA2 ou EphA4, attaché à un véhicule d'administration, et un ou plusieurs agents thérapeutiques ou prophylactiques traitant ou prévenant une maladie hyperproliférative, associés au véhicule d'administration. Dans un autre mode de réalisation, le procédé selon l'invention consiste à administrer à un sujet une composition contenant un acide nucléique présentant une séquence nucléotidique codant un groupe fonctionnel liant EphA2 ou EphA4, et un agent thérapeutique ou prophylactique traitant ou prévenant une maladie hyperproliférative. Dans un autre mode de réalisation, le procédé selon l'invention consiste à administrer à un sujet une composition contenant un groupe fonctionnel liant EphA2 ou EphA4, et un acide nucléique présentant une séquence nucléotidique codant un agent traitant ou prévenant une maladie hyperproliférative, associé au véhicule d'administration. L'invention concerne également des compositions pharmaceutiques.
PCT/US2004/041020 2003-12-04 2004-12-06 Administration ciblee de medicaments au moyen de groupes fonctionnels liant epha2 ou epha4 WO2005056766A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US52739603P 2003-12-04 2003-12-04
US60/527,396 2003-12-04
US11/004,794 US20050153923A1 (en) 2003-12-04 2004-12-03 Targeted drug delivery using EphA2 or EphA4 binding moieties
US11/004,794 2004-12-03
US11/004,795 2004-12-03
US11/004,795 US20050147593A1 (en) 2003-05-22 2004-12-03 EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders

Publications (2)

Publication Number Publication Date
WO2005056766A2 true WO2005056766A2 (fr) 2005-06-23
WO2005056766A3 WO2005056766A3 (fr) 2008-01-31

Family

ID=34682013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/041020 WO2005056766A2 (fr) 2003-12-04 2004-12-06 Administration ciblee de medicaments au moyen de groupes fonctionnels liant epha2 ou epha4

Country Status (1)

Country Link
WO (1) WO2005056766A2 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1617864A2 (fr) * 2003-04-11 2006-01-25 MedImmune, Inc. Epha2 et troubles cellulaires hyperproliferatifs non-neoplastiques
EP1618184A2 (fr) * 2003-04-11 2006-01-25 MedImmune, Inc. Epha2, troubles cellulaires hypoproliferatifs, et reconstitution epitheliale et endotheliale
WO2006026820A1 (fr) * 2004-09-08 2006-03-16 The University Of Queensland Methode de traitement et agents utiles pour celle-ci
EP1638514A2 (fr) * 2003-06-06 2006-03-29 MedImmune, Inc. Utilisation du epha4 et de ses modulateurs, pour le diagnostic, le traitement et la prevention du cancer
EP1689346A2 (fr) * 2003-11-20 2006-08-16 MedImmune, Inc. Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants
WO2008110624A3 (fr) * 2007-03-14 2008-11-27 Univ Milano Bicocca Composes modulateurs de la pharmacoresistance dans des cellules tumorales epitheliales
EP1999269A2 (fr) * 2006-03-08 2008-12-10 Wake Forest University Health Sciences Éphrine-a1 monomère soluble
US7662770B2 (en) 2002-05-23 2010-02-16 Purdue Research Foundation Low molecular weight protein tyrosine phosphatase (LMW-PTP) as a diagnostic and therapeutic target
US7776327B2 (en) 1999-08-17 2010-08-17 Purdue Research Foundation EphA2 as a therapeutic target for cancer
US8449882B2 (en) 2007-08-30 2013-05-28 Daiichi Sankyo Company, Limited Anti-EPHA2 antibody
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
AU2007311511C1 (en) * 2006-10-19 2021-11-04 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040028685A1 (en) * 2002-05-10 2004-02-12 Kinch Michael S. EphA2 monoclonal antibodies and methods of use thereof
US20040180823A1 (en) * 2002-09-24 2004-09-16 Pasquale Elena B. Novel agents that modulate Eph receptor activity
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US20040028685A1 (en) * 2002-05-10 2004-02-12 Kinch Michael S. EphA2 monoclonal antibodies and methods of use thereof
US20040180823A1 (en) * 2002-09-24 2004-09-16 Pasquale Elena B. Novel agents that modulate Eph receptor activity

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BRANTLEY ET AL.: 'Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo' ONCOGENE vol. 21, 2002, pages 7011 - 7026 *
CARLES-KINCH ET AL.: 'Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior' CANCER RESEARCH vol. 62, May 2002, pages 2840 - 2847 *
CHENG ET AL.: 'Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors' NEOPLASIA vol. 5, no. 5, 2003, pages 445 - 456 *
CHENG ET AL.: 'The Ephrins and Eph receptors in angiogenesis' CYTOKINE & GROWTH FACTOR REVIEWS vol. 13, 2002, pages 75 - 85 *
CROSASSO ET AL.: 'Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs' J. OF PHARMACEUTICAL SCIENCES vol. 86, no. 7, July 1997, pages 832 - 839 *
EASTY ET AL.: 'Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma' INT. J. CANCER vol. 71, 1997, pages 1061 - 1065 *
KOOLPE ET AL.: 'An ephrin mimetic peptide that selectively targets the EphA2 receptor' JOURNAL OF BIOLOGICAL CHEMISTRY vol. 277, no. 49, 2002, pages 46974 - 46979 *
MERIC ET AL.: 'Expression profile of tyrosine kinases in breast cancer' CLINICAL CANCER RESEARCH vol. 8, 2002, pages 361 - 367 *
OGAWA ET AL.: 'The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization' ONCOGENE vol. 19, 2000, pages 6043 - 6052 *
ZELINSKI ET AL.: 'EphA2 overexpression causes tumorigenesis of mammary epithelial cells' CANCER RESEARCH vol. 61, 2001, pages 2301 - 2306 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8591887B2 (en) 1999-08-17 2013-11-26 Purdue Research Foundation EPHA2 as a therapeutic target for cancer
US7776327B2 (en) 1999-08-17 2010-08-17 Purdue Research Foundation EphA2 as a therapeutic target for cancer
US7662770B2 (en) 2002-05-23 2010-02-16 Purdue Research Foundation Low molecular weight protein tyrosine phosphatase (LMW-PTP) as a diagnostic and therapeutic target
EP1618184A2 (fr) * 2003-04-11 2006-01-25 MedImmune, Inc. Epha2, troubles cellulaires hypoproliferatifs, et reconstitution epitheliale et endotheliale
EP1618184A4 (fr) * 2003-04-11 2006-06-21 Medimmune Inc Epha2, troubles cellulaires hypoproliferatifs, et reconstitution epitheliale et endotheliale
EP1617864A4 (fr) * 2003-04-11 2006-06-21 Medimmune Inc Epha2 et troubles cellulaires hyperproliferatifs non-neoplastiques
EP1617864A2 (fr) * 2003-04-11 2006-01-25 MedImmune, Inc. Epha2 et troubles cellulaires hyperproliferatifs non-neoplastiques
EP1638514A4 (fr) * 2003-06-06 2009-11-18 Medimmune Inc Utilisation du epha4 et de ses modulateurs, pour le diagnostic, le traitement et la prevention du cancer
EP1638514A2 (fr) * 2003-06-06 2006-03-29 MedImmune, Inc. Utilisation du epha4 et de ses modulateurs, pour le diagnostic, le traitement et la prevention du cancer
EP1689346A2 (fr) * 2003-11-20 2006-08-16 MedImmune, Inc. Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants
EP1689346A4 (fr) * 2003-11-20 2007-11-21 Medimmune Inc Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants
WO2006026820A1 (fr) * 2004-09-08 2006-03-16 The University Of Queensland Methode de traitement et agents utiles pour celle-ci
EP1999269A2 (fr) * 2006-03-08 2008-12-10 Wake Forest University Health Sciences Éphrine-a1 monomère soluble
EP2946786A1 (fr) * 2006-03-08 2015-11-25 Wake Forest University Health Sciences Récepteur Ephrin A1 monomère soluble
EP1999269B1 (fr) * 2006-03-08 2014-12-10 Wake Forest University Health Sciences Éphrine-a1 monomère soluble
AU2007311511C1 (en) * 2006-10-19 2021-11-04 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US8889643B2 (en) 2007-03-14 2014-11-18 Bionsil, S.r.l. Isoform of bruton's tyrosine kinase (BTK) protein
US8232085B2 (en) 2007-03-14 2012-07-31 Bionsil S.R.L. Isoform of bruton's tyrosine kinase (BTK) protein
KR101791981B1 (ko) * 2007-03-14 2017-11-01 비온실 에스.알.엘. 화학요법 약물-내성 상피성 종양을 치료하기 위한 siRNA-매개 유전자 침묵화
US9820987B2 (en) 2007-03-14 2017-11-21 Bionsil S.R.L. In Liquidazione Modulator compounds of drug resistance in epithelial tumor cells
WO2008110624A3 (fr) * 2007-03-14 2008-11-27 Univ Milano Bicocca Composes modulateurs de la pharmacoresistance dans des cellules tumorales epitheliales
US8449882B2 (en) 2007-08-30 2013-05-28 Daiichi Sankyo Company, Limited Anti-EPHA2 antibody
US9150657B2 (en) 2007-08-30 2015-10-06 Daiichi Sankyo Company, Limited Anti-EPHA2 antibody
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer

Also Published As

Publication number Publication date
WO2005056766A3 (fr) 2008-01-31

Similar Documents

Publication Publication Date Title
US20050153923A1 (en) Targeted drug delivery using EphA2 or EphA4 binding moieties
AU2003243228B2 (en) EphA2 monoclonal antibodies and methods of use thereof
EP1575509B1 (fr) Anticorps monoclonaux agonistes de la epha2 et utilisations de ceux-ci
US20080089931A1 (en) EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
US7604799B2 (en) EphA4 Antibodies
US20100143345A1 (en) Epha2 agonistic monoclonal antibodies and methods of use thereof
AU2004293034B2 (en) EphA2 agonistic monoclonal antibodies and methods of use thereof
EP2069795A1 (fr) Traitement synergique de cellules qui expriment epha2 et erbb2
WO2005056766A2 (fr) Administration ciblee de medicaments au moyen de groupes fonctionnels liant epha2 ou epha4
WO2005016381A2 (fr) Therapie combinee pour le traitement et la prevention du cancer avec epha2, pcdgf, et haah
AU2012202569A1 (en) EPHA2 agonistic monoclonal antibodies and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase